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 My time as a part of the Biomedical Engineering Department at Georgia Tech and 
Emory has allowed me to develop both scientifically and personally, preparing me for 
any challenges that may lie ahead. I could not have made it to where I stand today 
without the help and support of many people that I would like to take this opportunity to 
thank. 
 First, I would like to thank the members of my thesis committee for the invaluable 
support and feedback over the past years—Dr. Todd McDevitt, Dr. Barbara Boyan, Dr. 
Robert Guldberg, Dr. Julie O’Connell, Dr. Zvi Schwartz, and Dr. Johnna Temenoff. 
Their support and guidance has significantly impacted the success of my project, 
particularly through their push for scientific rigor. In addition to serving as liaison from 
my thesis committee to the MD/PhD Executive Committee, Dr. Boyan’s expert 
knowledge in bone biology and direct, thought provoking questions always kept me 
thinking about how my work fit within the larger context. Dr. Schwartz always 
challenged me to re-evaluate my data and conclusions during our regular meetings, and I 
owe the success of my in vivo studies completely to his expert surgical skills. Together, 
their generosity in opening the expertise and resources of their lab was fundamental and 
directly impactful to every stage of my project. Dr. Guldberg’s questions and comments 
during meetings also spurred me to think more critically about my work and to take a step 
back to see the bigger picture. Dr. Temenoff’s feedback was always very useful, and she 
provided invaluable suggestions that helped me to improve the statistical rigor with 
which I was able to analyze my data. Though we have only met in person once or twice, 
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it was always a pleasure to talk to Dr. O’Connell on the phone, and I appreciated her 
encouragement and perspective from the industry side with respect to evaluations of 
DBM. Each of my committee members has been encouraging through the completion of 
my project while challenging me to become a better scientist, and I thank them all for 
their time and commitment to my training. 
 Of course, the single person who has contributed the most to my growth and 
development as a scientist has been my advisor, Todd. I first approached Todd to be my 
co-advisor back during my time in Dr. Marie Csete’s lab at Emory. After a year and a 
half that included early morning meetings at Emory and supporting me through my 
qualifying exams, Todd stepped up to take me into his lab as a full time student when 
Marie left Emory to return to California. My graduate school experience was completely 
turned on end, but Todd guided me through the stress and uncertainty of completely 
changing labs and projects and has helped me find my way over the past several years 
(though it may have taken more than a few threats of shaking). Todd has challenged his 
students to do the best science possible with his attention to detail, but even as his lab has 
grown, he was always accessible and easy to reach out to with any new data or concerns 
that came up in the course of research. His dedication to his students is unparalleled, and 
I cannot imagine having a more outstanding mentor (other than the brief scare of 
becoming a lab orphan for a second time). Thank you Todd for you guidance, support, 
and encouragement in my growth as a scientist. I must also take a moment to thank his 
wonderful wife, Meg, for always looking out for us, Todd’s students, by making sure to 
keep Todd in check as he pushed for the best from us and of course by providing us with 
delicious food. 
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There are also a number of individuals I would like to acknowledge, including 
collaborators from various other labs in the BME department and the IBB, who 
contributed to my project with their expertise, advice, and help. First, I would like to 
thank Dr. Rene Olivares-Navarrete and Sharon Hyzy from the Boyan/Schwartz Lab for 
their significant contributions to my work throughout this entire dissertation. In addition 
to their work on the vitamin D3 studies, they performed several other protein assays 
included here and provided assistance and guidance through three iterations of the in vivo 
experiments. Countless times when I had to drop by their offices to ask them even the 
simplest of questions, they always welcomed me with a smile and helpful suggestions, 
even if I was not dressed in lab appropriate attire. Also from their lab, I thank Dr. David 
Deustch for his assistance with animal surgeries and troubleshooting histology, Chris 
Hermann for his help and advice with μCT analysis, and Rolondo Gittens for performing 
the material characterizations. I greatly appreciate the training and advice given to me in 
using μCT by Angela Lin of the Guldberg Lab. I would also like to thank the members of 
the Temenoff Lab, particularly Taymour Hammoudi, Peter Yang, and Jennifer Lei, for 
their help in teaching me more about statistics. Dr. Brani Vidokovic also provided 
additional valuable feedback for the statistical analyses in my project.   
In the IBB, Sha’Aqua Asberry in the histology core was tremendously helpful in 
training and helping me to troubleshoot histological methods that were imperative to my 
research. Megan Richards, though she has not been around long, has always been quick 
to offer assistance with anything I asked of her. I would also like to thank Dr. Laura 
O’Farrell, the veterinary consultant for the in vivo studies. Dr. O’Farrell, along with Kim 
Benjamin, helped ensure that all the appropriate tools were in place and that the surgeries 
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ran as smoothly as possible. I also appreciated the friendliness and helpfulness of the rest 
of the PRL staff, who always helped keep things running efficiently for my work, 
particularly over winter breaks and even during the snow/ice storm of January 2011. I 
would also like to thank the BME academic advisors past and present - Beth Bullock 
Spencer, Shannon Oliver Sullivan, and Sally Gerrish; as well as the financial staff – 
Sandra Wilson, Penelope Pollard for their patience and helping me with all the paperwork 
over the years. Outside of Tech, I thank Dr. Nick Liu of Zimmer, who provided me with 
a lot of feedback and advice regarding the in vitro evaluation of DBM osteoinductivity. 
There are many individuals at Emory that I would like to thank as well. Directly 
contributing to this project, I thank Jeanette Taylor of the Robert P. Apkarian Integrated 
Electron Microscopy Core for her assistance in acquiring the transmission electron 
microscope images. Many thanks go to the entire Emory Medical Scientist Training 
Program, including its students, staff, and administration, for their support through my 
many years in the program. I thank my fellow students, an amazing and inspiring group 
of people to be around socially and scientifically. I thank its staff, Sabrina Mallett, 
Rebecca Sandidge, and formerly Barbara Powley, for keeping the program running like a 
well oiled machine and constantly solving any problems that may have come up for us. I 
also thank its directors past and present, Mary Horton, Dr. Chuck Parkos, Dr. Kerry 
Ressler, Dr. Aron Lukacher, and Dr. Marie Csete, for their support and always being 
there to talk to about anything. A special thank you goes to Marie, who was also my 
original thesis advisor, for being such an amazing role model of all the things that a 
physician scientist can be, from the time she sat with me to help me revise my first 
abstract to when she was overseeing the administration of anesthesia during my 
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transplant. I thank the former members of the Csete lab for my introduction to the world 
of stem cell research during my first two years of graduate school, in particular my 
karaoke duet partner, Dr. Danielle Drury-Stewart, for the fun times we had while working 
together and since. 
Though it was difficult to leave the Csete Lab behind, I was welcomed with open 
arms by the members of the McDevitt Lab, without whom I now cannot imagine having 
made it through graduate school. The McDevitt Lab has been such an amazing place to 
be for my growth scientifically and personally, and for that I thank its members past and 
present. The three senior students in the lab when I arrived full time, Dr. Rekha Nair, Dr. 
Rich Carpenedo, Dr. Carolyn Sargent, having been Todd’s first guinea pigs, established 
an amazingly strong foundation that allowed the rest of us thrive and really set a high bar 
for what it meant to be a member of the lab, not only scientifically but also recreationally. 
Rekha, the trail blazer in the study of acellular EB matrices, was an inspiration with her 
work ethic, and I will always remember and appreciate her for making sure I had all my 
essential body parts intact after we hiked to the top of Mt. Si. Rich helped establish the 
high standard of scientific rigor in the lab by being the one to ask the tough questions in 
lab meeting but was also a role model in all things eating challenge, cycling, bacon, or 
crossword puzzle related. Carolyn was always approachable, helping me out and 
answering my stupid questions with a smile, and she really changed my life tremendously 
outside of the lab by encouraging me to become more active through the pilates and spin 
classes she taught at the CRC and by helping me to train for my first triathlon. 
In addition to the original group, three more students were in the lab when I 
joined, Dr. Alyssa Ngangan Kitchel, Dr. Andres Bratt-Leal, and Dr. Barbara Nsiah. 
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Alyssa, in addition to being my fellow Thai, Infiniti-driving foodie, expanded upon 
Rekha’s studies of acellular EB matrices and directly paved the way for my in vivo work 
with the techniques she developed. In addition to several other titles she has collected 
while being in the McDevitt lab, she has had the distinction of being my “workout wife,” 
which I am glad is OK with her actual husband, Brandon, who I also thank for frequently 
serving as my fashion consultant. Andrés was one of my original BME classmates, and 
from the first time I sat next to him waiting for lunch on the first day of orientation, he 
has truly been a great friend and colleague. I am especially grateful that he was able share 
the experience of Camp Independence with me as my assistant counselor. Like Carolyn, 
Andrés was instrumental in getting me into better shape by serving as trainer for our early 
morning “Pumping Iron” crew, and we also had many fun, long bike rides together with 
Alyssa, Rich, Carolyn, and his girlfriend Erin Spinner (my fellow yogi, tri-training 
partner, classmate, and friend). Barbara, who would drop in from time to time for our 
workouts, also started full time in the lab shortly before I did. Unwavering, in the face of 
peer pressure, her independence has shined through in everything she has done. She has 
been a great person to be around both inside and outside of lab, always helping to keep 
me on track and motivating me by serving as a sounding board through the ups and 
downs of graduate school. Barbara has always looked out for me, whether she was 
bringing me food from her lunch seminars or providing me consultation on my wardrobe 
choices. Though it was often difficult to overcome her love of her bed and to get her out 
past her bedtime, Barbara was a great companion for late night excursions to Disney 
World and definitely knew her way around the dance floor! As we have progressed 
through graduate school together, I have been so fortunate to have such a group of peers 
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to motivate and support me. Each hurdle has seemed that much more doable because we 
were meeting the challenge together. 
It was a little over a year before the next student, Melissa Kinney, entered the 
fold. As the baby of the lab for quite a while, we were always protective of her, but she 
has really come into her own as she has assumed the role of senior graduate student. Her 
dedication and hard work impressed me from the beginning, and she has only continued 
to surpass the high expectations set for her. Melissa and her boyfriend, Phil Keegan, have 
also been amazing hosts, and I appreciate them inviting us into their home for our lab 
Dexter viewing parties, even if it was only for me to fall asleep on the floor. After 
another dry spell, we welcomed Jenna Wilson, Anh Nguyen, and Doug White, and each 
has been a great addition to the lab, for both their scientific contributions and other 
qualities they bring, especially related to the many McDevitt Lab food traditions. I was 
lucky enough to be the beneficiary of Jenna’s birthday cake baking skills, and I was 
happy to see the foodie streak in the lab will live on in Anh as she works her way through 
the Eater 38 list. Since Doug splits his time with the Kemp lab, I have not had as many 
opportunities to assess his cooking or eating skills, but after a strong showing at our last 
holiday cookie exchange, I am confident he is up to the challenge. I look to them to carry 
on all the things that make the McDevitt Lab such a great environment to work in, 
scientifically and gastronomically. I have also had less time to get to know the newest 
batch of students to join our lab family—Marian Hettiaratchi (newly minted American 
driver), Denise Sullivan (the maker of a mean banana pudding), Melissa Goude (heir to 
my role as lab photographer), and Josh Zimmermann (fellow sci-fi/comic/tv 
aficionado)—but based on all they have accomplished so far in their short time in lab, I 
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have no doubt they will continue on to outstanding and productive graduate student 
careers. 
In addition to the graduate students, there are many others in the lab who have 
contributed to making it such a great place to work. The first post doc to join the lab was 
Dr. Priya Baraniak, and along with instituting the lab holiday cookie exchange, she has 
provided me with tremendous help with her feedback on experiments and writing. Dr. 
Ankur Singh and Dr. Krista Fridley both came to us from the Roy Lab at the University 
of Texas, and brought with them their great scientific minds and strong work ethics, 
which will no doubt continue to contribute to their success in our lab and beyond. As the 
lab has grown, its research technicians/lab managers/miracle workers past and present 
(Marissa Cooke, Jesse McClellan, Hallum Dickens, and Beth Krauth) have been a vital 
part of keeping the lab moving forward. A special thank you to Marissa whose hard work 
to keep things in order and running smoothly has always been accompanied by humor 
and a beautiful smile. I also thank Beth who performed the initial experiment that sparked 
the work leading to my dissertation. Though not actually a graduate student but an 
undergraduate researcher, Katy Hammersmith has been in the lab for so long and has 
worked so diligently that she has made it easy to forget she was not actually preparing to 
defend a PhD herself. Along with Barbara, she made for a fun and memorable night 
cavorting around the Magic Kingdom after hours. Last but most certainly not least from 
the lab, I would like to thank Lu Ling, an outstanding undergraduate researcher who has 
worked with me for the past two years and whose significant contributions to my work 
were critical to its completion. Lu has been an amazingly hard worker and thoughtful 
researcher, and I was very fortunate in having the opportunity to mentor her. With her 
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quiet and careful .work, she brought new perspectives and insights that helped to shape 
my project and the PFA studies in particular. Lu will no doubt continue to make major 
contributions to the lab as a new Petit Scholar, and I look forward to great things from her 
in the future. 
I must also thank all of my friends—BME classmates, med school classmates, and 
those outside of school—for their constant support and for helping me to maintain 
balance in my life. With frequent trips to Buford Highway, shows at the Fox or Alliance, 
and game nights playing Wii, they kept me sane through the roller coaster ride of 
graduate school. A special thank you goes to Matt Barnett for letting me borrow his 
laptop AC adapter when mine died while writing my dissertation. Another group of 
people very important to my life since beginning graduate school has been the transplant 
community. Having started graduate school a few short months after receiving my kidney 
transplant, the two experiences are inextricably intertwined for me. I would like to thank 
all of the people I have met along my journey for what they have taught me about life and 
about living—my campers at Camp Independence, my teammates from Team Georgia 
and everyone from the Transplant Games, the children at Egelston, my fellow volunteers 
for the Georgia Transplant Foundation and Lifelink of Georgia, and those strangers 
whose negative opinions about organ donation I changed by sharing the story of my 
success. I would also like to thank the Georgia Transplant Foundation for the great honor 
of selecting me as its first Meg Jeffrey Memorial Scholarship recipient. I thank everyone 
with the Emory Transplant Center for the outstanding care I have received that has 
allowed me to continue on with my plans for graduate and medical school without having 
to miss a beat. I am especially thankful for their letting me set up my own personal work 
 xiii 
station in the outpatient clinic while I worked on my dissertation. I also remember those 
from our community who have passed, in particular Mikey Leggett and Meg Jeffrey, as 
they remind me what this whole MD/PhD thing is ultimately for. Mikey, a heart 
transplant recipient, was my camper for four summers at Camp Independence, and his 
genuine excitement and innocence about everything always brought a smile to my face 
(particularly his short stint on the radio). Not a recipient herself, Meg ushered me into the 
transplant world as my first contact with the Emory Transplant Center while serving as a 
nurse coordinator. We became friends through our shared volunteer activities—pouring 
wine at fundraisers, handing out doughnuts while signing up organ donors, and playing 
bingo with the kids at CHOA—and seeing her wave at me from the audience during my 
Christmas concerts was something I looked forward to every year. She never met a 
stranger and was always there to offer a helping hand to all those she came across. Hers is 
an example by which I will always strive to live. I would also like to take this opportunity 
to thank all of the tissue donors from whom the DBM used for my studies was derived. 
As a transplant recipient, the magnitude of their gift in choosing to be organ and tissue 
donors has definitely not been lost on me. 
Last and most importantly, I thank my family, without whom I would most 
certainly not be where I am today. My mom and dad, Dr. Rumpa Amornmarn and Dr. 
Surachai Sutha, as well as my grandparents, Che Peng and Me Cho Moy, and close 
extended family, Mittira Amornmarn, Anna Moy, Lina Amornmarn, Dr. Lulu 
Amornmarn, and Amy Amornmarn, have always loved and supported me. When I was a 
kid and got stuck on the first dungeon of Super Mario Bros, I was so frustrated and ready 
to give up, but my mom would not let me, telling me, “Don’t give up! You can do it.” 
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She was right, as moms always are. My dad has always showed me what no nonsense 
hard work can achieve. While my parents never pressured me and let me find my own 
interests and path in life, the knowledge that they were the top students in their country 
when they were growing up always pushed me to set a high academic standard for 
myself. My dad also happened to give me one of his kidneys, a gift for which I can never 
fully thank him. Thank you Mom and Dad for always pushing me towards excellence by 
your example! 
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 With a growing elderly population, increased bone disease and decreased bone 
repair observed with aging are significant causes of morbidity and mortality. As a result, 
the investigation of novel strategies, including materials, used to promote bone growth 
and regeneration is an area of great interest and active investigation. One widely used and 
studied material is demineralized bone matrix (DBM). Since the discovery of its 
osteoinductivity, the ability to induce bone formation when implanted in ectopic sites, it 
is now used in various formulations for clinical applications to heal bony defects. The 
observed osteoinductive properties of DBM are attributed to its ability to capture in an 
acellular form the naturally regenerative microenvironment present within bone, 
including its collagenous matrix and associated growth factors, in particular bone 
morphogenetic proteins (BMPs). This material, however, is derived from allograft 
sources, and as such, is limited by donor availability and subject to donor to donor 
variability in potency and efficacy. As a result, the derivation of similar osteoinductive 
materials derived instead from a single cell source and generated in vitro remains an 
attractive goal to remove the variability associated with allograft tissue. 
Stem or progenitor cells, which can differentiate to multiple cell types, are a 
promising candidate for use to derive such osteoinductive materials. Specifically, 
pluripotent embryonic stem cells (ESCs) can be directed to differentiate into a variety of 
phenotypes, including osteogenic cells. ESCs are commonly differentiated in vitro as 
embryoid bodies (EBs), three dimensional cellular aggregates that recapitulate many 
cellular and molecular aspects of early mammalian development. Therefore, ESCs, 
 xxv 
specifically after directed osteogenic differentiation, may recreate a more regenerative, 
embryonic-like microenvironment that may be lacking from current adult allograft-based 
therapies, such as DBM. Taken together, harnessing the ESC microenvironment and the 
unique mixture of growth factors it contains in an acellular therapy may be an effective 
means to modulate cell behavior and tissue formation by delivering signals deficient in 
adult tissues, in particular for bone regenerative applications. Thus, the objective of this 
project was to examine the osteoinductive potential harbored within the embryonic 
microenvironment, in vitro and in vivo. 
To better understand the osteoinductive potential harbored within the EB 
microenvironment, in vitro, the osteogenic differentiation of ESCs was characterized in 
response to administration of phosphate to cells in the form of β-glycerophosphate (βGP) 
(Chapter 4). In this work, the increasing presence of calcium phosphate mineralization 
was readily apparent throughout EBs differentiated for up to 14 days in the presence of 
βGP (starting at day 5), as evaluated by phase contrast microscopy, histological stains 
(von Kossa and Alizarin red), and micro-computed tomography (μCT). Coincident with 
EB mineralization, phenotypic markers of osteogenic differentiation (runx2, osteopontin, 
osteocalcin, and bone sialoprotein expression and osteopontin and osteoprotegrin 
secretion) were significantly increased by βGP treatment (10 mM). Additionally, 
phosphate induced differentiation involved activation of ERK 1/2. As a further 
characterization of osteogenic phenotype, the expression and responsiveness of two 
1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) receptors were assessed, the classical 
vitamin D receptor (VDR) and a membrane 1α,25(OH)2D3-binding protein (protein 
disulfide isomerase family A, member 3 [PDIA3]). In order to determine if the observed 
 xxvi 
effects were specific to ESCs or a general property of osteogenic cells, both receptors 
were evaluated in mesenchymal stem cells. EBs expressed both VDR and PDIA3, but 
VDR increased as cells underwent osteogenic differentiation. Mesenchymal stem cells 
expressed PDIA3 at constant levels throughout differentiation, but VDR increased in 
cells treated with osteogenic medium. These results suggested that both 1α,25(OH)2D3  
signaling mechanisms were important, with PDIA3 playing a greater role during early 
developmental events and VDR playing a greater role in later stages of differentiation. 
Taken together, the results of this in vitro work demonstrated that phosphate treatment 
was sufficient to induce osteogenic differentiation of EBs. 
To further clarify the mechanism by which phosphate treatment induced 
osteogenic differentiation, the mineral deposits formed within osteogenic EBs were 
further characterized (Chapter 5). It was hypothesized that phosphate-induced 
differentiation was mediated through changes in the microenvironment induced by 
mineral deposit formation within differentiating EBs. The mineralization was evaluated 
and quantified by phase imaging, staining, and μCT, and further material characterization 
studies were undertaken to determine the mineral structure and composition by 
transmission and scanning electron microscopy, energy dispersive spectroscopy, Fourier 
transform infrared spectroscopy, and X-ray diffraction. Along with the observation that 
non-viable cells mineralized in βGP-containing media, additional material 
characterization suggested that the mineral present within EBs was comprised of calcium 
phosphate precipitation nucleated by non-viable cells and was not matrix mineralization. 
The relationship of calcium phosphate precipitates to the previously observed osteogenic 
differentiation was then further assessed. When precipitate formation was blocked by 
 xxvii 
addition of phosphonoformic acid (PFA, 0.5 mM), ERK 1/2 activation and downstream 
osteogenic differentiation were also blocked; however no inhibition of signaling or 
differentiation were seen if PFA treatment was delayed until after precipitate formation 
had begun, suggesting that the precipitates themselves were somehow initiating signaling 
and differentiation, a finding that was in agreement with recent studies in pre-osteoblasts 
and vascular smooth muscle cells. Finally, osteogenic matrix molecules and 
osteoinductive growth factors were found to be produced by EBs at varying levels, 
regardless of phosphate treatment. Taken together, further characterization of osteogenic 
differentiation, in vitro demonstrated that calcium phosphate precipitation under 
phosphate treatment altered the microenvironment of osteogenic cells within EBs, 
leading to differentiation. 
Lastly, the ability to harness and deliver the osteoinductive microenvironment 
within osteogenic EBs as an acellular material (EBM) was evaluated in vivo in a mouse 
intramuscular osteoinduction assay (Chapter 6). EBM was found to retain several growth 
factors known to be important for the induction of bone formation and was particularly 
enriched in BMP-4. Osteogenic EB-derived EBM was determined to be osteoinductive in 
vivo, while EBM derived from spontaneously differentiating EBs was not osteoinductive, 
as evaluated by mineralized tissue formation visualized and quantified by X-ray and μCT, 
semi-quantitative scoring of osteoinduction, and histomorphometric quantification of new 
bone formed. Additionally, the EBM that was osteoinductive performed as well as active 
DBM positive controls, even though half the mass dose was delivered, which may have 
been explained by the abundant BMP-4 in EBM. In summary, the in vivo work 
demonstrated osteoinductivity of material derived from osteogenic EBs. 
 xxviii 
In conclusion, this work demonstrated that phosphate can induce osteogenic 
differentiation of EBs that modulates 1α,25(OH)2D3 receptor expression and activation, 
that this differentiation is mediated through alterations in the EB microenvironment 
created by the introduction of calcium phosphate precipitates within EBs, and that the 
osteoinductive microenvironment within osteogenic EBs can be harnessed to yield in vivo 
osteoinductivity. The in vivo study represents the first use of EBM for a tissue specific 
application after material derivation from ESCs undergoing directed differentiation. More 
broadly, the embryonic-like microenvironment of EBs undergoing directed 
differentiation can be harnessed in an acellular biomaterial for a tissue specific 
application, an approach that avoids the donor to donor variability that limits adult, 
allograft tissue-derived therapies, such as DBM. Furthermore, as methods are in place to 
direct the differentiation of ESCs to a variety of other cell types, such as endothelial cells, 
use of the same technique to derive other tissue specific EBMs may have a broad range of 
clinical applications beyond bone tissue engineering, such as promoting angiogenesis in 
ischemic myocardium following myocardial infarction. This work not only provides new 
insights into the dynamic microenvironments of differentiating stem cells but also 
establishes an approach for the development of additional ESC-derived, tissue specific 







 The ability of tissue to heal and regenerate changes over an animal’s lifespan. 
Specifically, bone healing declines through development and aging, resulting in 
prolonged or incomplete fracture repair in aged animals; conversely, fetal animals heal 
defects that cannot be healed postnatally. The loss of regenerative capacity, from fetal to 
adult to aged animals, has been attributed not only to a decline in the function of cells 
involved in bone formation (i.e. osteoblasts, mesenchymal stem cells (MSCs)) but also to 
alterations in the bone microenvironment that occur through development and aging, 
including extracellular matrix (ECM) composition and growth/trophic factor content [1]. 
Clinical scenarios in which defect repair is the desired outcome must overcome the 
impaired healing ability resulting from these changes in the bone microenvironment in 
order to promote complete tissue regeneration. Consequently, a variety of therapies 
directed at serving as bone grafts or bone substitutes to augment incomplete bone repair 
and implant integration have been developed. 
 Autograft bone, the gold standard in bone defect repair, has been associated with 
significant donor site morbidity. Molecular approaches stimulating endogenous 
osteogenic repair have focused on administration of specific morphogens, such as bone 
morphogenetic proteins (BMPs), or on application of acellular matrices derived from 
adult tissue sources, such as demineralized bone matrix (DBM). However, single factor 
treatments lose the rich molecular complexity of acellular matrix-based approaches, 
making supraphysiologic doses of single growth factors required, while allograft bone-
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derived treatments, including DBM, originate from cadaveric sources, lending inherent 
donor-to-donor and batch-to-batch variability. DBM osteoinductivity varies with donor 
characteristics and, specifically, is known to decrease with increasing donor age due to 
the changes in bone ECM composition that occur with aging [2]. Therefore, the 
development of alternative acellular therapies with not only high but also consistent 
osteoinductive potential remains a goal. 
In the investigation of novel treatments for bone repair, one potential therapeutic 
goal is the restoration of a more regenerative microenvironment, as found during 
embryonic development. One approach to creating such a microenvironment is through 
the use of stem cells. In recent years, stem cells have emerged as a key element of 
regenerative medicine due to their inherent ability to differentiate into a variety of cell 
phenotypes, providing numerous potential cell therapies for an array of degenerative 
diseases and traumatic injuries. In addition to serving as a differentiated cell source, 
pluripotent stem cells, such as embryonic stem cells (ESCs), may possess the unique 
potential to modulate tissue environments via local production of ECM and growth 
factors that may be harnessed as an acellular therapy to promote functional tissue 
regeneration. Though such an approach to generate a naturally derived material has been 
employed successfully to deliver osteoinductive factors found within adult bone, in the 
form of DBM, the development of treatments derived instead from developing, more 
regenerative tissues or cells remains attractive. The derivation of regenerative therapies 
from an ESC source also presents the added benefit of eliminating donor to donor 
variability of adult, cadaveric tissue-derived materials, such as DBM. Thus, study of the 
microenvironment generated by embryonic cells, including growth factors produced and 
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retained within that environment, may provide insights into restorative, osteoinductive 
strategies to augment bone regenerative ability. 
The objective of this project was to examine the osteoinductive potential harbored 
within the embryonic microenvironment, in vitro and in vivo. The central hypothesis of 
this work was that the embryonic microenvironment is rich in osteoinductive signals and 
that this microenvironment along with these signals, captured in a devitalized material, 
would harbor greater osteoinductive capacity or potency than adult tissue-derived 
matrices or materials. The rationale for this work was that, even in tissues, like bone, that 
regenerate and remodel readily, developing tissues regenerate more robustly than adult 
tissues and, furthermore, that the difference in regenerative ability is due in part to 
changes in the microenvironment, including growth factors present, which occur between 
embryonic and adult life. As such, embryonic stem cell-derived materials may possess 
enhanced inductive capabilities compared to ECM derived from adult tissues. The central 
hypothesis of the proposal was examined by completion of the following specific aims: 
 
Specific Aim 1. Determine how modification of the embryonic microenvironment 
impacts osteogenic differentiation, in vitro. The hypothesis of this aim was that 
perturbations in ESC microenvironment, including the formation of calcium phosphate 
precipitates induced by phosphate treatment, would alter ESC phenotype to promote 
osteogenic differentiation. Differentiation was assessed by evaluation of gene and protein 
expression of osteogenic growth factors, extracellular and matrix molecules, as well as 
expression and activation of receptors and signaling molecules known to be important in 
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osteogenic differentiation, including two 1α,25(OH)2D3 receptors, VDR and PDIA3, and 
ERK 1/2. 
 
Specific Aim 2. Compare the osteoinductive potential of the embryonic 
microenvironment from osteogenic and non-osteogenic embryonic cell sources, 
captured as an acellular biomaterial, with that of an adult tissue ECM, in vivo. The 
hypothesis of this aim was that material derived from ESCs undergoing osteogenic 
differentiation would exhibit greater osteoinductive capacity and potency than both 
material from spontaneously differentiating ESCs and adult DBM, in vivo, stimulating 
ectopic bone formation in a mouse intramuscular osteoinduction assay. Acellular 
materials derived from embryoid bodies (EBM) were implanted into the hindlimb of mice 
in order to assess ectopic bone formation in vivo, and osteoinductive capacity was 
compared with that of active and inactive DBM by mineralization formed, quantified by 
MicroCT, and histological assessments.  
 
This research was significant because it demonstrated that the embryonic 
microenvironment of cells undergoing directed differentiation could be harnessed as an 
acellular biomaterial that impacted tissue formation in vivo. This work was innovative 
because it examined how the microenvironment of osteogenic cells, particularly 
mineralization, may impact further differentiation and because it evaluated the 
osteoinductive potential of ESC derived material. Characterization of the instructive 
factors and osteoinductive cues produced by embryonic stem cells while undergoing 
osteogenic differentiation have provided insights into interactions between osteogenic 
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cells and their microenvironment. Furthermore, identification and characterization of 
such factors has lead to the development of novel regenerative medicine therapy derived 
from stem cell sources that can improve not only bone repair but also the quality of life 
for many patients by reducing the morbidity and mortality associated with their own 






Bone Extracellular Matrix (ECM) 
The ECM of bone provides structural support and presents cues that direct cell 
growth, differentiation, and mineralization. Illustrating their importance in bone 
development, mutations in bone extracellular matrix proteins lead to a variety of bone 
dysplasias in animal models and in humans [3]. During intramembranous bone formation, 
osteogenic mesenchymal cells undergo proliferation, matrix production, and then 
mineralization, after which the cells either become trapped as osteocytes or undergo 
apoptosis [4]. Endochondral bone formation proceeds through a cartilaginous 
intermediate, including a matrix rich in chondroitin sulfate and collagen type II that 
presents growth factors, particularly vascular endothelial growth factor, which promote 
vascular ingrowth [5]. Chondrocytes undergo hypertrophy, mineralization, and apoptosis, 
leaving a matrix that is then remodeled and further mineralized by infiltrating osteogenic 
cells [3]. The extracellular matrix of mature, native bone is comprised primarily of type I 
collagen, which constitutes nearly 90% of the organic material found in bone [6-8]. The 
collagen-I matrix itself is known to direct osteogenic differentiation. Osteoblast 
recognition of collagen-I by integrin binding has been shown to regulate early osteoblast 
differentiation and control the expression of key genes in osteoblastogenesis [9, 10]. 
Other important bone ECM molecules that have all been shown to regulate osteogenic 
differentiation and mineralization within developing bone include osteopontin [11, 12], 
osteocalcin [13], osteoprotegrin [14], bone sialoprotein [15], periostin [16], vitronectin 
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[17, 18], and fibronectin [4, 19]. In addition to providing signals that drive osteoblast 
growth and differentiation, individual ECM molecules may directly control 
mineralization by serving as nucleation points (e.g. bone sialoprotein) and inhibitors (e.g. 
osteopontin, osteocalcin) for hydroxyapatite formation [20]. Bone sialoprotein’s role as a 
nucleation point for mineral deposition, in particular, is critical for de novo bone 
formation [4]. Osteoblast secreted factors, such as osteoprotegrin, also regulate bone 
turnover and remodeling through their effects on osteoclasts [14]. The bone matrix also 
harbors growth factors, in particular bone morphogenetic proteins (BMPs), which were 
discovered through the molecular characterization of bone ECM [21, 22].  
Individual growth factors of particular relevance to bone forming ability include 
BMP-2 and VEGF. Since its first description in the 1960’s, the osteoinductivity of 
demineralized bone matrix (DBM) has long been known to be due mostly to its BMP-2 
content [22-24]. BMP-2 is directly osteoinductive, and as such, recombinant human 
BMP-2 has been employed clinically as a single factor therapy used to promote bone 
growth and regeneration, although at supraphysiologic doses in the milligram range 
[InFUSE; Medtronic Sofamor Danek, Memphis, TN] compared to nanogram amounts 
present in DBM used for similar applications [25]. When delivered with inactive DBM, 
BMP-2 induced robust new bone formation [24]. Smad signaling has been found to be 
activated by BMPs, leading to many of their osteoinductive effects [8, 26]. Though BMP-
2 is the most potent factor in mediating new bone formation, resident within bone, other 
factors are important as well. The bone extracellular matrix also contains VEGF, which is 
vital to osteoinductivity, as it is required for endochondral bone formation and promotes 
neovascularization allowing for the recruitment of the mesenchymal progenitor cells that 
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are acted upon by BMPs to form new bone [5, 27, 28]. Additionally, VEGF acts directly 
on osteoblasts, increasing their chemotaxis [29], and, when used to supplement DBM, 
improves graft neovascularization and increases bone formation [30]. 
Another osteoinductive factor of interest but not abundant in native, adult bone is 
BMP-4. Like BMP-2, BMP-4 is directly osteoinductive, due to their high level of 
homology [31]. During endochondral ossification in vivo, knockout of either Bmp2 or 
Bmp4 was rescued by endogenous expression of the other, allowing for normal bone 
formation, suggesting interchangeable roles during osteogenesis; however, removal of 
both BMP-2 and BMP-4 together completely inhibited osteoblast differentiation and long 
bone development in vivo [32]. Although BMP-4 was found to be upregulated during 
fracture repair, a process related to bone growth [33, 34], it alone was not actually 
necessary for either long bone skeletogenesis or limb fracture healing[35]. However, 
BMP-4 was also determined to be critical during development and necessary for 
gastrulation and mesoderm formation [36].  
 
Mineralization 
Mineralization of the extracellular matrix is a cell mediated process resulting in 
the deposition of calcium phosphate as hydroxyapatite (HA - Ca10(PO4)6OH2), and this 
process requires alkaline phosphatase activity and a source of inorganic phosphate, such 
as β-glycerophosphate (βGP). Mineral accumulation occurs within membrane bound 
matrix vesicles before association with the collagenous matrix within bone [6, 37]. 
Mineralization can be assessed by several methods including stains for calcium (Alizarin 
Red) and phosphate (von Kossa) and, in three dimensional systems, can be demonstrated 
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by micro-computed tomography (μCT) due to its higher radio-opacity compared to other 
tissues and cellular material[38]. Though mineralization is often used as a readout of 
differentiation towards osteoblasts, several different cell types, primarily of the 
mesenchymal lineage, may be induced towards osteogenic differentiation and are capable 
of mineralization, including mesenchymal stem cells [39], skeletal myoblasts [40], and 
even fibroblasts [41, 42] and vascular smooth muscle cells [43] under certain 
physiological or pathological conditions. 
In addition to being a process actively promoted within mineralizing tissues such 
as bone, it is one that is actively inhibited in non-mineralizing tissues. One factor 
promoting this inhibition is pyrophosphate (PPi), a naturally occurring, cell produced 
molecule that is present ubiquitously in soft tissues and known to be a potent inhibitor of 
mineralization both in vivo and in vitro [44-47]. Direct inhibition of crystal formation is 
one of the mechanisms by which it blocks precipitation and mineralization (Fig. 2.1) [47]. 
In mineralized tissues, alkaline phosphatase cleaves PPi to yield inorganic phosphate, 
thus removing inhibition and allowing for mineralization to occur [48].  
 
Demineralized bone matrix (DBM)  
The osteoinductive potential of demineralized freeze dried bone allograft, also 
commonly referred to as DBM, was first discovered in the 1960s [22], and it remains a 
leading molecular therapy to induce bone formation. DBM is an acellular matrix 
extracted from the native bone ECM, which has been found to be a natural material 
capable of harboring osteogenic growth factors and morphogens. Extraction of the 
mineral phase of bone by acid treatment yields a demineralized matrix comprised of 
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mostly collagen and associated growth factors, which may additionally have increased 
bioavailability after demineralization due to increased hydration [49], explaining why 
DBM is osteoinductive but non-demineralized allograft bone matrix is not [50]. Factors 
found to be present in DBM include primarily BMPs in combination with, but to a far 
lesser extent, other factors (e.g. TGFs, VEGF, FGFs) [31, 51]. 
The individual amounts of specific factors within DBM and overall 
osteoinductive bioactivity are confounded by donor and lot variability, making 
standardization difficult due to inconsistencies not only between preparations from 
different manufacturers but also independent batches of the same product formulation 
[25, 52, 53]}. The variability in DBM is due to the fact that allograft bone is used as the 
donor tissue source for the material and, as such, age, sex and other physiologically 
relevant parameters can affect DBM bioactivity [2, 25, 51, 54, 55]. Molecular 
characterization of DBM to identify key constituents imparting DBM with osteoinductive 
ability led to the discovery of BMPs [21-23, 56]. Thus, recombinant, single factor 
treatment has become a widely used approach for clinical applications, in particular, 
rhBMP-2 [InFUSE; Medtronic Sofamor Danek, Memphis, TN] and rhBMP-7/osteogenic 
protein-1 [Stryker Biotech, Hopkinton, MA]. Current approaches to deliver BMPs focus 
on administration of recombinant, singular factors in solution, within a carrier, commonly 
a collagen sponge [57]. One caveat of single factor treatment is the loss of the rich 
molecular complexity found in DBM and other acellular matrices, like porcine small 
intestinal submucosa [58]. 
The osteoinductive potential of demineralized bone matrices can be characterized 
by a variety of in vitro and in vivo techniques. In vitro characterization of DBM products 
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is usually based upon measuring the level of individual growth factors within DBM by 
ELISA, or comparable methods [52]. The evaluation of the in vitro osteoinductive 
capacity of DBM formulations has primarily been examined by cell seeding experiments 
[59]. Such studies have used a variety of cell types, including mesenchymal stem cells 
(MSCs) [39], myoblasts [40], and fibroblasts [42]; however, the choice of cell and 
predictive ability of in vitro cell assays for in vivo performance of DBM formulations 
remains arguable [60]. Compared to single cell types used to evaluate osteoinductivity in 
vitro, a complex mixture of multiple cell types and competing signals are present in vivo, 
leading to in vitro osteoinductivity not supported by in vivo osteoinductivity While some 
studies have demonstrated a correlation between single growth factor content and in vivo 
bioactivity [61], continued difficulty in identifying reliable predictors of in vivo 
osteoinductivity underscore the complex interplay between various factors contained in 
DBM [59]. Thus, the bulk of DBM characterization studies have utilized in vivo models, 
where osteoinduction, the ability to stimulate ectopic bone-like formation, is assessed 
either subcutaneously or intramuscularly. The latter method is currently accepted by the 
American Society of Testing and Materials (ASTM) International standards for the 
testing of DBM bioactivity [53, 62]. In the intramuscular model, it is believed that DBM 
particles recruit MSCs to the implantation site before inducing the formation of a 
cartilage intermediate and eventual bone, in a manner analogous to endochondral bone 
formation [26]. Measures of chondroinductive and osteoinductive potential, in vivo, can 
be assessed, including chondroitin sulfate production and ossicle formation [42, 63, 64]. 
In addition to its use in evaluating DBM, this model has also been used to evaluate the 
osteoinductivity of other types of ECM-based materials and formulations [65]. 
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While successful isolation of DBM is routinely accomplished with acid treatment 
to remove the mineral phase of bone, the wide range of physical and chemical properties 
of different tissues indicates the need for a variety of decellularization processes to 
effectively yield tissue-specific bioactive acellularized products [66]. Most protocols 
generally involve a combination of physical and chemical means of disrupting cellular 
membranes and structure in order to effectively remove cellular elements. Physical 
methods can involve freeze-thaw, pressure, sonication, and lyophillization techniques 
[67-69]. Acellular biomaterials lack viable cells but retain natural ECM components, 
such as structural adhesive proteins, glycosaminoglycans and bioactive growth factors 
embedded within the native matrix from the tissue of origin [70-73]. Successful use of 
these materials has been demonstrated in soft and hard tissue repair, ranging from heart 
valves and nerve grafts to osteoinduction, demonstrating that acellular therapies retain 




 Similar to DBM, the ECM of osteogenic cells cultured in vitro have been found to 
be osteoinductive. Like DBM, the in vitro osteoinductivity of ECM generated by 
MC3T3-E1 pre-osteoblast cells has been attributed to BMP content and interactions of 
exogenously seeded cells with the collagenous matrix produced [74]. Such matrices have 
been used to direct the differentiation of ESCs [75]. Mesenchymal stem cells (MSCs) 
undergoing osteogenic differentiation have also been used to generate matrices for 
potential therapeutic purposes like DBM but have yielded mixed results with 
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demonstrated in vitro osteoinductivity not leading to in vivo osteoinductivity [65, 76, 77]. 
In a series of studies, MSCs were first differentiated in media containing dexamethasone, 
a common osteogenic media supplement, and then seeded onto titanium scaffolds for 
varying lengths of time before decellularization and rat intramuscular implantation. 
Though these matrices were found to induce osteogenic differentiation of MSCs in vitro 
[78], they were not found to be osteoinductive in vivo but instead were surrounded by a 
fibrous capsule [65], similar to results obtained in response to ectopic implantation of 
non-demineralized, allograft bone [50]. With the multiple, non-osteoprogenitor cell types 
present in vivo and in the absence of strong enough osteoinductive cues within the matrix, 
the fibrous tissue response trumped the response of the osteoprogenitor cell population to 
form new bone. 
 
Developmental Changes in Bone Composition and Repair 
Bone regenerative capacity is known to decline through development and aging, 
from the embryonic to adult and aged life of an animal. The decline in bone formation 
and healing ability in aged human populations is well demonstrated clinically [79]. The 
loss in regenerative capacity may be attributed to changes both in cellular function and in 
bone extracellular environment [1]. Cellular causes for this decline include a smaller pool 
of available MSCs [80], decreased proliferation of aged cells in response to matrix cues 
[81], and decreased expression of Runx2, an osteoblast transcription factor, resulting in 
decreased extracellular matrix production [82]. In contrast, fetal bone development and 
healing is augmented compared to that in adult animals. Fetal endochondral bone healing 
has been demonstrated to be a scar-free process. Fetal long bone fractures in sheep and 
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rabbits lack callus formation [83], and fractured embryonic chick radii heal without 
hematoma or callus formation typical after fracture [84]. Furthermore, fetal animals heal 
“critical-size” defects that would not be healed in postnatal animals [85]. Taken together, 
characteristics unique to the fetal/embryonic microenvironment promote improved bone 
regenerative ability compared to adult bone but are lost over the course of development 
towards and through adult life. 
The difference in the bone-forming ability of children and adults has in part been 
attributed to differential expression of several growth factors such as BMPs, TGF-1, 
TGF-3, and FGF-2. Microarray analysis of calvarial regenerates from juvenile and 
adult mice demonstrated a marked upregulation of pro-osteogenic cytokines (such as 
BMP-2, -4, and -7, FGF-2, and IGF-2) and increased levels of markers for osteogenic 
differentiation (such as Sparc, osteonectin, and osteopontin) in juvenile samples. 
Additionally, increased levels of bone-related ECM proteins were seen in juvenile 
regenerates compared to adult. These included procollagens Col6a1, Col3a1, Col4a1, 
MMP-2, MMP-14, pleiotrophin, and cathepsin K [86]. Furthermore, the osteoinductivity 
of DBM declines with donor age, suggesting a decrease in the amounts of osteoinductive 
molecules present in bone with aging, specifically BMP-2 [2]. Though differences in 
composition have been found, direct comparisons of osteoinductivity between adult 
tissue-derived and embryonic-like or pluripotent cell-derived matrices have not been 
examined. 
 
Pluripotent Stem Cells. 
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Embryonic stem cells (ESCs) are pluripotent cells derived from the inner cell 
mass of the blastocyst stage of development that are capable of self-renewal and 
differentiating into cells from all three germ layers (ectoderm, mesoderm and endoderm), 
as well as germ cells. ESCs can be used as a resource to experimentally probe 
mechanisms of early development and differentiation processes. In addition, the inherent 
plasticity of pluripotent ESCs suggests they could be effectively used as a robust cell 
source in regenerative medicine and tissue engineering applications for the treatment of a 
wide variety of degenerative diseases and traumatic tissue injuries. One additional 
advantage of ESCs compared to other multipotent stem cells, such as MSCs, is a 
significant capacity for self-renewal in a pluripotent state which readily permits the 
expansion of large numbers of cells. Successful derivation of ESCs from mouse 
blastocysts [87-89], eventually led to the ability to isolate ESCs from non-human 
primates [90, 91] and human embryos [92, 93]. The phenotypic and functional 
characterization of pluripotent stem cells paved the way for the recent ability to create 
“induced pluripotent” stem cells (iPSCs) from adult somatic cell types [94-97]. Though 
promising as a new tool in the development of regenerative therapies, particularly due to 
the potential for their derivation from autologous cell sources, many barriers must still be 
overcome before their clinical implementation [98]. Though much attention has been 
directed at evaluating the differentiation potential of these cells, with an eye towards cell-
based therapies, like ESCs, the direct implantation of iPSC-derived cells presents the risk 
of teratoma formation. Consequently, the isolation of biomolecules, such as extracellular 
matrix and growth factors, isolated or extracted from pluripotent cells remains an 
attractive option.  
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ESCs are exquisitely sensitive to a variety of microenvironmental cues that 
regulate both self-renewal and differentiation. Differentiation of ESCs is influenced by 
soluble factors (produced endogenously or added exogenously), interactions with 
extracellular matrix components, cell-cell adhesions (both homotypic and heterotypic), 
and various combinations of these different types of stimuli [99]. Differentiation of ESCs 
in vitro can be induced in a variety of formats, the most common of which is via 
formation of cell aggregates in suspension culture referred to as “embryoid bodies” (EBs) 
[89, 100, 101]. EBs provide a three dimensional model of tissue morphogenesis that 
recapitulates many early aspects of embryological development and are an attractive 
format for tissue engineering and regenerative medicine applications because their 
production is intrinsically scalable due to suspension culture. However, transport 
limitations within EBs may limit the ability to yield a homogenous cell population when 
methods of directed differentiation are employed utilizing bulk administration of 
inductive factors to the media alone [102]. Additionally, if even a small population of 
undifferentiated, pluripotent cells persists within EBs, direct implantation of viable cells 
for therapeutic purposes will lead to teratoma formation.  
 
Osteogenic Differentiation of Pluripotent Cells. 
Based on MSC and osteoblast precursor studies, general protocols have been 
developed for the differentiation of ESCs to bone forming osteoblasts [103, 104]. In order 
to promote osteogenic differentiation, EBs are commonly treated with soluble factors (β-
glycerophosphate (βGP), ascorbic acid, and dexamethasone or 1α,25-dihydroxy-vitamin 
D3 (1α,25(OH)2D3)), to encourage osteoblast maturation and matrix mineralization [105, 
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106]. Treatment with osteogenic supplements is usually initiated after the first five days 
of EB differentiation to allow for initial spontaneous induction of primitive mesodermal 
cells. βGP is necessary as a source of inorganic phosphate required for mineralization, 
though inorganic phosphate has also been found to induce osteogenic gene expression 
when administered alone [107]. Osteogenic differentiation cues are thought to be 
provided by supplementation with either dexamethasone or 1α,25(OH)2D3, which directly 
induce osteogenic gene transcription, while ascorbic acid (AA) is necessary for collagen 
fibril formation, which in turn promotes further osteogenic differentiation [9, 108, 109]. 
The influence of numerous other exogenous factors, including directly osteoinductive 
growth factor BMP-2, have also been investigated [104, 110-114], as well as osteogenic 
cell-derived matrices [75], highlighting the complexity of signals that may influence 
osteogenic differentiation and mineralization. 
 
Phosphate Induced Osteogenic Differentiation 
The ability of phosphate alone to induce mineralization and osteogenic 
differentiation has been demonstrated in multiple somatic cell types that exhibit the 
capacity to mineralize, including osteoblasts and vascular smooth muscle cells [43, 115], 
either by direct administration of inorganic phosphate or by addition of βGP. Both 
phosphate-induced mineralization and differentiation of these cells have been inhibited 
by blocking phosphate transport into cells, specifically through Type III Na,Pi co-
transporters (PiT-1), using phosphonoformic acid (PFA), suggesting that phosphate needs 
to enter the cell for these phenotypic changes to occur (Fig. 2.1) [43, 115]. Additionally, 
phosphate-induced differentiation has been found to be mediated through activation of 
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the mitogen activated protein kinase (MAPK) pathway, specifically extracellular signal 
regulated kinase (ERK 1/2), in pre-osteoblast MC3T3-E1 cells [107, 116], and 
phosphate-induced ERK signaling in calcific vascular smooth muscle cells leads to 
upregulation of the gene encoding Runx-2 [43], an early osteoblast transcription factor 
that regulates the osteogenic phenotype [117]. Though it is ubiquitously expressed, Pit-1 
gene expression has been found to increase with osteoblast differentiation of MC3T3-E1 
cells, coincident with the observation of mineralization, while Pit-2, which is also 
ubiquitously expressed, remains constant at an invariably low level, suggesting that PiT-1 
but not PiT-2 is important in osteoblast phosphate transport [118]. At the protein level, 
phosphate transport through PiT-1 is increased by BMP-2 stimulation following 
upregulation of Pit-1 expression and is required for BMP-2-induced matrix 
mineralization in MC3T3-E1 cells [119] and vascular smooth muscle cells [120]. 
Phosphate transport via PiT-1 has also been found to be important in chondrocyte 




Figure 2.1. Phosphate-induced osteogenic differentiation. Phosphate-induced 
osteogenic differentiation of osteoblast [115] and vascular smooth muscle cells [43] was 
originally characterized to require transport of Pi into cells through type III Na, Pi co-
transporters, PiT-1 [124] and activation of the ERK signaling pathway [116]. ERK 
signaling is activated by a variety of other pro-osteogenic signals [125, 126] and has been 
found to stabilize and activate Runx-2 [127]. Studies of phosphate-induced osteogenic 
differentiation found that ERK activation and subsequent differentiation were blocked 
with PFA treatment, thought to inhibit Pi uptake though PiT-1; however, more recent 
studies have suggested PFA may not block Pi transport at concentrations typically used 
[128]. Instead, PFA has been found to inhibit calcium phosphate precipitation directly 
[129], in a mechanism similar to that of PPi [47]. The presence of calcium phosphate 
precipitates have since been demonstrated to induce osteogenic differentiation 
independent of Pi concentration alone [130, 131] through activation of ERK signaling 
[132]. 
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More recent electrophysiological studies of PiT-1 expressed exogenously in 
Xenopus oocytes have found that its transport of Pi was not actually blocked by PFA 
treatment at the concentrations typically used (0.5 mM), pointing towards another 
mechanism of action [128]. PFA is also an analogue of PPi, a natural inhibitor of 
extracellular mineralization that is known to directly interfere with calcium phosphate 
crystal formation, and additional studies of vascular smooth muscle cell calcification 
have suggested that PFA may inhibit mineralization by a similar mechanism [129] and 
therefore that the presence of extracellular mineral deposits, and not increased Pi 
concentrations, might actually induce osteogenic differentiation (Fig 2.1) [131, 132]. 
 
ERK Signaling in Osteoblast Differentiation 
 ERK 1/2 is an important signaling molecule in osteogenic differentiation, as ERK 
1/2 signaling is activated by a diverse set of signals present within bone (Fig 2.1). It has 
been found to be activated by inorganic phosphate in a variety of mineralizing cell types, 
including, osteoblasts [116], chondrocytes [121], dental pulp cells [133], and vascular 
smooth muscle cells [134]. BMP-2 has also been found to activate ERK signaling by 
non-Smad pathway activity in osteogenic cells including the mesenchymal progenitor cell 
line C3H10T1/2 [135] and C2C12 skeletal myoblast cells [125]. BMP-2 induced ERK 
activation has additionally been demonstrated to increase Runx-2 transcriptional activity 
in concert with Smad activation [127] and to induce transcription and activity of Osterix 
[136]. ERK activation may also be induced by 1α,25(OH)2D3 [126]. 
 
Vitamin D and Receptors 
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Another important factor known to impact osteogenic differentiation and 
osteoblast maturation is 1α,25(OH)2D3. Effects of 1α,25(OH)2D3 in osteoblasts are 
mediated by two vitamin D receptors, the nuclear receptor (VDR) [137]and a membrane-
associated 1α,25(OH)2D3-binding protein called protein disulfide isomerase A3 (PDIA3, 
also known as ERp60, ERp57, Grp58, and 1,25-MARRS) [138-140]. In classical VDR 
activation, 1α,25(OH)2D3 is recognized by cytoplasmic VDR, which then dimerizes with 
the retinoic acid receptor (RXR). This complex binds to vitamin D responsive elements 
(VDREs) in target genes and induces expression of osteoblast markers as such 
osteocalcin and Runx-2 [141, 142]. The interaction of 1α,25(OH)2D3 with PDIA3 in the 
membrane associated vitamin D receptor complex activates a rapid membrane-initiated 
signaling cascade that involves protein kinase C (PKC) and ERK activation, resulting in 






Mouse Embryonic Stem Cell (ESC) Culture  
Undifferentiated mouse ESCs (D3 line) were cultured in media containing 
DMEM (Mediatech, Herndon, VA) supplemented with 15% FBS (Hyclone, Logan, UT), 
2mM L-glutamine (Mediatech), 1x non-essential amino acids (Mediatech), 100U/ml 
penicillin/ 100 μg/ml streptomyocin/ 0.25 μg/ml amphotericin (GIBCO, Carlsbad, CA), 
0.1 mM β-mercaptoethanol (Fisher, Fairlawn, NJ), and 10
3
 U/mL of leukemia inhibitory 
factor (LIF, Chemicon, Temecula, CA) on 0.1% gelatin coated tissue culture dishes. 
Media was changed at least every 2 days, and cells were passed every 2-3 days before 
reaching 70% confluency with 0.05% trypsin (GIBCO). 
 
Embryoid Body (EB) Rotary Formation 
Single cell suspensions of undifferentiated ESCs were inoculated into 100mm 
bacteriological grade Petri dishes at 2 x 10
5
 cells/ml in 10 ml of ESC media without LIF 
and then cultured as EBs on rotary orbital shakers, as previously described by Carpenedo 
et al [147], at 40 rotations per minute of continuous shaking (Lab-Line Lab Rotator, 
Model #2314, Barnstead International, Dubuque, IA). For re-feeding every 2 days, EBs 
were collected by sedimentation, and 90% of media was exchanged with fresh ESC 
media.  
 
EB Ultra-High Throughput (UHTP) Formation 
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Forced aggregation was used to generate individual EBs of identical cell number 
in 6 well cell culture plates [148].  ESCs were inoculated at 6 million cells per 1 ml of 
media (6 well plate). There were 6000 microwells for each microwell insert, 
corresponding to approximately 1000 cells per microwell.  Plates were centrifuged 5 
minutes at 200xg at 25°C to promote aggregation. After 24 hours of microwell culture, 
EBs were collected by wide bore pipette, transferred to 100 mm bacteriological Petri 
dishes (~2500 EBs/dish), and maintained on a rotary orbital shaker at 40 rotations per 
minute of continuous shaking Lab Rotator, Model #2314, Barnstead International, 
Dubuque, IA) in 10 ml of ESC media without LIF. 
 
Histology 
All samples collected for histology were dehydrated via an increasing series of 
ethanol and xylene rinses (Shandon Pathcentre Enclosed Processor), embedded in 
paraffin (Shandon Histocentre 2 Embedding System), cut into 5 μm-thick sections 
(Microm HM 355S Rotary Microtome), and placed on positively charged glass slides. 
Sections were deparaffinized in xylene, rehydrated in graded ethanol washes, and rinsed 
in deionized water (Leica AutoStainer XL) in preparation for staining. Tissue 
morphology was assessed by routine hematoxylin and eosin (H&E) staining (Leica 
AutoStainer XL), and digital brightfield images of stained slides were obtained using a 
Nikon 80i Upright Microscope and a Spot Flex camera (Diagnostic Instruments, Sterling 
Heights, MI). 
For EB histology, EBs were collected, fixed in 10% formalin solution, rinsed in 
PBS, and embedded in Histogel™ (~200 EBs in 200 μl gel; Richard Allen Scientific, 
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Kalamazoo, MI). For von Kossa staining, deparaffinized sections were incubated in a 1% 
silver nitrate solution in water under UV for 15 min. Sections were rinsed in deionized 
water, transferred to 5% sodium thiosulfate for 5 minutes, rinsed in deionized water, and 
then counter stained for 5 minutes in 0.1% nuclear fast red stain before dehydration in 
graded ethanol, clearing in xylene, mounting in Cytoseal™ 60 (Richard-Allan Scientific), 
and cover-slipping. The number of EBs with positive staining (black) was quantified 
based on brightfield images. 
Alizarin red staining was accomplished by incubating deparaffinized sections in a 
2% Alizarin red solution in water for 2 minutes. Slides were blotted dry and then 
dehydrated in 100% acetone followed by an acetone-xylene solution (1:1) before clearing 
in 100% xylene, mounting with Cytoseal™ 60 mounting medium (Richard-Allan 
Scientific), and cover slipping. Brightfield images were acquired for quantification of 
positively stained EBs (red). 
 
Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-
PCR) 
For real-time PCR analysis, total RNA was extracted using the RNeasy Mini kit 
(QIAGEN, Valencia, CA). Complementary DNA was synthesized from 1 µg total RNA 
using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA), and quantitative PCR was 
performed with SYBR green technology on the MyiQ cycler (Bio-Rad). Amplification 
was performed using a two-step cycling program including 35 cycles, 1 minute/cycle. To 
assess EB osteogenic differentiation, primers for osteocalcin, bone sialoprotein, 
osteopontin, collagen type I, osterix, and Runx-2 were used, in addition to housekeeping 
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gene GAPDH.  MC3T3-E1 pre-osteoblast cells differentiated for 10 days with ascorbic 
acid were used as positive controls for primer validation and generation of standards. 
Gene expression was expressed as a fold change compared to undifferentiated ESCs and 
same day untreated EBs, calculated by the ΔΔCt method [149].  
 
Table 3.1 Primer sequences used for qRT-PCR analysis 
Gene Forward Reverse Annealing 
Temp 
osteocalcin CCGGGAGCAGTGTGAGCTTA TAGATGCGTTTGTAGGC GGTC 56°C 
bone 
sialoprotein 
CAGAGGAGGCAAGCGTCACT CTGTCTGGGTGCCAACACTG 54°C 
osteopontin GATGCCACAGATGAGGACCTC CTGGGCAACAGGGATGACAT 58°C 
collagen 
type I 
GCATGGCCAAAAGACATCC CCTCGGGTTTCCACGTCTC 56°C 
osterix AGCCTCTGGCTATGCAAATGA TGTAGACACTAGGCAGGCAGTCA 67°C 
Runx-2 GTGCGTGCAAACTTTCTCC AATGACTCGGTTGG TCTCGG 55°C 




Osteogenic Protein Expression 
 To measure alkaline phosphatase (ALP) specific activity, EB pellets were 
resuspended, vortexed, and incubated with substrate solution (3 mM p-nitrophenyl 
phosphate, 0.7 M 2-amino-2-methyl-1-propanol, 6.7 mM MgCl2, pH 10.3; Sigma, St. 
Louis, MO) for 30 min at 37 °C, and quenched by the addition of 0.2 M NaOH. The 
absorbance of reacted sample solutions were read at 405 nm wavelength on a Bio-Rad 
Benchmark plate reader, and the alkaline phosphatase specific activity was calculated 
using a standard curve generated with p-nitrophenol. 
Osteocalcin protein concentration in EB media conditioned for 24 hours was 
measured by a competitive radioimmunoassay (Biomedical Technologies Inc, Stoughton, 
MA) according to manufacturer protocol. Briefly, conditioned media samples were 
incubated at room temperature with 
125
I labeled osteocalcin and anti-osteocalcin antibody 
followed by secondary goat anti-rabbit IgG. After removing the supernatant, the 
radioactivity of the remaining pellet was measured and compared to a standard curve of 
known osteocalcin concentrations (1.5 – 200 ng/ml).   
 
Enzyme Linked Immunosorbent Assay (ELISA) 
For sandwich ELISAs, capture antibodies were adsorbed to wells of an 
immunosorbent 96-well plate. All samples (conditioned media or solubilized cell pellets) 
were centrifuged at 14,000 RPM for 5 minutes at room temperature to remove any 
insoluble material, and the supernatant was added to the antibody-adsorbed wells, 
followed by a biotinylated detection antibody and streptavidin-conjugated horseradish 
peroxidase (HRP). For the human BMP-4,  human VEGF-A ELISAs, human 
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osteoprotegrin, and human osteopontin (R&D Systems, Minneapolis, MN), a 
chromogenic HRP substrate (3,3’,5,5’-tetramethylbenzidine, TMB) was added and 
stopped by adding 1N sulfuric acid to produce a colorimetric result that was read at 
450nm.  For the human BMP-2 ELISA (PeproTech, Rocky Hill, NJ), the chromogenic 
substrate used was ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid), and 
color development was monitored at 405 nm with wavelength correction at 650 nm. 
Unknown values were compared to a standard curve generated from known 
concentrations of individual proteins in Tissue Protein Extraction Reagent (TPER, Pierce, 
Rockford, IL) buffer. Though the antibodies used were directed against human isoforms 
of each molecule, they are known to exhibit cross reactivity with their mouse 
counterparts as well. 
 
Western Blotting 
To assess extracellular signal-related kinase (ERK) signaling, EBs were collected 
at day 14 of differentiation for Western blot analysis, lysed by the addition of ice cold 
RIPA buffer (Pierce) supplemented with 500x protease inhibitor cocktail (Calbiochem, 
San Diego, CA) and 50x phosphatase inhibitor cocktail (Calbiochem), and stored at -
80°C. The insoluble fraction was pelleted at 16,000g for 10 minutes, and the protein 
concentration of the supernatant was determined by use of the BCA Protein 
Quantification Kit (Pierce). Equal amounts of protein (20 μg) per sample were mixed 
with loading buffer containing 0.1 M Tris-HCl, SDS, glycerol, biomophenol blue, and 2-
mercaptoethanol, incubated at 95°C for 5 minutes, and loaded on 4-20% Tris-HCl 
polyarcylamide precast gels (Bio-Rad) for electrophoresis. Proteins were transferred to 
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polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA) overnight at 4°C 
with 30V. Blots were stained using the Snap ID system (Bio-Rad). Membranes were 
blocked and with Near Infrared blocking medium (Rockland Immunochemicals, 
Gilbertsville, PA) and probed with anti-ERK, anti-pERK (1:250, Cell Signaling 
Technology, Danvers, MA), and anti-GAPDH (1:2000) antibodies overnight at 4°C 
before being pulled through by vacuum. Primary antibody incubation was followed by a 
continuous rinse under vacuum with 0.01% Tween-20 in PBS. Membranes were then 
incubated with infrared secondary antibody (1:5000, 800 anti-rabbit, Li-Cor Biosciences, 
Lincoln, NE) for 10 min at room temperature, rinsed, and imaged using the Odyssey 
Infrared Imager (Li-Cor). Blot images were converted to grayscale to obtain black protein 
bands on a white background in Image J (NIH, Bethesda, MD). Membranes were stripped 
prior to re-probing using 6 M guanidine HCl with 0.2% Triton-X  and 0.1 M 2-
mercaptoethanol at room temperature as described by Yeung and Stanley [150]. 
 
Micro-Computed Tomography (μCT) Evaluation of EB Mineralization 
To evaluate the mineralization within EBs, approximately 200-500 EBs were 
suspended in 200 µl of Histogel™ (Richard Allen Scientific) in a 10 mm by 10 mm vinyl 
specimen mold (Sakura Finetek, Torrance, CA). Reference images of EB samples were 
taken using a dissecting stereomicroscope (Nikon SMZ1500) to determine EB 
distribution within the gel. The samples were scanned in air
 
using a µCT 40 (Scanco 
Medical, Brüttisellen, Switzerland)
 
at 45 kVp, 177 µA, 200-ms integration time, and a 
voxel size
 
of 12 µm in a 12 mm scanning tube. Evaluation of µCT scans used sigma, 
support and threshold values set at 0.8, 1, and 70, respectively, setting for all samples 
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what was to be considered mineral volume. The total volume of mineralization within the 
entire Histogel-embedded samples was determined and normalized to estimated EB 
volume to calculate the average percentage of EB volume comprised of mineral. EB 
diameter was measured by phase contrast microscopy and used to calculate the average 
estimated volume of embedded EBs. 
 
Statistical Analysis 
Two-way ANOVA analysis, followed by Tukey’s post-hoc test, was performed to 
determine statistical differences (p<0.05), using Systat 12™ statistical software unless 
otherwise noted. If data did not approximate a normal distribution when first examined 
by exploratory data analysis, including five number data summary and box and whisker 
plot, Box-Cox estimations were used to transform the data set to a normal distribution, as 
reviewed by Spitzer [151]. Outliers were identified by examination of studentized t-
residuals. Based on power analysis after preliminary studies, sample sizes of n=3-8 were 
used as noted for individual assays. Results are reported as mean ± standard error of non-
transformed data for a minimum of triplicate independent samples from each experiment 
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CHAPTER 4 
PHOSPHATE INDUCED MINERALIZATION AND OSTEOGENIC 
DIFFERENTIATION OF MOUSE EMBRYONIC STEM CELLS* 
 
Introduction 
An important goal of regenerative medicine is to provide a source of cells with 
potential to proliferate, thereby increasing the available pool, and to differentiate into 
specific lineages of interest. Embryonic stem cells (ESCs) are pluripotent cells derived 
from the inner cell mass of a pre-implantation blastocyst [88, 92]. Not only can ESCs be 
maintained indefinitely as undifferentiated, self-renewing cells in culture under 
appropriate growth conditions without losing their pluripotent phenotype, but they have 
the unique ability to differentiate into cell types comprising all three germ lineages 
including osteoblasts (mesoderm), hepatocytes (endoderm), and neurons (ectoderm) [87, 
152-154]. In addition to their use in tissue engineering and regenerative therapies [155-
158], ESCs have also been used as an in vitro model to study early stages of cellular 
differentiation. ESCs spontaneously form three-dimensional cell aggregates called 
“embryoid bodies” (EBs) when grown in suspension culture conditions and differentiate 
into three lineages [89, 101, 159, 160]. EBs undergo morphogenic events similar to 
normal embryogenesis, and simultaneously yield cell types from endoderm, ectoderm, 
and mesoderm germ layers [161, 162]. Differentiation of ESCs and EBs to specific 
phenotypes can be induced by supplementing culture medium with specific stimulatory 
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or inhibitory agents and molecules [99, 163, 164]. Alternatively, multipotent adult stem 
cells, such as mesenchymal stem cells (MSCs), may be used to provide cells of specific 
lineages, as they also have the capacity to divide and differentiate into several cell 
phenotypes and are found in diverse tissues or organs.  
Although there are a number of protocols that promote the differentiation of ESCs 
and MSCs into osteoblasts, most studies indicate that this can be achieved by establishing 
an environment rich in phosphate, which results in formation of a mineralized 
extracellular matrix [165, 166]. The most commonly used osteogenic medium (OM) 
formulations contain β-glycerophosphate (βGP), dexamethasone, and ascorbic acid [167-
169]. Specifically, βGP, an organic phosphate, is cleaved by extracellular alkaline 
phosphatase upon addition to the culture media, serving as a source of inorganic 
phosphate (Pi). The ability of phosphate alone to induce mineralization and osteogenic 
differentiation has been demonstrated in multiple somatic cell types that exhibit the 
capacity to mineralize, including osteoblasts and vascular smooth muscle cells [43, 115], 
either by direct administration of inorganic phosphate or by addition of βGP. Both 
phosphate-induced mineralization and differentiation of these cells have been inhibited 
by phosphonoformic acid (PFA), thought to block phosphate transport into cells, 
specifically through Type III Na, Pi co-transporters (PiT-1), suggesting that phosphate 
needs to enter the cell for these phenotypic changes to occur [43, 115]. Additionally, 
phosphate-induced differentiation has been found to be mediated through activation of 
the mitogen activated protein kinase (MAPK) pathway, specifically extracellular signal 
regulated kinase (ERK 1/2) [43, 107, 116],through activation of Runx-2, an early 
osteoblast transcription factor that regulates the osteogenic phenotype [117].  
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Some studies have also shown that addition of the vitamin D metabolite 1α,25-
dihydroxy vitamin D3 [1α,25(OH)2D3] to osteogenic medium enhances osteoblastic 
differentiation of stem cells [170, 171]. 1α,25(OH)2D3 plays an important role in calcium 
and phosphate homeostasis and both catabolic and anabolic effects of this hormone have 
been demonstrated in bone cells [172]. Moreover, 1α,25(OH)2D3 regulates the expression 
of bone marker genes like Runx-2, collagen type I, osteocalcin (Ocn) and bone 
sialoprotein in osteoblasts [137, 173], indicating that it plays a role in their 
differentiation. Effects of 1α,25(OH)2D3 in osteoblasts are mediated by two vitamin D 
receptors, the nuclear receptor (VDR) [137]and a membrane-associated 1α,25(OH)2D3-
binding protein called protein disulfide isomerase A3 (PDIA3, also known as ERp60, 
ERp57, Grp58, and 1,25-MARRS) [138-140].  
Previous studies have focused primarily on directing differentiation of ESCs in 
two dimensional, adherent culture but more recently have attempted osteogenic 
differentiation of encapsulated cells [38, 174] and EBs [175-177]. Further investigation 
of the mineralization and differentiation processes as they occur in three dimensions, 
which more closely recapitulates in vivo environment, will provide a better understanding 
of bone development and regeneration not only as they occur in utero but also in 
emerging cellular therapies by identifying endogenous differentiation cues and cell-
microenvironment interactions that are present. Therefore, additional characterization of 
the mineralization process as it occurs within the three dimensional and more primitive 
environment of EBs may provide insights into the initial differentiation associated with 
the earliest stages of bone development, which are not evident from studies employing 
more terminally differentiated pre-osteoblast and osteoblast-like cell lines.  
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The objective of this study was to assess the mineralization capacity of 
differentiating mouse ESCs and to examine the accompanying differentiation process 
induced by phosphate treatment. As further assessment of osteogenic phenotype, the 
response to exogenous 1α,25(OH)2D3 was also examined. To assess whether phosphate 
treatment can induce osteogenic differentiation of ESCs as has been observed in more 
committed cell types with osteogenic potential, EBs were cultured with βGP, a source of 
inorganic phosphate. First, mineralization was evaluated and quantified given this 
minimal substrate based on phase images, histological staining, and micro-computed 
tomography. Next, to evaluate accompanying osteogenic differentiation in the presence 
of the mineralization process, ERK 1/2 signaling in response to phosphate treatment was 
evaluated, and the expression of specific osteogenic marker genes activated downstream 
of this signaling was quantified. In addition, we characterized how this phosphate 
induced differentiation was associated with differential expression and responsiveness of 
two 1α,25(OH)2D3 receptors, PDIA3 and VDR. In this study, EBs provide a model for 
interrogating the interplay between differentiating cells and their microenvironment, 
including mineralization, extracellular matrix, and associated growth factors, during the 
earliest stages of bone development, lending novel insights into the potential interactions 
between the processes of mineralization and differentiation. 
 
Materials and Methods 
Mouse ESC culture and EB formation 
Undifferentiated mouse ESCs (D3 line) were grown and maintained in the 
undifferentiated state on tissue culture dishes coated with 0.1% gelatin with the addition 
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of leukemia inhibitory factor (LIF). EBs were formed from single cell suspensions of 2 x 
10
5
 cells/ml in ESC medium without LIF and formed on rotary orbital shakers at 40 
rotations per minute as described previously (see Chapter 3 – General Methods) [147]. 
 
EB osteogenic differentiation 
EBs were supplemented with 0, 2.5, 5, and 10 mM βGP from day 5 of suspension 
culture onward (MP Biomedical, Solon, OH). Phase images of EBs in each βGP 
treatment group were taken throughout the duration of the experiments (up to 14 days of 
differentiation) and were analyzed using Metamorph™ software (v. 7.5, Molecular 
Devices, Sunnyvale, CA).  Mineral deposits were visualized as dark, irregularly shaped 
deposits compared to surrounding cells and media by phase contrast. EBs exhibiting 
characteristics of mineral deposition were identified by the software based on brightness, 
and the percentage of EBs containing mineral accumulation was determined. 
 
Histology 
EBs were collected, fixed in 10% formalin solution, rinsed in PBS, and embedded 
in Histogel (~200 EBs in 200 μl gel; Richard Allen Scientific, Kalamazoo, MI) before 
paraffin processing and embedding. Mineralization was assessed by von Kossa and 
Alizarin red staining. Slides were imaged using a Nikon 80i Upright Microscope, and 
digital brightfield images were acquired for quantification of positively stained EBs (see 
Chapter 3 – General Methods). 
 
Micro-computed tomography (μCT) 
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Approximately 200-500 day 14 EBs were suspended in 200 µl of Histogel™ 
(Richard Allen Scientific). Reference images of EB samples were taken, and samples 
were scanned in air
 
using a µCT 40 (Scanco Medical, Brüttisellen, Switzerland)
 
at 45 
kVp, 177 µA, 200-ms integration time, and a voxel size
 
of 12 µm in a 12 mm scanning 
tube. Evaluation of µCT scans used sigma, support and threshold values set at 0.8, 1, and 
70, respectively. The total volume of mineralization within each entire Histogel-
embedded sample was determined and normalized to estimated EB volume to calculate 
the average percentage of mineralization (see Chapter 3 – General Methods). 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
For real-time PCR analysis, total RNA was extracted from undifferentiated ESCs 
or EBs after 7 and 14 days of differentiation. Complementary DNA was synthesized, and 
quantitative PCR was performed with SYBR green technology on the MyiQ cycler (Bio-
Rad). Primers for osteocalcin, bone sialoprotein, collagen type I, osterix, and Runx-2 
were used to assess osteogenic differentiation, in addition to housekeeping gene GAPDH 
(see Chapter 3 – General Methods, Table 3.1). Gene expression was examined to 
determine if levels of mRNA for several other key proteins were sensitive to osteoblastic 
differentiation. VDR and PDIA3 are receptors for 1α,25(OH)2D3; osteoprotegerin (OPG) 
is secreted by differentiated osteoblasts [178]; osteopontin is a 1α,25(OH)2D3-sensitive 
extracellular matrix protein that possesses a VDRE [179] and is regulated via PDIA3 
[126]; and α2β1 integrin expression is associated with osteoblast differentiation through 
collagen type 1 recognition [9, 10]. Expression of mRNA was measured for mouse Vdr, 
Pdia3, Tnfsf11 (the gene that codes for osteoprotegerin), osteopontin (Opn), integrin 
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alpha 2 (Itga2), and integrin beta 1 (Itgb1) (primer sequences listed in Table 4.1). Pit-1 
expression was verified by conventional PCR of cDNA samples with 35 cycles using 
GoTaq Flexi DNA Polymerase (Promega, Madison, WI). 
 
Table 4.1. Primer sequences used in qRT-PCR analysis. 
Vdr 
F AGG CAG GCA GAA GAG ATG AG 
R AGG GAT GAT GGG TAG GTT GTG  
Pdia3 
F CCA ATG ATG TGC CTT CTC 
R TGT GCC TTC TTC TTC TTC 
Tnfsf11 
F CGC CAA CAT TTG CTT TCG 
R TGC TCC CTC CTT TCA TCA 
Opn 
F AAC TCT TCC AAG CAA TTC C 
R TCT CAT CAG ACT CAT CCG 
Itga2 
F ACT GTT CAA GGA GGA GAC 
R GGT CAA AGG CTT GTT TAG G 
Itgb1 
F ATT ACT CAG ATC CAA CCA C 
R TCC TCC TCA TTT CAT TCA TC 
Gapdh  
F TTC AAC GGC ACA GTC AAG G 
R TCT CGC TCC TGG AAG ATG G 
Pit-1 
F CAC CCA TAT GGC TTC TGC TT 
R CAG GAA TTC ATA GCC CAG GA 
 
Immunohistochemistry 
Immunohistochemistry was performed to assess the distribution of PDIA3 and 
VDR in the EBs. EBs were fixed in 10% formalin, embedded in Histogel (Richard Allen 
Scientific, Kalamazoo, MI), processed, and embedded in paraffin. For each sample, 5µm 
sections were taken every 50µm and affixed to positively charged glass slides. 
Deparaffinized slides were used for staining. Samples were stained with antibodies 
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against PDIA3 and VDR, with Alexa Fluor 488 phalloidin (Invitrogen) to stain actin 
filaments, and DAPI to stain the nucleus (Invitrogen). 
 
Osteogenic protein production 
In addition to verifying that the EBs expressed mRNAs for proteins associated 
with osteoblastic differentiation, immunoassay was used to quantify production of 
secreted proteins. After 14 days culture in control medium or medium supplemented with 
βGP, EBs were treated for 24h with 10 nM 1α,25(OH)2D3 (Enzo Life Sciences, Plymouth 
Meeting, PA). The dose of 1α,25(OH)2D3 was based on previous studies examining the 
effects of the vitamin D metabolite on differentiation of ESCs into mineralizing 
osteoblasts [105]. Osteocalcin in the conditioned medium was measured using a 
commercially available radioimmunoassay (Biomedical Technologies, Inc., Stoughton, 
MA). Osteoprotegerin and osteopontin in the conditioned media were measured using 
commercially available ELISAs, according to manufacturer’s specifications (DuoSet, 
R&D Systems, Minneapolis, MN, ).In EBs, levels of secreted proteins in conditioned 
media were normalized to total DNA content (Quant-iT PicoGreen Assay, Invitrogen). 
EBs were then lysed in 0.05% Triton X-100 and alkaline phosphatase specific activity 
was measured as the release of p-nitrophenol from p-nitrophenylphosphate at pH 10.2. 
Alkaline phosphatase specific activity in the cell pellet was normalized to total protein 
content (Pierce BCA Protein Assay, Thermo Fisher, Rockford, IL) [180]. 
 
Protein Kinase C assay 
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 PKC activity was measured in response to 1α,25(OH)2D3 in order to determine if 
PDIA3 was functional. EBs were cultured as above until day 14. Based on previous 
studies showing that 10 nM 1α,25(OH)2D3 causes rapid PDIA3-dependent activation of 
PKC in mouse osteoblasts within 9 minutes [126], both cell types were then treated for 9 
minutes with either 0.01% ethanol (vehicle) or 10 nM 1α,25(OH)2D3. After incubation, 
EBs were spun for 3m at 2000xg, the medium removed, and lysed in 1ml cold RIPA 
buffer (20mM Tris-HCl, 150mM NaCl, 5mM disodium EDTA, 1% Nonadet P-40). PKC 
activity was measured using a commercially available assay kit (GE Biosciences, 
Piscataway, NJ) and results normalized to total protein content of the lysates as described 
above. 
 
Human mesenchymal stem cells 
The expression of receptors for 1α,25(OH)2D3 in EBs was compared to 
expression in human mesenchymal stem cells (MSCs, Lonza Walkersville, Walkersville, 
MD) during osteoblastic differentiation. MSCs were cultured in MSC growth medium 
(GM, Lonza Walkersville) or hMSC Osteogenic BulletKit (OST, Lonza Walkersville) for 
14 days. Western blots were performed for VDR, PDIA3, and GAPDH as described 
above. Effects of 1α,25(OH)2D3 on differentiation were assessed as a function of alkaline 
phosphatase specific activity, and osteocalcin and osteoprotegerin production. MSCs 
cultured for 14 days in GM or OST. 1α,25(OH)2D3 (10 nM) was added to the cultures for 
an additional 24h and the conditioned medium was collected. Enzyme activity was 
measured in cell lysates. Secreted proteins were normalized to total cell number (Z2 Cell 
Counter, Beckman Coulter, Hercules, CA). 
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Presence of functional PDIA3 was determined by assessing 1α,25(OH)2D3-
dependent PKC activity. MSCs were cultured in growth medium until confluence. Cells 
were treated with 1α,25(OH)2D3 for 15 minutes, and lysed in RIPA immediately after 
treatment. PKC was assayed as described above. 
 
Western blotting 
EBs were collected at day 14 of differentiation for western blot analysis of ERK 
pathway activation. Membranes were probed with anti-ERK, anti-pERK (1:250, Cell 
Signaling Technology, Danvers, MA), and anti-GAPDH (1:2000) antibodies. Membranes 
were then incubated with infrared secondary antibody (1:5000, 800 anti-rabbit, Li-Cor 
Biosciences, Lincoln, NE), and imaged using the Odyssey Infrared Imager (Li-Cor) (see 
Chapter 3 – General Methods). 
Additional Western blots of VDR and PDIA3 were performed to validate the 
presence of these proteins in the EBs. Treated EBs were lysed in 300µl RIPA buffer and 
resolved on 4-20% Tris glycine gels (LongLife, NuSep, Bogart, GA) using gel 
electrophoresis. Proteins were transferred from the gel onto a nitrocellulose membrane 
using the iBlot® Dry Blotting transfer method (Invitrogen, Carlsbad, CA). Membranes 
were then incubated overnight using specific primary antibodies against PDIA3 (sc-
18620, Santa Cruz Biotechnology, Santa Cruz, CA), VDR (sc-1008, Santa Cruz 
Biotechnology) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH, MAB374, 
Millipore, Billerica, MA). After primary antibody incubation, membranes were then 
incubated in 1% BSA in PBS with either goat anti-rabbit or goat anti-mouse horseradish 
peroxidase-conjugated secondary antibodies (Bio-Rad Laboratories) for one hour. Blots 
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were developed using SuperSignal West Pico Chemiluminescent System (Thermo Fisher 
Scientific, Rockford, IL). Membranes were imaged using VersaDoc imaging system 
(Bio-Rad Laboratories). Pixel intensity of bands was quantified using Quantity One 
Software (Bio-Rad Laboratories) and normalized to pixel intensity of GAPDH. 
 
Statistical analysis 
Two-way ANOVA analysis, followed by Tukey’s post-hoc test, was performed to 
determine statistical differences (p<0.05), using Systat 12™ statistical software unless 
otherwise noted. Results are reported as mean ± standard error of the mean for a 
minimum of triplicate experiments from each experiment unless otherwise noted; a 
minimum of two independent experiments were analyzed by each of the assays 
described.  
For 1α,25(OH)2D3 experiments, each data point is the mean + standard error for 
six independent cultures, with the exception of the mRNA expression experiment, where 
n=4. The data shown for the mRNA analyses are ratios of the mRNA for the gene of 
interest to Gapdh rather than treatment/control ratios to enable analysis of experimental 
variability. Data were analyzed by analysis of variance and significant differences 
between groups determined using Bonferroni’s modification of the Student’s t-test. 
P<0.05 was considered to be significant.  
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Results 
Mineralization within EBs 
D3 ESC derived EBs were cultured in media supplemented with 10 mM βGP as a 
phosphate substrate to assess the endogenous mineralization capacity of differentiating 
EBs. Small von Kossa positive foci of mineral deposits were apparent by day 10 of 
differentiation within βGP treated EBs, but were not readily apparent in untreated 
cultures, and the mineral accumulations increased in size and number per EB through day 
14, while untreated samples exhibited little positive staining (Fig. 4.1 A). EBs cultured 
with lower concentrations of βGP (1, 2.5, and 5 mM) were additionally examined and 
each dose exhibited an increase in mineralization throughout the EB populations over the 
14 day differentiation, but less prominent than at 10 mM, with smaller mineralized 
regions and fewer mineral deposits per EB, assessed by light microscopy (Fig. 4.2 A). 
Therefore, all subsequent experiments were carried out comparing untreated EBs with 10 
mM βGP treated EBs, which was also equivalent to concentrations used in common 
osteogenic differentiation methods for both mesenchymal stem cells and ESCs [105, 108, 
181]. The presence of calcium phosphate, as seen in bone, was verified by staining serial 
sections of EBs with von Kossa and Alizarin red. Previous studies have suggested that 
the use of one characterization technique alone may not be sufficient to demonstrate 
calcium phosphate deposition in vitro since each stains independently for either calcium 
(Alizarin red) or phosphate (von Kossa) species [37]. EBs at day 14 contained 
overlapping areas that stained positive for both von Kossa (in black) and Alizarin red (in 
red), therefore indicating that the mineral deposits were composed of calcium and 
phosphate (Fig. 4.1 B). Equivalent percentages of βGP-treated EBs contained regions of 
positive staining for each stain (60.2 ± 15.6% von Kossa positive, 40.0 ± 17.6% Alizarin 
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red positive), with minimal staining (< 7%) present in untreated samples (p<0.001, t-test) 
(Fig. 4.1 C). To test whether the formation of mineral deposits was limited to the ESC 
cell type used (D3), another mouse ESC line (R1) was used, and similar mineralization 
was also observed (Figure 4.2 B). Based on histological analysis, βGP treated D3 EBs 
produce calcium phosphate mineralization that increases throughout differentiation, 
however further quantification of mineralization was undertaken because histological 




Figure 4.1. Calcium phosphate deposition within EBs. Von Kossa staining of EBs 
differentiated with βGP increased in EBs/ population and per EB compared to untreated 
samples (A). Further histological analysis of serial sections of untreated and treated 
embryoid bodies demonstrated that the deposits stained positively by both von Kossa and 
Alizarin red staining (B). Quantification of both von Kossa and Alizarin red staining by 
image analysis demonstrated equivalent increases in both stains with treatment at day 14 
(C) (n=3 cultures, t-test, *p<0.001). (Scale bar in A = 100 µm, B = 50 µm, C = 500 µm). 
 44 
 
Figure 4.2. Mineral deposits within EBs. Phase imaging and von Kossa staining of EBs 
differentiated with varying concentrations of βGP demonstrated a dose response with 
increasing βGP (A). Mineral deposit formation occured with 10 mM βGP treatment of R1 
line mouse ESCs, similar to that observed in D3 line ESCs used primarily in this study. 
(Scale bar in A and B = 100 µm, C = 50 µm). 
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The overall mineralization within EB populations was further analyzed by 
quantifying the percentage of EBs with regions of mineralization. Mineralization was 
observed by phase contrast as dark, irregularly shaped regions within treated EBs (Fig. 
4.3 A, B). The overall mineral deposition at day 10 throughout the treated EB population 
was greater than had been apparent based on histological analyses. The percentage of 
EBs with mineral deposits significantly increased in βGP treated EBs at days 10 (75.5 ± 
3.9%, p<0.001) and 14 (84.3 ± 3.8%, p<0.001) compared to untreated samples (<10%) 
(Fig. 4.3 A, C). This was in good agreement with the histological analysis (Fig. 4.1 A). 
Based on the distribution of EB sizes, measured in Metamorph™ image analysis 









 untreated, p<0.001, t-test) (Fig. 4.3 D, E).  The 
degree of mineralization of EBs, defined as the number of mineralized EBs compared to 
total number of EBs of the same size, remained at this same level across the distribution 
of EB sizes, with between 70-100% of treated EBs containing mineral deposits at any 
given size (Fig. 4.3 D, E). However, the presence of mineralization within untreated EBs 
remained low (<15%) across all EB sizes. Based on stains for calcium and phosphate and 
phase images of differentiating EBs, mineralization occurs within EBs with βGP 
treatment, and mineral deposits increase in size and number through the duration of 
treatment in this study. 
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Figure 4.3. Quantification of mineralization. βGP treated EBs accumulate mineral 
deposits much more readily and abundantly than untreated samples based upon phase 
contrast images (A). EBs were treated with 10 mM βGP from day 5-14 of differentiation. 
Mineral accumulation within the EBs, visualized by phase contrast as dark regions within 
EBs, were observed abundantly in treated EBs but not untreated EBs (B). The percentage 
of the total, treated population with mineral accumulation increased significantly by day 
10 of EB culture (n=3 cultures, two-way ANOVA, Tukey’s post-hoc test, p<0.001) (C). 
The percentage of EBs that exhibited mineral accumulation (grey overlay bars) within 
treated EBs was consistent across the distribution of EB sizes observed, though average 
EB size was smaller with treatment (n=3 cultures, t-test, p<0.001) (D,E). (Scale bar in A 
= 200µm, scale bar in B = 100 µm) 
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µCT analysis of mineral deposition 
While the histological assessments used have allowed for the identification and 
localization of the EB mineralization, μCT allows for the quantification of mineralization 
volume in three dimensions [182]. µCT also provided the added benefit of enabling one 
easily to assess the mineralization within an entire population and to quantify this volume 
of mineralization for comparison across treatment groups in a non-destructive manner. 
This imaging technique has been routinely used to assess mineralization and bone 
formation within in vivo applications [183]. μCT analysis was performed on day 14 of 
differentiation because previous histological and phase analyses illustrated that mineral 
deposits were present within the resolution of μCT. Images of the Histogel™-embedded 
EBs were first taken using a stereomicroscope to verify comparable numbers of EBs were 
loaded in each sample and to determine the distribution of the EBs within the gels (Fig. 
4.4 Ai, Aiii). The volume of mineralization determined by µCT was normalized to the 
total calculated volume of EBs loaded into each gel. Treatment with βGP resulted in a 
greater amount of radio-opaque material than in untreated samples, as seen by scans of 
day 14 EB samples (Fig. 4.4 Aii, Aiv). Abundant mineralization was evident in EBs with 
βGP treatment (31.06 ± 9.66%), but was significantly less in EBs without 
supplementation (0.06 ± 0.02%) (p<0.05, t-test). The mineral deposits from µCT images 
at higher magnifications (regions indicated within boxes) overlapped within the 
respective regions containing EBs imaged by stereomicroscopy (Fig. 4.4 B). µCT 
provided visualization and quantitative analysis of the mineralization deposits within EBs 
in three-dimensions, and in this study, presented further evidence of the calcium 




Figure 4.4. Quantification of mineralization by µCT. An equivalent number of 
Histogel embedded, day 14 EBs, first imaged by stereomicroscope (-βGP (A i) and +βGP 
(A iii), were analyzed by µCT to assess degree of mineralization. The percentages of 
mineralized volume, normalized to EB volume, were found to be 31.06 ± 9.66% for 
treated EBs (A ii) vs. 0.06 ± 0.02% for untreated EBs (A iv) (t-test, p<0.05,  n = 3 
samples). EBs and mineral deposits overlap in stereoscope (B top) and µCT (B middle) 
images (regions indicated by boxes) (merge – B bottom). (Scale bar in A = 1mm, scale 
bar in B = 100 µm) 
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Phosphate induced signaling 
 Because phosphate transport has been suggested to be necessary for matrix 
mineralization and to induce osteogenic differentiation, the gene level expression of the 
Na, Pi co-transporter PiT-1 was assessed. Pit-1 has been found to be ubiquitously 
expressed at the message level, but its expression and not that of the related Na,Pi co-
transporter, Pit-2, has been demonstrated to be increased during the course of osteoblast 
differentiation in MC3T3-E1 cells [118]. Additionally, phosphate transport through PiT-1 
is required for matrix mineralization to occur [119, 120, 124]. Undifferentiated ESCs 
express mRNA for Pit-1, and maintain expression through day 14 of EB differentiation, 
regardless of βGP treatment (Fig. 4.5 A). qRT-PCR for Pit-1 was also performed and 
confirmed that gene expression remained constant throughout EB differentiation and was 
the same as differentiated MC3T3-E1 controls (Fig. 4.5 B). 
 Phosphate induced osteogenic differentiation, which accompanies mineralization 
in response to phosphate treatment, has been found to occur through ERK 1/2 pathway 
signaling [107, 116], so ERK phosphorylation in βGP treated EBs was assessed. βGP 
treated EBs exhibited an increase in the ratio of phosphorylated to non-phosphorylated 
ERK at day 14 compared to untreated EBs. The finding by Western blot was in good 
agreement with the increased mineralization observed earlier, suggesting enhanced 




Figure 4.5. Phosphate transport and signaling. At the gene level, ESCs differentiated 
as EBs express the Type III Na,Pi co-transporter, Pit-1, which permits the entry of Pi into 
cells (A). No difference in Pit-1 expression was observed by qRT-PCR throughout EB 
differentiation with or without βGP compared to MC3T3-E1 cells (n=3, two-way 
ANOVA, Tukey’s post-hoc test). When βGP was provided in the culture media, the ratio 
of pERK to ERK was increased (C). Western blot samples were collected at day 14 of EB 
differentiation and are shown in triplicate. 
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Osteogenic gene expression 
Based on the observed time course for mineralization within differentiating EBs, 
osteogenic marker gene expression was assessed at days 7 and 14 of differentiation. 
Previous work in our lab has demonstrated that by day 5 of EB suspension culture, the 
expression of mRNA for Brachyury T, an early, transient mesoderm transcription factor, 
was increased compared to undifferentiated ESCs, confirming initial mesoderm 
differentiation, corresponding to the time when βGP administration was initiated in this 
study [184]. At day 7 of EB culture (two days after beginning βGP supplementation), no 
significant changes in the gene expression of osteogenic markers were found with βGP 
supplementation compared to both undifferentiated ESCs and untreated EBs. However by 
day 14 of EB differentiation, the expression level of several osteogenic marker genes 
were significantly increased with βGP treatment, in conjunction with the observed 
increase in EB mineralization and ERK phosphorylation (Fig. 4.6). The expression level 
of osteogenic transcription factor Runx-2 increased 9-fold with βGP treatment compared 
to untreated EBs (p<0.05), and since mineralization was known to be mediated by 
interactions with the extracellular matrix, the expression of genes encoding several 
osteogenic matrix proteins was also quantified. The gene expression was increased for 
bone sialoprotein (14-fold, p<0.05), and osteocalcin (9-fold, p<0.05) in βGP treated EBs 
compared to untreated EBs (Fig. 4.6). However, the expression of collagen-I and osterix, 
an osteogenic transcription factor expressed downstream of Runx-2, did not increase with 
treatment over the 14 day time course of this experiment. Additionally, the observed 
increase in osteogenic gene expression corresponded with the increases in mineralization 
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Figure 4.6. Osteogenic gene expression. The expression of several osteoblast marker 
genes was assessed by RT-PCR. The expression of the gene for the osteoblast 
transcription factor, RUNX-2, along with genes encoding several bone matrix proteins, 
including bone sialoprotein (BSP) and osteocalcin (OCN), were increased with βGP 
treatment by day 14. Osterix (OSX), and collagen-I (Coll-I) were unchanged. No 
differences between treated and untreated EBs were observed at Day 7 (t-test, # p<0.05, n 
= 3 samples). 
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Vitamin D receptor expression 
To further characterize the osteogenic differentiation, vitamin D receptor 
expression at the gene and protein levels were then determined. EBs expressed mRNAs 
for VDR and PDIA3 and expression of each receptor mRNA was differentially regulated 
(Fig 4.7). After 7 days of differentiation, expression of Vdr was higher in EBs cultured in 
medium supplemented with βGP when compared to control medium (Fig. 4.7 A); this 
effect was more pronounced after 14 days. Expression of Pdia3 was similar at days 0 and 
7 in both media (Fig. 4.7 B). After 14 days, expression of Pdia3 in control cells was 
higher than at day 0 or day 7, but 14 days of culture in the presence of βGP decreased 
expression of Pdia3.  
The presence of both vitamin D receptors was confirmed using Western blot (Fig. 
4.7 C). The ratio of VDR/GAPDH increased from day 0 to day 14 in both control and 
βGP culture groups (Fig. 4.7 C, D). In contrast, PDIA3/GAPDH decreased at 14 days in 
cultures grown in medium containing βGP compared to day 0 (Fig. 4.7 C, E). The 
presence of PDIA3 and VDR was also demonstrated by immunofluorescence staining 
(Fig. 4.7 F). VDR and PDIA3 were distributed throughout the cell aggregates in control 
cultures after 14 days (Fig. 4.7 F, left panels). However, EBs cultured with βGP had more 
VDR staining and less PDIA3 staining (Fig. 4.7 F, middle panels), an effect more evident 
at higher magnification (Fig. 4.7 F, right panels; 100x). 
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Figure 4.7. Evaluation of vitamin D receptors in mouse EBs. Embryoid bodies were 
cultured with control medium or medium supplemented with β-glycerophosphate (BGP). 
Real-time qPCR was performed on samples at embryoid body formation (day 0), or after 
7 or 14 days in culture. mRNA expression of Vdr (A) and Pdia3 (B) were measured and 
are presented as normalized to GAPDH. *p<0.05, vs. day 0; #p<0.05, vs. control. VDR 
and Pdia3 proteins were analyzed by Western blot using GAPDH as a reference (C). 
Ratios of VDR/GAPDH (D) and PDIA3/GAPDH (E) were calculated using pixel 
intensity of Western blot bands. *p<0.05, vs Day 0. Immunofluorescent staining of 
embryoid bodies was performed for VDR and Pdia3 after 14 days culture in control 
medium or medium supplemented with BGP (F). Cells were stained for β-actin (red), 
DAPI nuclear staining (blue) and antibodies against either VDR or Pdia3 (green) and 
imaged at 63x or 100x magnification. 
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Responsiveness to 1α,25(OH)2D3 stimulation 
 Changes in markers associated with osteogenic differentiation showed that EBs 
cultured in medium containing βGP exhibited an osteoblast-like phenotype and were 
more responsive to 1α,25(OH)2D3 than untreated cells. DNA content of EBs was similar 
among groups, independent of treatment (Fig. 4.8 A). In cells cultured in control medium, 
alkaline phosphatase specific activity was unaffected by 1α,25(OH)2D3 treatment (Fig 4.8 
B). However, culture with βGP stimulated alkaline phosphatase specific activity, and this 
effect was enhanced by 1α,25(OH)2D3 (Fig. 4.8 B). Osteocalcin (Fig. 4.8 C), 
osteoprotegerin (Fig. 4.8 D), and osteopontin (Fig. 4.8 E) were equally stimulated by 
1α,25(OH)2D3 or βGP treatment alone. Culture with βGP followed by 1α,25(OH)2D3 
treatment stimulated greater osteocalcin and osteopontin secretion than 1α,25(OH)2D3 
alone.  
 This treatment regime also affected expression of other genes. In EBs cultured in 
control medium, Tnfsf11 mRNA expression was upregulated after 1α,25(OH)2D3 
treatment in comparison to control cultures (Fig. 4.9 A). This effect was more robust 
when cells were cultured in medium containing βGP. Opn expression was not affected in 
cells cultured in medium with βGP or in control cultures treated with 1α,25(OH)2D3 (Fig. 
4.9 B). However, expression increased when EBs that had been grown in osteogenic 
medium were treated with 1α,25(OH)2D3. Itga2 mRNA was higher in cells cultured with 
βGP and treated with 1α,25(OH)2D3 than control cells (Fig. 4.9 C). 1α,25(OH)2D3 
stimulated Itgb1 expression in control medium and expression was also higher in 
osteogenic medium compared to control medium. There was a synergistic increase in 
expression in cultures grown in osteogenic medium and then treated with the vitamin D 
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metabolite (Fig. 4.9 D). With respect to phosphate treatment alone, osteogenic marker 
and matrix proteins were upregulated by βGP treatment, paralleling results observed in 
gene level assessments, suggesting that providing the minimal substrate to induce 
mineralization was sufficient to alter and influence differentiation but that additional 
inductive signals were required for more directed commitment to the osteogenic lineage 
by cells within EBs. 
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Figure 4.8. Osteogenic phenotype of mouse EBs. Embryoid bodies were cultured for 14 
days in medium or medium supplemented β-glycerophosphate (BGP). EBs were then 
treated with 0.01% ethanol or 1α,25(OH)2D3 for 24h. DNA content (A) and alkaline 
phosphatase specific activity (B) were measured in cell lysates. Secreted osteocalcin (C), 
osteoprotegerin (D), and osteopontin (E) were measured in the conditioned medium. 
*p<0.05, vs. control; #p<0.05, vs. 1α,25(OH)2D3. To assess rapid, membrane-initiated 
signaling, protein kinase C activity was measured in EBs treated with 0.01% ethanol or 




Figure 4.9. Osteogenic gene expression of mouse EBs. Embryoid bodies were cultured 
for 14 days in medium or medium supplemented with β-glycerophosphate (BGP). EBs 
were then treated with 0.01% ethanol or 1α,25(OH)2D3 for 12h. Expression of Tnfsf11 
(A), osteopontin (Opn, B), Itga2 (C), and Itgb1 (D) were measured by real-time qPCR. 
Gene expression was normalized to expression of Gapdh mRNA per 1 ug RNA. *p<0.05, 
vs. control; #p<0.05, vs. 1α,25(OH)2D3.  
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Finally, to evaluate whether the effects of 1α,25(OH)2D3 on EBs were a general 
property associated with multipotent cell osteogenic differentiation, receptor expression 
and responsiveness to 1α,25(OH)2D3 were tested in MSCs. Human MSCs exhibited 
differential levels of VDR and PDIA3 when cultured in GM or OST in a manner 
comparable to EBs. VDR in cell lysates was higher in cells cultured in OST than in GM 
(Fig. 4.10 A, B) and PDIA3 was similar in cells cultured in GM and OST (Fig. 4.10 A, 
C). Levels of alkaline phosphatase specific activity (Fig. 3.11 A), osteocalcin (Fig. 4.11 
B), and osteoprotegerin (Fig. 4.11 C) were higher in cells cultured in OST than in cells 
cultured in GM.  
 PDIA3 was functional in both EBs (Fig. 4.8 F) and in MSCs (Fig. 4.11 D).  PKC 
activity was comparable in control EB cultures and in EB cultures grown in medium 
containing βGP. 1α,25(OH)2D3 treatment caused a rapid increase in PKC activity in EBs 
cultured in both medium but the effect was 50% greater when EBs were grown in 
osteogenic medium. Similarly, 1α,25(OH)2D3 treatment caused a rapid increase in PKC 
activity in cultures of MSCs. 
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Figure 4.10.  Western blot of Vitamin D receptors in human MSCs. MSCs were 
cultured with growth medium (GM) or osteogenic medium (OST) for 14 days as 
described. Western blots against VDR and PDIA3 were performed. (A) Western blots of 
MSC lysates against VDR, PDIA3, and GAPDH. Calculated ratios of VDR/GAPDH (B) 
and PDIA3/GAPDH (C) using pixel intensity of Western blot bands. *p<0.05, vs. GM. 
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Figure 4.11. Osteogenic phenotype of human MSCs. MSCs were cultured in growth 
medium (GM) or osteogenic medium (OST) for 14 days. MSCs were treated with fresh 
medium for 24h. Alkaline phosphatase specific activity (A) was measured in the cell 
lysates. Levels of secreted osteocalcin (B) and osteoprotegerin (C) were measured in the 
conditioned medium. *p<0.05, vs. control; *p<0.05, vs. GM. To assess rapid, membrane-
initiated signaling, protein kinase C activity was measured after 9 minutes treatment with 
0.01% ethanol or 1α,25(OH)2D3 (D). *p<0.05, vs. control; #p<0.05, vs. 1α,25(OH)2D3.  
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Discussion 
This study demonstrated that ESCs mineralize and undergo osteogenic 
differentiation when cultured with an inorganic phosphate source and that the observed 
differentiation was characterized by changes in vitamin D receptor expression and 
responsiveness. Though previous studies have suggested enhanced osteogenic 
differentiation in adherent, two dimensional culture systems [185, 186], βGP treated EBs 
produced mineralization, which was also accompanied by an induction of ERK signaling 
and osteogenic differentiation, demonstrated at the message and protein levels.  
Calcium phosphate containing mineral deposits were formed in βGP treated EBs, 
as demonstrated by von Kossa and Alizarin red staining, the combination of which 
provide stronger evidence for calcium-phosphate deposition, as opposed to precipitation 
of calcium or phosphate individually out of solution [37]. Phase contrast microscopy and 
µCT were used to more thoroughly quantify the observed mineralization in addition to 
histological analysis. Analysis of mineralization by phase contrast also allowed for the 
study of the correlation between EB size and mineralization. The rotary culture method of 
EB formation method employed here can be used to form EBs of more uniform size than 
static culture, limiting variability in EB size that may impact differentiation [147]. The 
size distribution of EBs with mineral deposits matched that of the entire EB population, 
suggesting no tendency for EBs of a particular size being more or less likely to 
mineralize. However, it was noted that EB size within the entire βGP treated population 
was significantly smaller than in the untreated EB population. Potentially, this 
observation mimics in vivo and in vitro osteoblast differentiation, in which a shift to 
matrix production and matrix mineralization results in decreased proliferation[4]. 
Additionally, µCT was used as an added method to assess mineralization in three 
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dimensions to fully capture the three dimensional architecture, including size, shape, and 
distribution, of the mineralization occurring within three dimensional EBs. The volume 
of mineralization was significantly increased in βGP treated EBs, and overlays of µCT 
and stereoscope images confirmed histological and phase imaging findings of multiple 
mineral deposits per EB throughout most of the population of treated EBs. 
ESCs differentiated as EBs expressed Pit-1 at levels similar to differentiated MC-
3T3-E1 cells, suggesting a route for phosphate uptake by differentiating ESCs, and βGP 
treated EBs exhibited an increase in ERK 1/2 signaling compared to untreated EBs that 
was not associated with increased PKC activity. Both ESCs and osteoblasts maintain high 
levels of alkaline phosphatase activity, suggesting that the handling of phosphate is 
important to key functions in both cell types. Phosphate transport into cells via PiT-1 has 
been demonstrated to be necessary for BMP-2 induced mineralization [119, 120], but its 
role in the accompanying ERK signaling and osteogenic differentiation is not as clear. 
Numerous studies in cell types including osteoblasts [116], dental pulp cells [133], and 
vascular smooth muscle cells [134] have suggested that phosphate induced activation of 
the ERK 1/2 pathways leads to osteogenic gene transcription and differentiation. Many 
previous studies of phosphate induced ERK signaling and osteogenic differentiation have 
employed treatment with phosphonoformic acid (PFA), thought to inhibit phosphate 
transport into cells, specifically through PiT-1, suggesting that phosphate needs to enter 
the cell for these phenotypic changes to happen [43, 107]. However, more recent 
electrophysiological studies of PiT-1 expressed exogenously in Xenopus oocytes have 
found that its transport of Pi was not actually blocked by PFA treatment at the 
concentrations typically used (0.5 mM), pointing towards another mechanism of action 
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[128]. PFA is also an analogue of pyrophosphate (PPi), a natural inhibitor of extracellular 
mineralization that is known to directly interfere with calcium phosphate crystal 
formation. Additional studies of both osteoblast and vascular smooth muscle cell 
calcification have suggested that PFA may inhibit mineralization by a similar mechanism 
to PPi [129] and therefore that the presence of extracellular mineral deposits, and not 
increased Pi concentrations, might actually lead to changes in the cellular 
microenvironment that induce ERK signaling followed by osteogenic differentiation 
[131, 132]. This alternate mechanism was explored further within the context of EB 
osteogenic differentiation in Chapter 5. Regardless of the mechanism of induction, 
phosphate treatment of EBs, provided in the form of βGP, induced ERK signaling leading 
downstream to osteogenic differentiation. 
Phosphate induced mineralization and ERK signaling activation in EBs was 
accompanied by robust osteogenic differentiation, demonstrated at both the 
transcriptional and protein levels (Fig. 4.6, 4.8, 4.9). βGP treatment alone was sufficient 
to induce osteogenic differentiation within EBs. Upon establishing the ability of 
differentiating cells within βGP treated EBs to robustly mineralize, coincident osteogenic 
differentiation was demonstrated by increased expression of Runx-2, an early osteogenic 
transcription factor that controls the expression of most genes characteristic of the 
osteogenic phenotype [117], along with genes encoding extracellular matrix molecules. 
Additionally, vitamin D receptor expression and responsiveness were also characterized 
as additional assessments of osteogenic differentiation. These results revealed that 
embryonic stem cells expressed mRNA and protein for both receptors for 1α,25(OH)2D3, 
VDR and PDIA3, and they continued to be present as ESCs differentiated in the form of 
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EBs. Interestingly, the expression of Vdr increased in EBs at 14 days after βGP treatment, 
while Pdia3 expression decreased during the same period. The presence of both receptors 
in adult stem cells was also examined. The results showed that osteogenic induction 
increased VDR whereas levels of PDIA3 remained stable after osteogenic induction. 
These results demonstrated that expression levels of these receptors were modulated 
during the course of osteogenic differentiation of stem cells. However, it is not known if 
changes in mRNA were required to initiate a change in osteoblast differentiation state or 
if they were a consequence of that state. 
The results also indicated that EBs were sensitive to 1α,25(OH)2D3 at all stages of 
embryonic development, but effects were more robust in cultures induced to differentiate 
along an osteoblast lineage. This was correlated positively with increased expression of 
VDR and, not surprisingly, there was an increase in genes and proteins that possess 
VDREs including Opn and osteocalcin. Similar results were found by zur Nieden et al 
when ESCs were cultured in a osteogenic induction media containing ascorbic acid, β-
glycerophosphate and 1α,25(OH)2D3. In that study, the authors found an increase in 
alkaline phosphatase, osteocalcin, bone sialoprotein, osteopontin, osteonectin, collagen 
type 1,  and Runx-2 after treatment with 1α,25(OH)2D3[105]. 
The increase in the classical VDR may have been due to the cells differentiating 
into osteoblasts, which require a microenvironment higher in calcium in order to 
mineralize their extracellular matrix. This is supported by the observation that VDR 
knockout mice do not exhibit rickets until they are weaned and no longer have high 
serum calcium provided by their mother [187]. This suggested that at least some of the 
early 1α,25(OH)2D3-dependent differentiation is via PDIA3 and later osteoid production 
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and mineralization were dependent on VDR. The differential roles of VDR and PDIA3 
are not exclusive, however, as VDR is required for development of growth plate tethers, 
even in Ca
++
-replete mice [188].  
1α,25(OH)2D3 caused a dose-dependent rapid increase in PKC in the EBs, 
indicating that PDIA3 was functional as a receptor for the vitamin D metabolite. 
1α,25(OH)2D3 induces PKC activation via a membrane-associated rapid-response 
mechanism and downstream gene expression in a number of cell types [126, 139, 189]. 
This effect is abolished in PDIA3-knockdown cells, indicating that PDIA3 mediates the 
1α,25(OH)2D3 membrane response [126]. The PDIA3 knockout mouse is embryonically 
lethal by day E10.5 [190], confirming the importance of this protein in stem cell 
differentiation and embryonic development. In addition, PDIA3 deficiency in PDIA3
+/-
 
mice results in skeletal anomalies that affect trabecular and cortical bone [190]. 
Interestingly, the stimulatory effect of the 1α,25(OH)2D3 on PKC activity was greater in 
both EBs and MSC cultures grown in osteogenic medium. These results suggested that 
1α,25(OH)2D3 may have diverse effects in stem cell differentiation and embryogenesis. It 
is not clear if cells with a more differentiated osteoblastic phenotype have higher affinity 
to 1α,25(OH)2D3 or if PDIA3 and VDR form a complex that trigger the rapid membrane 
response.  
EBs also exhibited increased expression of mRNAs for α2 and β1 integrin 
subunits in cultures grown in osteogenic medium. Moreover, 1α,25(OH)2D3 caused a 
further increase in expression and this was particularly evident in the levels of β1. 
Integrin receptors recognizing collagen type I have been shown to regulate early 
osteoblast differentiation and control the expression of key genes in osteoblastogenesis 
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[9, 10]. We have observed that maturation of osteoblasts on microtextured biomaterial 
surfaces are dependent on signaling by α2β1 [191] and that expression of β1 is regulated 
by 1α,25(OH)2D3 [192, 193]. This suggests that α2β1 expression may play a similar role 
in EB differentiation. 
 
Conclusions 
In conclusion, minimal manipulation of the EB environment by the addition of 
βGP was sufficient to induce mineralization, ERK 1/2 signaling pathway activation, and 
subsequent osteogenic differentiation within EBs, characterized at both the gene and 
protein levels. Furthermore, taken together, our results demonstrate for the first time that 
1α,25(OH)2D3 caused rapid activation of PKC in embryonic stem cells and this activation 
increased during osteogenic differentiation. In addition, 1α,25(OH)2D3 also induced PKC 
activation in adult stem cells. The two receptors for this vitamin D metabolite were 
expressed differentially during osteoblastic differentiation, with increased Vdr expression 
in osteogenic medium. These results correlated with an increase in the expression of 
genes containing VDREs. Although there was a decrease in PDIA3 in EBs cultured in 
βGP containing medium, PKC activity in these cells was sensitive to 1α,25(OH)2D3 
demonstrating that the receptor was still functional. These data indicated the important 
role of 1α,25(OH)2D3 signaling in osteogenic differentiation of embryonic and 
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CHAPTER 5 
CALCIUM PHOSPHATE PRECIPITATES FORMED 
ENDOGENOUSLY WITHIN EMBRYOID BODIES PROMOTE 
OSTEOGENIC DIFFERENTIATION  
 
Introduction 
Pluripotent cells, such as embryonic stem cells (ESCs), are promising for many 
potential applications in tissue engineering and regenerative medicine, including for bone 
repair. ESCs are a renewable source of cells derived from the inner cell mass of 
blastocyst stage embryos, and various directed differentiation protocols have been 
reported to derive diverse cellular populations from ESCs, including neural, 
cardiovascular, and musculoskeletal cells [103, 194-196]. One common method of 
inducing ESC differentiation is as cell aggregates, referred to as embryoid bodies (EBs), 
which recapitulate many of the morphogenic events in three dimensions that occur during 
embryogenesis [89, 100, 101]. Recently, work in our lab has demonstrated control of the 
cellular microenvironment within EBs through the incorporation of biomaterial 
microparticles, which may be used to recapitulate and study cell-microenvironment 
interactions found in development [99, 102, 197]. Using such techniques, ESCs present 
not only great potential for use in regenerative medicine applications but also a readily 
accessible model system of early development and differentiation processes. 
Specifically, EBs may be used as a model for early bone formation events as 
osteogenic differentiation of ESCs and the accompanying mineralization observed in 
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vitro parallels bone development in vivo, progressing in order through stages of 
proliferation, matrix production, and mineralization [105]. β-glycerophosphate (βGP) is 
typically provided as part of the commonly used cocktails as a source of inorganic 
phosphate (Pi) required for mineralization [106, 185, 198]. The most common protocols 
for the osteogenic differentiation of mouse ESCs include supplementation with not only 
βGP but also ascorbic acid and dexamethasone [103, 110, 198], but phosphate is required 
for production of a mineralized matrix. ESCs express membrane alkaline phosphatase 
that can cleave organic phosphates such as βGP and liberate Pi, which is then available as 
the substrate necessary for mineralization [199, 200], and cells maintain this activity as 
they spontaneously differentiate within EBs (see Chapter 4).  
Within the context of physiological mineralization of bones, calcium phosphate 
precipitation occurs in a controlled manner locally and is deposited on a collagen-I rich 
matrix [37]. Mineralization of the extracellular matrix during bone development is a cell 
mediated process resulting in the deposition of calcium phosphate (CaP) as 
hydroxyapatite (HA - Ca10(PO4)6OH2) and requires alkaline phosphatase activity to 
cleave organic phosphate sources in the cellular environment, yielding the free, inorganic 
phosphate needed to mineralize [199, 200]. Matrix vesicles release high concentrations of 
calcium (Ca) and Pi locally allowing for matrix mineralization, while osteogenic matrix 
proteins produced by resident bone forming cells, osteoblasts, regulate this mineralization 
process [20].  
Pyrophosphate (PPi), produced by all cells and present ubiquitously, serves to 
modulate mineralization by acting as a direct inhibitor of CaP precipitation and 
mineralization [44, 201]. In bone, alkaline phosphatase cleaves PPi, thus removing the 
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inhibition of local CaP crystal formation and allowing for mineralization to proceed [46-
48]. In non-mineralizing tissues, inhibitors of mineralization produced by cells, including 
PPi, are present in the cellular microenvironment, but under pathological conditions, 
mineralization can occur either because of loss of these inhibitory factors, as seen in 
dystrophic calcification, or because of an increase in conditions that promote CaP 
precipitation, such as increased Ca and Pi concentrations as seen in metatstatic 
calcification [202]. Decrease in PPi within microenvironment can occur either because 
live cells express phosphatase activity to cleave PPi or because non-viable cells within 
that region are unable to produce PPi  
Phosphate treatment, administered either directly in the form of Pi or indirectly 
cleaved from βGP by alkaline phosphatase, induces mineralization and osteogenic 
differentiation of osteoblast like cells (MC3T3-E1) [115], vascular smooth muscle cells 
[43], and ESCs (See Chapter 4). Both osteoblasts and ESCs maintain high alkaline 
phosphatase activity, further suggesting that Pi is an important molecule for cellular 
functions in both cell types. Phosphate induced differentiation involves activation of 
mitogen-activated protein kinase (MAPK)/ extracellular-signal related kinase (ERK 1/2) 
signaling cascade with increased ERK 1/2 phosphorylation [107, 116]. Phosphate 
induced differentiation and mineralization may be blocked by treatment with 
phosphonoformic acid (PFA) [43, 115]. Though the exact mechanism of inhibition 
remains unclear, PFA has a similar structure to PPi and so is thought to act similarly by 
inhibiting crystal formation [129]. Given this more recently understood mechanism of 
PFA action, newer studies have suggested that induction of osteogenic differentiation 
only requires the presence of extracellular CaP deposits, independent of Ca and P 
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concentrations individually, and in fact, exogenous CaP administration has been found to 
induce ERK phosphorlyation and subsequent osteogenic gene expression in MC3T3-E1 
and vascular smooth muscle cells [130-132]. 
 After establishing the ability of mouse ESCs differentiated as EBs to form mineral 
deposits and undergo osteogenic differentiation in response to phosphate treatment (see 
Chapter 4), here the deposits formed were further characterized to determine if they were 
forming through a controlled, cell mediated process, as in bone, or were precipitates of 
CaP. Then, in light of osteogenic differentiation of other, more commited cell types 
directly induced by CaP precipitation, the relationship of these endogenously formed 
mineral deposits with the observed phosphate-induced ERK signaling and osteogenic 
differentiation was investigated by inhibiting mineral formation with PFA treatment, and 
subsequent changes in osteogenic gene expression were observed. Finally, to further 
assess the induced osteogenic differentiation, as well as to shed light upon a potential 
mechanism by which CaP induced changes could create an osteoinductive 
microenvironment in vitro, osteogenic protein expression, including production of matrix 
molecules and osteoinductive growth factors, was assessed. As a model for early bone 
formation, studying mineralization by differentiating ESCs in EBs would provide an 
avenue to investigate the potential interrelationship between differentiation and 
mineralization and how manipulating the microenvironment of cells can alter their 
differentiation. 
 
Materials and Methods 
Mouse ESC culture, EB formation, and osteogenic differentiation 
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  Undifferentiated mouse embryonic stem cells (D3 line) were cultured as described 
in Chapter 3 – General Methods. Forced aggregation was used to generate individual EBs 
of identical cell number in 6 well cell culture plates with approximately 1000 cells/ 
microwell [148] as described in the General Methods, and EBs were supplemented with 
10 mM βGP (MP Biomedical, Solon, OH) from day 5 of suspension culture onward to 
promote mineral deposit formation. 
Phase images of EBs in each treatment group were taken throughout the duration 
of the experiments (up to 14 days of differentiation) and were analyzed using 
Metamorph™ software (v. 7.5, Molecular Devices, Sunnyvale, CA) to measure EB size. 
Mineral deposits were visualized as dark, irregularly shaped deposits compared to 
surrounding cells and media by phase contrast. For studies including PFA treatment 
(Sigma, St. Louis, MO), samples were treated from day 5 through 14 of EB 
differentiation with 10 mM βGP alone (+βGP), 0.5 mM PFA alone (+PFA), both βGP 
and PFA starting at day 5 (+βGP +D5 PFA), or left untreated. EBs receiving “Day 10 
PFA treatment” were treated from day 5 through 14 with βGP and then supplemented 
with PFA from day 10 through 14 only (+βGP +D10 PFA). 
In separate experiments, the effects of osteogenic supplements and EB size on 
calcium phosphate precipitation were evaluated. For additional osteogenic supplement 
studies, EBs were formed by the rotary method described in Chapter 3 – General 
Methods with a cell seeding concentration of 2x10
5
 cells per 1 ml of media in 10 ml. EBs 
were supplemented with 10 nM dexamethasone, 50 μg/ml ascorbic acid, and 10 mM βGP 
from day 5-14 of differentiation, individually or in combination (DAG). For the EB size 
experiment, the UHTP, forced aggregation method was used to form EBs as described in 
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Chapter 3 – General Methods, and the cell seeding concentration was varied to 3 million 
cells and 9 million cells per 1 ml of media in order to achieve EBs of 500 and 1500 cells 
per EB respectively, in addition to the 1000 cells per EB used throughout the remainder 
of the study. EBs of the three different sizes were cultured with 10 mM βGP from day 5-
14. EBs from both of these experiments were evaluated for calcium phosphate precipitate 
formation by phase contrast and von Kossa staining described in the General Methods. 
 
Histology and fluorescence imaging 
Preparation of EBs for histological evaluation were performed by embedding in 
Histogel, and mineral deposits were stained by von Kossa and Alizarin red, as described 
in Chapter 3 - General Methods. 
To investigate the association of non-viable cells with mineral deposit formation, 
LIVE/DEAD® staining was used (Molecular Probes, Eugene, OR). Day 14 EBs were 
incubated in serum free, phenol free media containing 1 μM calcein AM and 2 μM 
ethidium homodimer I at 4°C for 30 min. EBs were washed three times in PBS, 
transferred onto glass coverslips, and imaged using a Zeiss LSM/NLO Multi-photon 
microscope. To assess the ability of non-viable cells or cellular debris to nucleate calcium 
phosphate precipitation under EB culture conditions, non-viable EBs were maintained in 
rotary culture with ESC media for 14 days, with supplementation with 10 mM βGP from 
day 5-14 of culture. Non-viable EBs were derived from untreated EBs collected at either 
day 5 or 10 of EB differentiation and were devitalized by overnight lyophilization as 
previously described [69]. Non-viable EBs were collected at day 14, fixed, and processed 
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as described above, and mineralization by calcium phosphate precipitation was evaluated 
by von Kossa and Alizarin red staining. 
Masson’s Trichrome stain was employed to visualize collagen composition within 
EBs (stained in blue). Briefly, deparaffinized slides were incubated in Bouin’s solution 
for 1 hour at 56°C, and after cooling to room temperature, they were incubated in 
Weigert’s hematoxylin (2 minutes), Bierbrich’s scarlet acid fuchsin (5 minutes), 
phosphotungsic-phosphomolybdic acid (1 minute), aniline blue (5 minutes), and 1% 
acetic acid (5 minutes), with intermittent water rinses between incubations. Slides were 
dehydrated, cleared, and cover-slipped before imaging. 
For immunofluorescent staining, histological sections were deparaffinized before 
being permeabilized and blocked using a 0.05% Triton X-100/2% goat serum solution. 
Slides were incubated with the primary antibody directed against either collagen-I 
(1:200) or collagen-II (1:200) at 4ºC overnight in the blocking solution. Samples were 
then incubated (1 hour, room temperature) with the fluorescently-tagged secondary 
antibody and rinsed in PBS (3x, 5 minutes). Nuclei were counterstained using Hoechst 
fluorescent dye and cover-slipped. 
 
Micro-computed tomography (μCT) 
Evaluation of the formation of mineral deposits within EBs was also performed 
by μCT, described in detail in Chapter 3 - General Methods. The total volume of 
mineralization within the entire Histogel-embedded samples was determined and 
normalized to estimated EB volume to calculate the average percentage of EB volume 
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containing calcium phosphate precipitates. EB diameter was measured by phase contrast 
microscopy and used to calculate estimated volume of embedded EBs. 
 
Mineralization analysis 
EBs were fixed at day 14 of differentiation in 2% glutaraldehyde in 0.1M sodium 
cacodylate buffer and postfixed in 1% osmium tetroxide for one hour at room 
temperature (Electron Microscopy Sciences, Hatfield, PA). Transmission electron 
microscopy (TEM) samples were dehydrated by a series of graded ethanol washes, 
embedded in epoxy resin medium (Fluka, St. Louis, MO), and sectioned with a RMC 
MT-7000 ultra-microtome using a diamond knife (Boeckeler, Tucson, Ariz.). Thin 
sections (60-80 nm thick) were collected on 200 mesh copper grids, and post-stained with 
5% Uranyl Acetate and Reynold’s Lead Citrate stains. The imaging was achieved using a 
JEOL JEM-1210 TEM set to 80 KV accelerating voltage. For scanning electron 
microscopy, samples were dehydrated in graded acetone washes, dried in liquid CO2 
(31.58°C, 1100 psi) using an E3000 series critical point dryer (Quorum Technologies, 
ON, Canada), and mounted on aluminum stubs (Electron Microscopy Sciences) before 
sputter coating in gold for 90 s in a Polaron Sputter Coater SC 7640 (Quorum 
Technologies) and imaging with a Hitachi S-800 Field Emission Gun Scanning Electron 
Microscope (SEM) with iXRF EDS2004 image acquisition software.  
Samples were prepared from day 14 EBs for X-ray diffraction (XRD), energy 
dispersive X-ray spectroscopy (EDS), and Fourier transform infrared spectroscopy 
(FTIR). EBs were collected in deionized water and frozen at -80°C, before being placed 
under vacuum in a lyophillizer (Labconco, Kansas City, MO) overnight. Surface structure 
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was first qualitatively evaluated before EDS using an Ultra 60 field emission (FE) SEM 
(Carl Zeiss SMT Ltd., Cambridge, UK).  Lyophillized EBs were imaged directly using a 
5 kV accelerating voltage and 30 µm aperture. The SEM equipment was coupled with an 
INCA EDS (Oxford Instruments, Bucks, UK) used for non-surface-sensitive analysis of 
elemental composition of samples. For XRD, crystal structure of the samples was 
identified using an X‘Pert PRO Alpha-1 diffractometer (PANalytical, Almelo, The 
Netherlands). XRD scans were collected using 1.8 kW Cu Kα radiation. A 1° parallel 
plate collimator, ¼ divergence slit and a 0.04 rad soller slit were used for controlled axial 
divergence.  Bragg-Brentano parafocusing setup was used to analyze samples. Infrared 
spectroscopy in attenuated total internal reflection mode (ATR) (Pike Technologies, 
Madison, WI) was performed using a Nexus 870 FT-IR bench (Nicolet Instrument 
Corporation, Madison, WI).  Each spectrum was the mean of 64 acquisitions (between 
1800 and 400 cm-1) with a spectral resolution of 4 cm
-1
.  Sample disks were placed on 
top of the transmission crystal and pressed with the sample holder.  Two spectra were 
collected per sample analyzed. Observed spectra were compared to references for pure 
hydroxyapatite crystal, as well as sodium (NaCl) and potassium (KCl) salts. 
 
Western blotting 
EBs were collected at day 14 of differentiation for western blot analysis of ERK 
phosphorylation, as described in Chapter 3 - General Methods.  
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
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For real-time PCR analysis (see Chapter 3 - General Methods), total RNA was 
extracted from undifferentiated ESCs or EBs after 10 and 14 days of differentiation. 
Primers for osteocalcin, bone sialoprotein, osteopontin, collagen type I, osterix, and 
runx2 were used, in addition to housekeeping gene GAPDH.  Gene expression was 
expressed as a fold change compared to same day untreated EBs, calculated by the ΔΔCt 
method [149].  
 
Osteogenic protein expression 
 Alkaline phosphatase (ALP) activity was determined at day 14 in EB cell pellets, 
with and without βGP treatment. Day 14 EB conditioned media was also assayed by 
sandwich ELISA (enzyme linked immunosorbent assay) for osteopontin and 
osteoprotegrin (DuoSet, R&D Systems, Minneapolis, MN), and EB cell pellets at day 14 
of differentiation were solubilized in T-Per Tissue Protein Extraction Reagent (~2 mg/ml 
T-Per; Pierce) and assayed by sandwich ELISA for BMP-4 (bone morphogenetic protein; 
DuoSet, R&D Systems), and BMP-2 (PeproTech, Rocky Hill, NJ) protein levels. 
Measurements were normalized to total protein for alkaline phosphatase specific activity 




Two-way ANOVA analysis, followed by Tukey’s post-hoc test, was performed to 
determine statistical differences (p<0.05), unless otherwise noted. If data did not 
approximate a normal distribution when first examined by exploratory data analysis, 
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Box-Cox estimations were used to transform the data set to a normal distribution, as 
reviewed by Spitzer [151]. Outliers were identified by examination of studentized t-
residuals. Results are reported as mean ± standard error of the mean of non-transformed 
data for a minimum of triplicate experiments from each experiment unless otherwise 




Calcium phosphate precipitation within EBs 
 EBs were cultured with βGP, ascorbic acid, and dexamethasone supplements 
individually and in combination in order to test whether βGP was the minimal essential 
component of this cocktail required for the formation of mineral deposits within EBs. 
After culture with these supplements from day 5-14 of EB differentiation, mineral 
deposits were visible by phase contrast microscopy in only EBs treated with βGP: the 
group receiving all three supplements and the group treated with βGP alone (Fig. 5.1 A). 
The extent and distribution of the mineral deposits was then further examined by von 
Kossa staining of the two treatment groups containing mineral deposits (Fig 5.1 B). The 
addition of dexamethasone and ascorbic acid did not appear to alter the mineral deposits 
formed in response to βGP treatment (in black). Because the goal of this study was to 
investigate the influence of calcium phosphate precipitates and mineralization on 
osteogenic differentiation, βGP treatment alone was used for all subsequent experiments 
in order to remove any confounding effects or bias towards osteogenic differentiation that 
may have been introduced by the addition of dexamethasone and ascorbic acid, both of 
which are known to promote osteogenic differentiation. 
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Figure 5.1. Effects of osteogenic supplements and EB size on mineral deposit 
precipitate formation. Calcium phosphate precipitates form when βGP is provided in 
the culture media, regardless of starting EB size. EBs were treated from day 5-14 of 
differentiation with βGP, ascorbic acid (AA), and dexamethasone (Dex), either 
individually or in combination. Mineral deposits were visible by phase contrast at day 14 
only in those cultures supplemented with βGP (A) and stained positively by von Kossa 
staining (B). In a separate experiment, EBs of different sizes, formed by forced 
aggregation, were all found to contain mineral deposits by day 14 after culture with βGP 
(C). Scale bars = 100 μm. 
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Next, to remove variability in mineral deposit formation and osteogenic 
differentiation that may arise from heterogeneity in the EB starting population [97, 203, 
204], experiments were undertaken employing techniques to control EB size. Though the 
rotary formation method used in Chapter 4 lead to increased EB homogeneity and some 
control of EB size compared to static formation methods [147], forced aggregation EB 
formation techniques have allowed more finely tuned manipulation of EB size by control 
of the number of cells used to form each EB, leading to improved homogeneity [148]. 
Previous data examining the size distribution of EBs with βGP induced mineral 
deposition did not reveal any bias for EBs of a particular size to contain mineralization 
(See Chapter 4, Fig. 4.3 E). To confirm the result that mineral accumulation was 
independent of size, EBs of different sizes were formed by forced aggregation and 
cultured with βGP. Mineral deposits formed in EBs of each of the three sizes examined, 
those formed from 500, 1000, and 1500 cells per EB. When evaluated by von Kossa 
staining at day 14, qualitatively similar amounts of mineral were present in the 1000 and 
1500 cell formed EBs; however, a larger portion of each 500 cell formed EB was found 
to be comprised of mineral deposits (Fig. 5.1 B). As had been observed in highly 
mineralized populations of rotary formed EBs, the increased mineralization in the 500 
cell EBs also lead to increased agglomeration, and coupled with the decreased EB size 
with βGP treatment (Fig. 4.3 E), resulted in low EB yield. To maximize EB yield and to 
reduce the possibility of transport limitations that might be experienced in the larger, 
1500 cell EBs, EBs formed at 1000 cells per EB were used for all subsequent 
experiments. 
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Using 1000 cells/EB, the ultra-high throughput, forced aggregation method of EB 
formation yielded EBs of uniform starting size that remained homogeneous through the 
initiation of βGP treatment at day 5, thus reducing intraexperimental variability before 
βGP was introduced that may have confounded the results and allowing for differences 
arising directly from βGP treatment to be more easily interpreted. EBs were visualized at 
day 7, 10, and 14 by phase contrast microscopy, and mineral deposits were noted to be 
visible in βGP treated samples beginning at day 7 (Fig. 5.2 A). Mineralization was 
observed by phase contrast as dark, irregularly shaped regions within treated EBs (Fig. 
5.2 B). Both untreated and βGP treated EBs decreased in size over the 14 day time period 
(p<0.005), but by day 10, +βGP EBs were 17% smaller than untreated (p<0.005) and 
32% smaller by day 14 (p<0.005) (Fig. 5.2 C). Overall, mineral deposit formation 




Figure 5.2. Mineral accumulation within βGP treated EBs. EBs were treated with 10 
mM βGP from day 5-14 of differentiation. βGP treated EBs accumulated mineral 
deposits much more readily and abundantly than untreated samples based upon phase 
contrast images (A). Mineral accumulation within the EBs, visualized by phase contrast 
as dark regions with irregular borders within EBs, were observed abundantly in treated 
EBs but not untreated EBs at day 14 (B). The size of EBs decreased over the 14 day EB 
differentiation time course, but βGP treatment caused a larger decrease in size. (C). 
(Scale bar in A = 500 µm, scale bar in B = 100 µm). n=3 cultures, two-way ANOVA, 
Tukey’s post-hoc, +p<0.005 compared to same day untreated, *p<0.005 compared to Day 
7 untreated and Day 7 +βGP, # p<0.005 compared to Day 7 untreated, Day 7 +βGP, Day 
10 untreated, and Day 10 +βGP. 
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The mineral deposits were next stained by von Kossa and Alizarin red to assess 
the composition of the mineral and to visualize their size and distribution within EBs. 
The presence of calcium phosphate (CaP) containing deposits was assessed by staining 
serial sections of EBs at days 7, 10, and 14 with von Kossa and Alizarin red (Fig. 5.3). In 
untreated EBs, positive von Kossa staining (in black) was found at day 14 that did not 
correspond with regions of positive Alizarin red (in red) staining in adjacent sections 
(Fig. 5.3 A). In fact, when the populations of day 14 untreated EBs stained by von Kossa 
and Alizarin red were quantified and compared, significantly more stained positively by 
von Kossa (18.3 ± 10.6% Alizarin red vs. 64.8 ± 1.4% von Kossa, p<0.05) (Fig. 5.3 B). 
In +βGP EBs, few, small foci of positive staining for both von Kossa and Alizarin red 
were observed at day 7 that increased in size and number at days 10 and 14 (Fig 5.3 A). 
By day 14, nearly the entire cross sectional area of some EBs was comprised of positive 
staining. Quantitatively, the percent of EBs stained positively for both stains increased 
over time and in βGP treated EBs compared to untreated EBs at days 7 and 10 by both 
von Kossa and Alizarin red (p<0.005) (Fig. 5.3 B). At day 14, however, only von Kossa 
staining was significantly increased within βGP treated EBs (p<0.05). The amount of 
mineral deposits was quantified to increase over time with phosphate treatment, 
supporting observations based on phase contrast imaging.  
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Figure 5.3. Calcium phosphate mineral deposits within EBs. Mineral deposits within 
EBs stained positively by von Kossa and Alizarin red stains in adjacent sections, 
indicating a composition of both phosphate and calcium; were present more in βGP 
treated EBs; and increased in size and distribution over the 14 day time course of EB 
differentiation (A). Quantification of von Kossa and Alizarin red stains confirmed 
significant increases in the number of EBs (% of total EB population) containing calcium 
phosphate precipitates with βGP treatment over 14 days. n=3 cultures, Box-Cox 
transformation, three-way ANOVA, Tukey’s post-hoc test, ***p<0.005, *p<0.05 
comparing treatment at same day with same stain, +p<0.05 comparing stain with same 
treatment and day, ^^^p<0.005 for marked comparison of Alizarin red stain, ###p<0.005 
for marked comparison of von Kossa stain. 
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The measurement of percent population containing mineral, determined from 
staining, did not fully capture the increases in size and number of mineral deposits 
apparent from looking at the deposits within EBs, therefore additional volumetric 
quantification of mineral accumulation was used. Volume of CaP mineral deposits within 
intact EBs was quantified in three dimensions by μCT and was measured to increase over 
time in βGP treated EBs while remaining low in untreated EBs. EBs at day 7, 10, and 14 
were embedded in Histogel, imaged by stereomicroscope to determine EB distribution 
within the gels, and scanned by μCT to quantify the mineral volume. Based on previous 
EB size measurements (Fig. 5.2 C) and the number of EBs loaded per gel, estimates of 
total EB volume were obtained and used to normalize the mineral volume quantified per 
gel sample, giving the percentage of total EB volume comprised of calcium phosphate 
deposits. At day 14, the percent mineral deposit volumes were found to be 16.72 ± 1.47% 
for treated EBs ( Fig. 5.4 A iii) compared with 0.02 ± 0.01% for untreated EBs (A iv) 
(p<0.001). Overlay of stereoscope and uCT images demonstrated that CaP mineral 
visualized by uCT was contained within βGP treated EBs (Fig. 5.4 B). Quantitatively, the 
percent mineral volume remained unchanged in untreated EBs and increased with βGP 
over time and compared to untreated EBs (p<0.001) (Figure 5.4 C). Taken together, 
mineral deposits form upon βGP treatment, increase during the treatment period, and may 
be quantified based on histological and μCT based measures, supporting findings 




Figure 5.4. Quantification of calcium phosphate mineral deposits by µCT. Day 7, 10, 
and 14 EBs were analyzed by µCT to quantify degree of mineralization based on volume 
of calcium phosphate mineral deposits. An equivalent number of Histogel embedded day 
14 EBs were also imaged by stereomicroscope (-βGP (A i) and +βGP (A ii)). The 
percentage volume comprised of calcium phosphate deposits at day 14, normalized to EB 
volume, were found to be 16.72 ± 1.47% for treated EBs (A iii) vs. 0.02 ± 0.01% for 
untreated EBs (A iv) (p<0.001,  n = 3 samples). EBs and mineral deposits overlapped in 
stereoscope (B i) and µCT (B i) images (regions indicated by boxes) (merge – B iii). 
Degree of mineralization, calculated from the % of total EB volume comprised of 
calcium phosphate deposits and plotted as mean ± relative error, was then compared 
across time and treatment groups and found to increase over time in βGP treated EBs 
compared to untreated EBs (C). Scale bar in A = 1mm, scale bar in B = 1 mm. n=3 
samples, Box-Cox transformation of % of EB volume mineralized, two-way ANOVA, 
*p<0.001 compared to same day untreated, #p<0.001 compared to Day 7 untreated and 
Day 7 +βGP, +p<0.001 compared to Day 7 untreated, Day 7 +βGP, and Day 10 
untreated. 
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Characterization of mineral deposition 
Though mineral deposits were demonstrated by phase contrast, von Kossa and 
Alizarin red staining, and μCT, none of these assessments distinguished between CaP 
precipitation and biologically mineralized matrix, as found in bone. Therefore, additional 
material characterizations were required to distinguish between these processes. CaP 
mineral deposits within day 14 βGP treated EBs were visualized using electron 
microscopy techniques to further evaluate the mineral deposition process occurring 
within EBs. Transmission electron microscopy further elucidated the organization and 
distribution of mineral deposits within EBs. Mineralization was not found in untreated 
samples (Fig. 5.5 A) but was visible both intra- (B) and extracellularly (C) in treated EB 
samples. Higher magnification images demonstrated that βGP treated EBs contained a 
poorly crystalline mineralization lacking clear collagen fibrils and matrix vesicles but 
containing material suggestive of cellular debris (Fig. 5.5 D). Regions of mineralization 
within βGP treated EBs were also visualized by scanning electron microscope and were 
noted to be present extracellularly as numerous globular structures with flattened surfaces 
(Fig. 5.5 E, F). 
 To identify the composition and structure of the mineral deposits, energy 
dispersive X-ray spectroscopy (EDS), Fourier transform infrared spectroscopy (FTIR), 
and X-ray diffraction (XRD), were used to analyze devitalized, day 14 EBs, a mixture of 
cellular, organic material and calcium phosphate mineral deposits. EDS demonstrated the 
presence of increased calcium and phosphate in βGP treated samples when compared to 
untreated samples, however the calcium phosphate ratio (0.75) did not match the ratio of 
pure hydroxyapatite (10 Ca/6 P = 1.67). Along with FTIR, these data suggested that the 
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mineral composition was distinct from that found in hydroxyapatite of native bone (Fig. 
5.5 G, H). Additionally, XRD did not demonstrate the ordered crystalline structure of 
hydroxyapatite within either the βGP treated or untreated samples (Fig. 5.5 I). βGP 
treated EBs exhibit calcium and phosphate accumulation not found in untreated samples 
but with differences in structure and composition to bone hydroxyapatite. Taken together 
with electron microscopic findings, phosphate treatment enhanced mineral deposit 
formation, and the structure and composition of these depositesse results were suggestive 
of CaP precipitates. In combination with the previous data, phosphate treatment 




Figure 5.5. Characterization of calcium phosphate precipitates. Transmission 
electron microscope images of untreated EBs (A) did not contain electron dense material 
present both intra- (B) and extracellularly (C, higher magnification view - D) in βGP 
treated EBs. Scanning electron microscope views of the interior of representative βGP 
treated EBs revealed regions of calcification within EBs (E, F) (Scale bar in A-C = 1 µm, 
D = 100 nm, E, F = 10 µm). Lyophilized preparations of day 14 EBs with βGP treatment, 
a mixture of cellular organic material and calcium phosphate precipitates, were further 
analyzed to characterize the mineral content. Calcium and phosphate content, calculated 
from EDS, were enriched in βGP EBs compared to untreated EBs, but the calcium 
phosphate ratio (0.75) did not match that of native bone hydroxyapatite (HA) (1.67) (G). 
Further analysis of EBs containing calcium phosphate precipitates confirmed distinct 
mineral composition and crystal structure than purified HA by FTIR (H) and XRD (I), 
respectively. 
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 Because of the visualization by TEM of material suggestive of cellular debris 
within the CaP precipitates, Live/Dead staining was used to investigate if dead cells were 
associated with the precipitates. The component of the stain which demonstrates dead 
cells is ethidium homodimer, which binds to exposed DNA from non-viable cells in non-
intact cells or cellular debris. Positive dead staining (red) in day 14 βGP treated EBs (Fig. 
5.6, top) overlayed with CaP precipitates visualized by phase contrast (Fig. 5.6, bottom), 
while portions of the βGP treated EBs not containing the CaP precipitates exhibited 
similar viability to untreated EBs. One possible explanation for the strong ethidium 
homodimer staining of the CaP deposits, supported by the TEM findings, was the 
presence of cellular debris within the precipitates themselves, as cellular debris may have 
acted as a nucleation point for CaP precipitation. Increased amounts of cellular debris and 
single cells were noted by phase imaging outside of EBs in +βGP cultures, particularly by 
day 14 (Fig. 5.2 A). Alternatively, CaP precipitates may have non-specifically bound the 
ethidium homodimer. To further investigate the possibility that cellular debris present in 
+βGP cultures and EBs was able to nucleate the formation of CaP precipitates, non-
viable EBs were maintained under the same culture conditions used to promote mineral 
formation within viable EBs. After addition of βGP to the non-viable EB culture from 
day 5-14, extensive calcium phosphate precipitation was observed as demonstrated by 
positive von Kossa and Alizarin red staining throughout all of the non-viable EBs 
collected (Fig. 5.7). In fact, the mineral deposition was far greater and extensive than 
typically seen within viable EBs, in agreement with previous studies of non-viable cell 
mineralization [129, 131]. The same observations were made when non-viable EBs 
devitalized at day 5 and day 10 were used. In combination, the data suggested that the 
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βGP induced mineral formation observed in EBs occured through a process of CaP 
precipitation. The precipitates contained and were nucleated by cellular debris, and their 




Figure 5.6. Live/Dead staining of calcium phosphate precipitates formed in EBs. 
Calcium phosphate precipitates contained dead cellular material. Day 14 EBs with and 
without βGP  treatment were stained with ethidium homodimer, a stain used to 
demonstrate dead cells in red, and calcein, to demonstrate viable cells in green, and 
imaged by confocal microscopy. Calcium phosphate precipitates within EBs, visible by 
phase contrast within βGP treated EBs (overlay, bottom), stained strongly positive for the 
presence of dead cells while the remainder of the EB stained similarly to untreated EBs. 
Scale bar = 100 μm. 
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Figure 5.7. Mineralization of devitalized EBs. Calcium phosphate precipitates formed 
in non-viable EBs maintained under EB culture conditions. Devitalized EBs (lyophilized, 
untreated Day 10 EBs) were cultured under the same conditions as viable EBs with βGP 
treatment from day 5-14 of culture and became mineralized by calcium phosphate 
precipitates by day 14 as demonstrated by von Kossa and Alizarin red stains of adjacent 
sections. Scale bars = 100 μm. 
 
ERK 1/2 activation and osteogenic gene expression 
Regardless of the structure and composition of the mineral deposits, the 
alterations in the EB microenvironment brought about by their presence alone were 
previously found to be sufficient to induce osteogenic differentiation (see Chapter 4). To 
test whether the osteogenic differentiation in response to phosphate treatment was in fact 
due to the formation and presence of CaP precipitates, studies blocking precipitation 
using PFA were performed. Here, PFA treatment initiated at day 5, concurrently with 
βGP administration, completely inhibited the CaP precipitates, visible by phase contrast 
and von Kossa staining, formed by day 14 with βGP treatment alone (Fig. 5.8 A). 
However, when blocking with PFA was delayed until day 10, after CaP formation had 
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begun (+βGP +D10 PFA), the amount and size of CaP precipitates was maintained at 
levels observed in day 10 +βGP samples. All groups receiving phosphate treatment were 
observed to have increased amounts of cellular debris. Next, ERK 1/2 activation was 
assessed by Western blot for phosphorylated and non-phosphorylated ERK. 
Phosphorylated ERK was increased at day 14 in samples containing CaP precipitates, 
both +βGP alone and +βGP +D10 PFA (Fig. 5.8 B). Since Runx-2 activation and 
osteogenic differentiation occur downstream of ERK activation [205], osteogenic gene 
expression was then examined. 
 The expression of several key osteogenic genes was increased in a coordinated 
manner at day 14 in response to the presence of CaP precipitates within EBs. Runx-2 
expression was increased in EBs treated with βGP (4.25 fold compared to untreated, 
p<0.05) (Fig. 5.8 C). This upregulation was inhibited with PFA treatment beginning at 
day 5 but not when it was begun at day 10 (8 fold compared to untreated, p<0.005), 
correlating with the presence of CaP precipitates and ERK phosphorylation. The 
expression of Bsp and Opn responded similarly to Runx-2 expression after βGP and PFA 
treatments, not surprisingly, as Runx-2 is an early osteogenic transcription factor known 
to control the expression of several osteogenic genes [117]. Not all osteogenic genes 
assayed were regulated in this coordinated manner. Interestingly, the expression of two 
late osteogenic marker genes for osteocalcin and osterix were actually increased in all 
PFA treated groups (10-20 fold compared to untreated), and there was a synergistic 
increase in both groups treated with both βGP and PFA (+βGP +D5 PFA and +βGP 
+D10 PFA). Coll-I expression was not increased with βGP treatment but was decreased 
compared to untreated cells with PFA treatment from day 5, both with and without 
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concurrent βGP treatment (3 fold and 5 fold decrease compared to untreated, p<0.005). 
Additionally, Coll-I expression was also decreased in +βGP EBs when they were treated 
with PFA that began only at day 10 (p<0.005). No significant changes in gene expression 
were seen between treatment groups except for decreases in Runx-2 expression for both 
PFA treated samples (+βGP +D5 PFA and +PFA) compared to untreated and +βGP 
samples (p<0.05). Taken as a whole, these data demonstrated that CaP precipitates 
induced by phosphate treatment were associated with activated ERK 1/2 and osteogenic 
gene expression. ERK phosphorylation and osteogenic differentiation were abolished 
when CaP precipitation was blocked completely with PFA treatment but not when CaP 
precipitates were allowed to form before PFA inhibition, suggesting that the precipitates 
themselves were altering the phenotype of the EBs. 
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Figure 5.8. Effect of PFA on CaP precipitation, ERK 1/2 signaling, and osteogenic 
gene expression. EBs were treated with βGP from day 5-14 of EB differentiation to 
promote the formation of calcium phosphate precipitates, visualized by phase contrast 
and von Kossa staining at day 14 (A). Precipitate formation was completely inhibited 
when PFA treatment was initiated at day 5 (+βGP +D5 PFA), arrested at amounts present 
at day 10 when PFA treatment began at day 10 (+βGP +D10 PFA),  and not observed in 
untreated and PFA only controls. ERK 1/2 phosphorylation at day 14 was assayed by 
Western blot to investigate activation of the ERK 1/2 signaling cascade (B). ERK 1/2 
activation was correlated with the presence of calcium precipitates and increased in +βGP 
and +βGP +D10 PFA samples. The expression of the genes for osteoblast transcription 
factors, Runx-2 and osterix (OSX), along with genes encoding several bone matrix 
proteins, including bone sialoprotein (BSP), Osteopontin (OPN), osteocalcin (OCN), and 
collagen-I (Coll-I) were assessed by qRT-PCR (C). Runx-2, Bsp, and Opn expression 
paralleled ERK 1/2 signaling. The expression of late osteogenic marker genes, Ocn and 
Osx, was upregulated in all PFA treated samples, and this upregulation was 
synergistically increased in samples receiving +βGP treatment (+βGP +D5 PFA and 
+βGP +D10 PFA). Osx expression was also increased with βGP treatment alone. Coll-I 
expression was decreased in +βGP +D5 PFA and +PFA samples compared to untreated 
samples. Data are from one representative experiment of two with similar results. n=3-4, 
Box-Cox transformation, two-way ANOVA, #p<0.05, ##p<0.01, ###p<0.001 compared 
to untreated, *p<0.05, **, p<0.01, ***p<0.005 compared to both +βGP and +βGP +D10 
PFA, ^p<0.05 compared to +βGP, +p<0.05, +++p<0.005 for marked comparison. 
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Protein level markers of osteogenic differentiation in differentiating EBs 
To further assess the osteogenic phenotype of EBs induced by CaP precipitates at 
the protein level, alkaline phosphatase activity and the production of several osteogenic 
proteins, including matrix molecules and growth factors, were assayed from EBs with 
and without βGP treatment. Extracellular matrices derived from osteogenic cell types are 
known to promote the osteogenic differentiation of exogenous cells seeded onto them 
[74, 75, 78]. As such, the endogenous production of an osteogenic matrix, including 
associated mineral deposition and osteoinductive growth factors, may promote the further 
osteogenic differentiation of cells within the EB microenvironment. Conditioned media 
and cell pellets were collected at day 14 from βGP treated and untreated EBs and were 
assayed for overall osteogenic differentiation via alkaline phosphatase activity, a 
functional assay, as well as for the production of the bone extracellular matrix molecules 
osteopontin and osteoprotegrin to evaluate the osteogenic phenotype at the protein level 
[206, 207]. Alkaline phosphatase (ALP) activity was detected in all EB samples 
regardless of treatment but was increased with βGP treatment compared to untreated EBs 
(p<0.005) (Fig. 5.9 A). Osteoprotegrin (OPG) and osteopontin (OPN) protein secretion 
into conditioned media was detectable by ELISA in both treated and untreated samples 
(Fig. 5.9 B), but OPG was increased whereas OPN was decreased with βGP compared to 
untreated (p<0.001), suggesting osteogenic proteins are differentially regulated by 





Figure 5.9. Osteogenic protein analyses. Alkaline phosphatase (ALP) activity, a marker 
of mature osteogenic differentiation, was assayed at day 14 (A) and was increased with 
βGP treatment. Osteoprotegrin (OPG) and osteopontin (OPN), two matrix proteins 
secreted by osteoblasts, were assayed by ELISA (B). OPG was increased and OPN was 
decreased with βGP treatment compared to untreated samples. Day 14 EB cell pellets 
contained equivalent amounts of BMP-2 and BMP-4 regardless of βGP treatment (C). 
n=6 samples for ALP, OPG and OPN, n=5 samples for BMP4 and BMP2, t-test, * 
p<0.005. 
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To quantify EB growth factor content, EBs with and without βGP treatment were 
analyzed at day 14 of differentiation for BMP-4 and BMP-2. The retention of these 
osteoinductive factors within the EB microenvironment, potentially in association with 
CaP precipitates, may account for the observed CaP precipitate induced osteogenic 
differentiation [208, 209]. No differences in BMP-2 or BMP-4 content were observed 
with βGP treatment. Treated EBs contained 0.55 ± 0.10 pg BMP-2/μg total protein and 
1.29 ± 0.12 pg BMP-4/μg total protein, whereas untreated EBs contained 0.45 ± 0.06 pg 
BMP-2/μg total protein and 1.32 ± 0.27 pg BMP-4/μg total protein (Fig. 5.9 C). 
Finally, because interactions with a collagenous matrix promote osteogenic 
differentiation [9, 10], the presence of collagen within EBs was assessed by Masson’s 
Trichrome stain and immunofluorescence staining for collagen-I and collagen-II. EBs did 
not contain readily apparent staining for collagen, which stains in blue by Masson’s 
Trichrome stain, regardless of phosphate treatment (Fig. 5.10 A), which was in agreement 
with observations by TEM that mineral deposits were not associated with organized 
collagen fibers present in bone (Fig. 5.5). Immunofluorescence staining for both 
collagen-I (Fig. 5.10 B) and collagen-II (Fig. 5.10 C) confirmed these findings, though 
collagen-I was enhanced when EBs were cultured with ascorbic acid. Taken together, 
these stains demonstrated that while EBs produce osteogenic matrix molecules and 
growth factors, these molecules are not associated with the production of a collagenous 





Figure 5.10. EB collagen content. Day 14 EBs were stained by Masson’s Trichrome 
stain and immunofluorescence for collagen-I and collagen-II. EBs contained little 
positive staining for collagen (stained in blue) regardless of phosphate treatment (A). 
Immunofluorescence demonstrated little collagen-I, though there was an increase in 
positive staining in EBs treated with ascorbic acid (B). Staining for collagen-II also 
demonstrated little presence of the matrix protein.  
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In total, EBs differentially regulated the production and secretion of proteins in 
response to βGP treatment. In parallel with observed enhancements at the mRNA 
expression level, βGP treatment enhanced protein level markers of osteogenic 
differentiation, including osteogenic extracellular matrix molecule production, and this 
effect was directly associated with the formation of CaP precipitates. Additionally, even 
untreated EBs produced osteogenic and osteoinductive molecules endogenously, 
including osteogenic matrix proteins and growth factors, as they spontaneously 
differentiated to cells from all three germ lineages, including bone forming osteoblasts. 
Overall, these data suggest that not only did EBs produce CaP mineral deposits, given the 
minimal substrate (βGP), but changes in the EB micronenvironment resulting from CaP 
precipitate formation induced ERK signaling and subsequent osteogenic differentiation at 
the gene and protein levels. 
 
Discussion 
This study presented evidence that mineral deposits, which may be formed 
endogenously within EBs by culture with βGP, induced osteogenic differentiation of 
mouse ESCs, demonstrated at the gene and protein levels. Additionally, the mineral 
accumulation was formed from CaP precipitates, was quantifiable by multiple metrics, 
and induced activation of ERK 1/2 signaling and osteogenic differentiation. Previous 
work in our lab has demonstrated that alterations in the extracellular EB 
micrcoenvironment by controlled presentation and delivery of materials and soluble 
factors within EBs lead to phenotypic changes and differentiation [99, 102, 197]. Here, to 
understand the relationship between mineral formation and osteogenic differentiation, the 
EB microenvironment  was manipulated by the introduction of endogenously formed CaP 
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precipitates. Though the directed osteogenic differentiation of mouse ESCs has often 
been achieved by addition of a combination of soluble factors, including, βGP, ascorbic 
acid, dexamethasone [103, 110, 198], or 1α,25(OH)2D3 vitamin D [105], βGP alone was 
necessary for the development of mineral deposits within EBs (Fig. 5.1 A). Additionally, 
uniformly sized EBs, formed by forced aggregation, were used in order to reduce 
variability that may arise in EB differentiation due to variation in EB size within the 
starting population [97, 203, 204].  
CaP precipitates were found to form endogenously within EBs upon the addition 
of βGP and to increase over the course of EB differentiation in a quantifiable manner (Fig 
5.2, 5.3, 5.4). During histological evaluation of the CaP precipitates formed in EBs, 
regions of positive von Kossa staining that did not correspond with positive Alizarin red 
staining of adjacent sections were noted (Fig. 5.3). This discrepancy may have been 
attributed to several possible explanations. The contrast between positive staining and 
cell nuclei was greater with von Kossa staining, allowing for better resolution by eye of 
EBs containing positive staining by an observer evaluating the stain. Because of this 
difference, μCT was used to provide more reliable and less observer biased quantification 
of the CaP precipitates within EBs. Perhaps more importantly, though often used 
interchangeably to demonstrate mineralization, these two stains do not actually 
demonstrate the same thing. Whereas Alizarin red stain chelates calcium, von Kossa 
staining actually demonstrates phosphate. Alizarin red staining has its caveats, too, as in 
addition to CaP mineralization, calcium binding proteins and proteoglycans stain 
positively for Alizarin red as well. As described in detail by Bonewald et al, neither stain, 
nor μCT, can truly demonstrate true matrix mineralization, as observed in native bone, 
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with hydroxyapatite, collagen-I fibrils, and matrix vesicles [37], motivating more detailed 
material characterization. 
Though observed to be the same by gross examination used to quantify 
mineralization in this study, EB mineral deposits were not the same in structure and 
composition as ones observed in other osteogenic cell types and native bone and were 
found to be precipitates of CaP (Fig. 5.5), nucleated by cellular debris within EBs (Fig. 
5.6, 5.7). These material differences were not apparent based solely upon histological and 
μCT techniques often used to characterize bone formation and mineralization in vitro and 
in vivo. Additionally, the induction of osteogenic gene expression by these precipitates 
represents a reversal of expected relationship of mineralization and differentiation based 
on development [105]. These findings underscored the need to carefully characterize the 
apparent phenotype and mineral deposit formation of osteogenic cells generated in vitro 
[37, 75, 131]. Transmission electron microscopy of mineral deposits within EBs did not 
suggest the presence collagen-I mediated mineralization observed from osteoblasts in 
vitro and in vivo, including clear collagen fibril formation with matrix vesicles [6, 37], 
but demonstrated both intra-and extracellular accretions. Additionally, SEM, EDS, FTIR, 
and XRD suggested the presence of poorly crystalline calcium phosphate, distinct in 
elemental content and crystal structure from hydroxyapatite found in mature bone (Fig. 
5.5). The findings of this study suggested a different mineralization process than that 
observed in mature bone formation, but it supported gene level analysis, in which 
collagen-I gene expression was not upregulated at day 14 with βGP treatment. Mason’s 
Trichrome staining and immunofluorescence for both collagen-I and collagen- II proteins 
also did not provide evidence of abundant collagen within either treated or untreated EB 
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populations (Fig. 5.10). Collagen-I expression has been shown to be only transiently 
increased in embryonic and mesenchymal stem cells undergoing osteogenic 
differentiation [105, 113, 210], while other studies have demonstrated downregulation of 
collagen-I expression in MC3T3-E1 pre-osteoblast cells upon treatment with inorganic 
phosphate [211].  
Based on TEM, staining for cellular debris within precipitates, and the ability of 
non-viable EBs to form precipitation, CaP mineral deposits were suggested to have 
formed by nucleation of crystal formation on celluar debris within EBs (Fig. 5.5. 5.6, 
5.7). During embryogenesis, the mineralization of the collagenous extracellular matrix is 
a cell mediated process involving CaP deposition from matrix vesicles as hydroxyapatite 
[6, 37]. However, in addition to being an active, cell mediated process in mineralizing 
tissues, mineralization is a process that is actively inhibited by non-mineralizing tissues. 
Mineral precipitation onto non-viable cells can occur under physiologic conditions 
because the cells are no longer actively producing PPi, a potent inhibitor of CaP crystal 
formation [47]. Additionally, non-viable cell CaP precipitation has been demonstrated to 
occur to a greater extent and with different structure and composition from CaP 
precipitation produced in the setting of viable cells [131]. Comparisons of CaP 
precipitates in vascular smooth muscle cells with CaP precipitation in non-viable, fixed 
cells found that the precipitates formed were of different composition and structure by 
EDS, XRD, and TEM. Additionally less precipitation was present in live cells than non-
viable cells, suggesting that though initiated through the same passive process, viable 
cells modulate the CaP precipitate accumulation by controlling precipitation rate 
[131]and through templating provided by cell-produced osteogenic matrix molecules 
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[212]. Based on these findings, one may hypothesize a mechanism by which CaP 
precipitation occurs within the EB microenvironment. PPi was cleaved by alkaline 
phosphatase, whose activity was maintained within EBs through day 14 of differentiation 
regardless of βGP treatment (Fig 5.9 A). The removal of PPi thus created a 
microenvironment permissive of CaP precipitation, especially in the setting of media 
containing elevated levels of inorganic phosphate, which was also liberated from βGP by 
alkaline phosphatase.  
 Regardless of their mechanism of formation, composition, or structure, CaP 
precipitates were found to induce osteogenic differentiation of ESCs, paralleling findings 
previously reported in more mature cell types [130-132], and confirmed by studies 
blocking the formation of precipitates by PFA treatment (Fig. 5.8). Previous studies have 
found that phosphate treatment of MC3T3-E1 cells induces ERK 1/2 activation [107, 
116], which regulates Runx-2 activation and downstream osteogenic gene expression 
[205].The same ERK 1/2 pathway was activated in response to βGP treatment of EBs, 
leading to osteogenic differentiation (Fig 4.5). Both phosphate-induced mineralization 
and differentiation of MC3T3-E1 cells have been inhibited by treatment with PFA, 
thought to inhibit phosphate transport into cells, specifically through Type III Na,Pi co-
transporter PiT-1, suggesting that phosphate needed to enter the cell for  phenotypic 
changes to happen. However, more recent electrophysiological studies of PiT-1 expressed 
exogenously in Xenopus oocytes have found that its transport of Pi was not actually 
blocked by PFA treatment at the concentrations typically used (0.5 mM), pointing 
towards another mechanism of action [128]. PFA is also an analogue of PPi, which, as 
described above, directly interferes with CaP crystal formation [129]. Recent work 
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performed has demonstrated that both endogenously formed and exogenously provided 
CaP precipitates induced osteogenic differentiation independent of phosphate 
concentration and transport and that the induction occured via ERK 1/2 activation [130-
132]. In light of the recent findings, the mechanism of PFA inhibition of phosphate-
induced osteogenic differentiation observed previously may be reevaluated.  
In the current EB study, ERK 1/2 signaling was activated in the presence of CaP 
precipitates within EBs and was correlated with increases in osteogenic gene expression, 
including early osteoblast transcription factor Runx-2 and osteogenic matrix proteins Bsp 
and Opn (Fig. 5.8 B, C). Taken together these findings suggested that phosphate-induced 
osteogenic differentiation of EBs was actually induced by CaP precipitates and not by 
blocking of phosphate uptake by cells. This conclusion was further supported by the 
observation that ERK activation was still induced in PFA treated EBs when precipitate 
formation was allowed to occur before the initiation of PFA treatment (+βGP +D10 
PFA).  
 Not all osteogenic genes evaluated appeared to have been regulated through this 
mechanism. Interestingly, transcription of late osteoblast marker genes encoding 
osteocalcin and osterix were actually increased with PFA treatment (Fig 5.8 C). 
Additionally, coll-I expression at day 14 and Runx-2 expression at day 10 were 
significantly decreased with PFA treatment alone, pointing towards the ability of PFA to 
affect cell phenotype by itself. This highlighted the possibility that PFA may affect cell 
phenotype in multiple ways including inhibition of CaP precipitation, blocking phosphate 
uptake via PiT-1, and other as yet unidentified mechanisms. Furthermore, the role of 
phosphate transport by PiT-1 in promoting osteogenic differentiation cannot be 
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completely discounted either. PiT-1 expression at the protein level was required for 
BMP-2 induced matrix mineralization of MC3T3-E1 [119] and vascular smooth muscle 
cells [120]. Also in vascular smooth muscle cells, siRNA blocking of PiT-1 protein 
expression reduced phosphate induced osteogenic gene expression [124]. For future 
studies, in order to circumvent the ambiguity in PFA action, other agents to block CaP 
precipitation can be used, such as phosphocitrate [132], or the exogenous introduction of 
CaP in the form of microparticles [213] or nanocrystals [130] may be investigated. 
Though the precise mechanism still remains a point of contention, even in more 
committed and extensively studied cell types than ESCs, this study demonstrated a 
conservation of phosphate-induced osteogenic differentiation by activation of ERK 
signaling that has been reported in a variety of cells, including osteoblasts [116], dental 
pulp cells [133], and vascular smooth muscle cells[134]. 
In addition to the increases in gene expression, increases in protein markers of 
osteogenic differentiation were also observed in EBs with CaP precipitates, and some 
proteins were expressed at high levels regardless of treatment, which may provide a clue 
to how the extracellular microenvironment, including matrix molecules, growth factors, 
and CaP precipitates, and differentiation could be interrelated. Though the mechanism by 
which cells sense and respond to CaP precipitates and how that leads to osteogenic 
differentiation remain to be elucidated [130-132], it would be reasonable to hypothesize 
that this effect is mediated through interactions of the CaP material with osteogenic and 
osteoinductive molecules produced within the cellular microenvironment. Osteogenic 
cells themselves produce extracellular matrices that have been demonstrated promote 
osteogenic differentiation of exogenous cells re-seeded on them [74, 75, 78], suggesting 
 107 
the creation of a feedback loop within EBs between differentiating cells and their self-
produced osteoinductive extracellular environment. In addition to osteogenic matrix 
protein production, osteoinductive growth factors BMP-2 and BMP-4 were both 
produced by EBs (Fig 5.9). Based on previous studies of EBs, mesoderm differentiation 
was expected to be enhanced by day 5, when βGP treatment was initiated [184], and 
since BMP-4 is critical during embryonic development and mesoderm formation [36], it 
was not surprising that it was present in large amounts in EBs regardless of treatment. 
CaP precipitates may have the ability to bind and retain these growth factors within the 
EB microenvironment, either serving as a local reservoir or presenting the growth factors 
in a manner that can promote osteoinduction of cells within EBs. In fact, CaP coated 
microparticles have been proposed for the delivery of BMPs because of CaP affinity for 
binding proteins [213]. 
Osteogenic differentiation induced by CaP may also depend on surface 
characteristics of the precipitates and how they modulate osteoinductive protein 
entrapment or binding. CaP containing material surface geometry has been found to alter 
the dissolution and re-precipitation of CaP, leading to entrapment of organic material, 
including growth factors such as BMPs, which in turn may impart osteoinductivity [208, 
209]. Within the microenvironment of osteogenic cells, CaP containing materials with the 
appropriate surface characteristics have been suggested to be modified by proteins 
secreted by differentiating osteogenic cells. This cell-altered surface is in turn able to 
promote the osteogenic differentiation of additional neighboring cells. In a study of 
osteoinduction by calcium phosphate-containing materials, material implanted in the 
abdominal muscle of baboons induced new bone formation when its surface contained 
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concavities of specific geometry [214]. It was suggested that through an inductive 
feedforward loop, surfaces with specific topography interacted with soluble 
osteoinductive cues, which in turn induced osteogenic cells at the material surface to 
produce more osteoinductive molecules, ultimately inducing downstream bone formation. 
Additionally, osteoblastic differentiation of MG63 osteosarcoma cells  and mesenchymal 
stem cells on titanium surfaces has been found to be modulated in response to surface, 
micron-scale roughness and nanoscale features in a similar manner [215, 216]. Material 
stiffness has also been suggested to effect cell differentiation, with more rigid surfaces 
promoting osteogenic differentiation of mesenchymal stem cells [217]. 
This study presented the novel opportunity to interrogate the relationship between 
mineralization and differentiation by embryonic stem cells, cells present during the 
earliest stages of development. The paradigm has traditionally been that osteogenic 
differentiation in vitro parallels intramembranous and endochondral ossification in vivo 
with osteogenic differentiation preceding mineralization [105].The current study, as well 
as recent studies cited above, suggest that this process might be able to occur in reverse, 
with mineralization inducing differentiation by the creation of an osteoinductive 




In conclusion, markers of osteogenic differentiation in ESCs were responsive to 
the subtle manipulation of the culture environment achieved through introduction of 
endogenously formed CaP precipitates, created by the addition of just an organic 
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phosphate substrate, βGP. CaP precipitate-induced differentiation resulted in osteogenic 
gene expression and protein production by EBs and occurred via activation of the ERK 
1/2 signaling, a response conserved across multiple cell types. The current study 
established an EB model for studying the endogenous differentiation capacity harbored 
by differentiating ESCs, with minimal exogenous cues, allowing for the identification of 
more subtle processes and interactions that may be occurring within the cellular 
microenvironment of differentiating cells. Such a model provided a window to probe the 
interrelationship between differentiation and mineralization during the earliest stages of 
development and established a test bed for future mechanistic studies of osteogenic 
differentiation. This work not only provided insights into the physiology of calcified 
tissues but also raised the possibility devising a strategy to capture or mimic the cues 
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CHAPTER 6 
DEVITALIZED EMBRYOID BODY-DERIVED MATERIAL 
INDUCES BONE FORMATION IN VIVO 
 
Introduction 
Acellular matrix-derived therapies are attractive because of improved handling 
characteristics and stability over fresh tissue and may be derived by a variety of 
techniques, including chemical and physical treatments. The resultant acellular materials 
lack viable cells but retain natural ECM components, such as structural adhesive proteins, 
glycosaminoglycans and bioactive growth factors embedded within the native matrix 
from the tissue of origin [70-73]. One such acellular matrix in use commonly for clinical, 
bone regenerative applications is demineralized freeze-dried bone allograft, also 
commonly referred to as demineralized bone matrix (DBM). While autograft bone is the 
gold standard for bone repair, its use is limited by significant donor site morbidity and 
limited source of material [218]. An alternative, therefore, is the use of cadaveric-
sourced, allograft tissue, such as DBM [22]. Extraction of the mineral phase of bone by 
acid treatment yields a demineralized matrix comprised of mostly collagen, along with 
non-collagenous matrix proteins and associated growth factors. Extracellular matrix 
associated growth factors may additionally have increased bioavailability after 
demineralization, due to an increased hydration state [49] and unmasking of regions of 
matrix obscured and entrapped beneath mineralization [219]. Increased growth factor 
bioavailability after demineralization may therefore account for the observation that, 
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when implanted in an ectopic site in vivo, DBM is osteoinductive while non-
demineralized bone matrix is not osteoinductive [50]. Factors found to be present in 
DBM include primarily bone morphogenetic proteins (BMPs), which impart DBM its 
osteoinductivity, in combination with, but to a far lesser extent, other factors, including 
vascular endothelial growth factor (VEGF) [31, 51].  
Since its first description in the 1960’s, the osteoinductivity of DBM has long 
been known to be due mostly to its BMP-2 content [22-24]. BMP-2 is directly 
osteoinductive, and as such, recombinant human BMP-2 is employed clinically as a 
single factor therapy used to promote bone growth and regeneration, although at 
supraphysiologic doses in the milligram range [InFUSE; Medtronic Sofamor Danek, 
Memphis, TN] compared to the nanogram amounts present within clinical doses of DBM 
[25]. DBM also contains VEGF, which is vital to osteoinductivity, as it is required for 
endochondral bone formation and promotes neovascularization allowing for the 
recruitment of the mesenchymal progenitor cells that are acted upon by the BMP to form 
new bone [5, 27, 28]. Another osteoinductive factor of interest but not abundant in adult 
bone-derived DBM is BMP-4. Like BMP-2, BMP-4 is directly osteoinductive, due to 
their high level of homology [31]. During endochondral ossification in vivo, knockout of 
either Bmp2 or Bmp4 is rescued by endogenous expression of the other, allowing for 
normal bone formation, suggesting interchangeable roles during osteogenesis; however, 
removal of both BMP-2 and BMP-4 together completely inhibits osteoblast 
differentiation and long bone development in vivo [32]. However, BMP-4 is also critical 
during earlier stages of development and necessary for gastrulation and mesoderm 
formation [36]. With respect to DBM osteoinductivity, in vivo intramuscular 
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osteoinductivity has been found to be correlated with the amount of BMP-4 extractable 
from DBM, measured in vitro [61] though it has also been reported to be undetectable in 
DBM by other studies [25, 51]. 
The osteoinductivity of DBM preparations is often evaluated in vivo, by 
intramuscular implantation into the hindlimb of nude athymic mice [53]. This model is 
widely used for the evaluation of DBM [64, 220, 221] and is accepted as the ASTM 
standard for the evaluation of osteoinductivity of materials [62]. In the intramuscular 
model, it is believed that DBM particles recruit MSCs to the implantation site before 
inducing the formation of a cartilage intermediate and eventual bone, in a manner 
analogous to endochondral bone formation [26]. The osteoinductive factors within DBM 
can be inactivated by heating, and so inactive DBM may be used as a carrier for the 
evaluation of growth factors, which may modify the osteoinductivity of DBM [222]. For 
example, the approach of co-delivering a single,soluble growth factor with inactive DBM 
has been used to evaluate BMP-2 [24] and platelet derived growth factor (PDGF) [63], 
but the same technique can also be employed to deliver more complex mixtures and 
materials [223]. 
The use of DBM comes with its own caveats though. The in vivo osteoinductivity 
of DBM has been found to vary manufacturer to manufacturer and even batch to batch 
from the same manufacturer [53]. As with any cadaveric-sourced, allograft tissue, there is 
limited donor availability, as well as little control over donor characteristics, such as age, 
or environmental exposures, such as pharmaceutical use, that may impact the quality and 
osteoinductivity of DBM, which in turn leads to donor to donor and batch to batch 
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variability [2, 25, 51, 54, 55]. These donor tissue limitations motivate the identification of 
a more homogeneous and controlled material source. 
One approach that has been explored to overcome donor to donor tissue 
variability is the generation of extracellular matrix (ECM) and acellular biomaterials in 
vitro derived from a single, starting cell source. This method has been used to generate 
devitalized materials produced by MC3T3-E1 osteoblast-like cells [75] and mesenchymal 
stem cells (MSCs) [76, 78, 224] that were found to be osteoinductive when re-seeded 
with exogenous cell types in vitro. Though in vitro results were encouraging, when MSC-
derived ECM osteoinductivity was evaluated in vivo, no new bone formation was 
observed [65]. The disparity between in vitro and in vivo results may be explained by the 
heterogeneity of cell types that are able to respond to the implant in vivo compared with 
the single, osteogenic cell type that was seeded in vitro. Additionally, as the ECM was 
already highly mineralized pre-implantation, the bioavailability of associated growth 
factors may have been reduced, blunting their osteoinductive capability. In the absence of 
strongly osteoinductive cues, or ones masked by mineralization, other cell types resident 
within the tissue exhibited a stronger response to the implanted material than the 
osteoprogenitor cell population, forming a fibrous capsule and hindering further 
progenitor cell recruitment and infiltration before new bone could be formed. The fibrous 
response to the MSC-derived material was similar to that previously observed to non-
demineralized bone matrix [50]. For the given reasons, the MSCs used to generate the 
devitalized material, in vitro, may have had too mature an osteoblastic phenotype leading 
to a balance of ECM and osteoinductive cues that was not optimized to favor bone 
formation.  
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Pluripotent cells, including embryonic stem cells (ESCs), are an attractive 
alternative source of starting cells. Pluripotent ESCs, derived from the inner cell mass of 
blastocyst stage embryos, are capable of extensive self-renewal and differentiation into 
cell types comprising all three germ lineages (ectoderm, endoderm, and mesoderm) [89]. 
As such, these cells are capable of differentiating not only into osteogenic lineages, but 
also into associated cell types, such as endothelial and hematopoietic cells, that contribute 
to bone formation and maintenance [3, 105, 195]. Additionally, ESCs are capable of 
producing molecules that can affect the growth and injury response of somatic cells and 
tissues, a function that may be lost in mature cells [86]. ESCs may be differentiated as 
three dimensional cell aggregates, embryoid bodies (EBs), and devitalized EB material 
(EBM) may be derived from these cells by chemical[225, 226] and physical disruption 
techniques, including freeze-drying by lyophillization [69], while retaining bioactive 
factors. The use of an acellular therapy derived from devitalized ESCs, such as EBM, 
eliminates the risk of teratoma formation associated with the direct delivery of viable 
ESCs or EBs [87]. ESCs undergo osteogenic differentiation in response to a variety of 
different media supplements [103-105, 111], but previous studies presented here have 
looked specifically at osteogenic differentiation within EBs in response to β-
glycerophosphate (βGP) treatment alone (see Chapter 4, 5). Cell lysates from EBs with 
and without βGP treatment have previously been found to contain physiologically 
relevant concentrations of growth factors known to contribute to DBM osteoinductivity: 
BMP-2, BMP-4, and VEGF (see Chapter 5). 
Given the presence of osteoinductive factors within EBM, in particular BMP-2, 
BMP-4, and VEGF, the goal of this study was to evaluate whether or not this ESC-
 115 
derived material harbors osteoinductive potential. It was hypothesized that bioactive 
factors enriched within the embryonic-like microenvironment within EBs, in particular 
BMP-2 and BMP-4, would recruit and induce the differentiation of bone forming cells 
when implanted, in vivo, and that osteoinductive potential of EBM would be enhanced 
when derived from EBs undergoing osteogenic differentiation in response to phosphate 
stimulation. The use of a less mineralized material than investigated in previously 
unsuccessful MSC studies was expected to improve growth factor bioavailability and 
material osteoinductivity. The goals of the study were achieved by quantifying levels of 
BMP-2, VEGF, and BMP-2 extracted from EBM, and evaluating osteoinduction 
compared to active and inactive DBM in vivo by implantation into a nude athymic mouse 
hindlimb intramuscular implantation model. Osteoinductivity was measured by 
mineralization quantification, semi-quantitatitve bone induction score, and quantitative 
histomorphometric measurements of new bone formation. 
 
Materials and Methods 
Mouse ESC culture  
Mouse embryonic stem cells (D3 cell line) were maintained in the 
undifferentiated state on 0.1% gelatin coated tissue culture dishes in ESC media 
containing DMEM (Mediatech, Herndon, VA) supplemented with 15% FBS (Hyclone, 
Logan, UT), 2mM L-glutamine (Mediatech), 1x non-essential amino acids (Mediatech), 
100U/ml penicillin/ 100 μg/ml streptomyocin/ 0.25 μg/ml amphotericin (GIBCO, 
Carlsbad, CA), 0.1 mM β-mercaptoethanol (Fisher, Fairlawn, NJ), and 10
3
 U/mL of 
leukemia inhibitory factor (LIF, Chemicon, Temecula, CA). Media was changed at least 
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every 2 days, and cells were passaged every 2-3 days before reaching 70% confluency 
with 0.05% trypsin (GIBCO). 
 
EB formation and osteogenic differentiation 
EBs were formed by the ultra-high throughput, forced aggregation method using 
Aggrewell™ inserts [148] with 1000 cells per well, as described in Chapter 3 – General 
Methods. EBs were either left untreated, or osteogenic differentiation was initiated by 
addition of 10 mM β-glycerophosphate (βGP, MP Biomedical, Solon, OH) beginning 
from day 5 of EB differentiation. For cell pellet growth factor analysis, EBs were 
cultured in 10 nM dexamethasone, 50 μg/ml ascorbic acid, and 10 mM βGP from day 5-
10. 
 
Characteristics of DBM used 
DBM previously found to have high osteoinductive capacity was used as a 
positive control for bone formation (Musculoskeletal Transplant Foundation, Edison, NJ). 
DBM was derived from donated, human cadaveric tissue and processed by cleaning, de-
fatting, and disinfecting of the cortical bone; grinding bone to yield particles of sizes 
between 400-1000 μm; demineralization of the bone particles in dilute hydrochloric acid 
solutions to result in a residual calcium content less than 8% per American Associate of 
Tissue Banks (AATB) standards; and freeze-drying of the final product. DBM from the 
same lot as that used for the positive control was heated at 105 °C for 24 hours to 
inactivate osteoinductive factors present within the DBM, and inactive DBM was then 
used as a negative control and as a vehicle for the delivery of EBM.  
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Characterization of EBM 
Devitalized EB material (EBM) was isolated at day 5, 10, and 14 of EB 
differentiation by lyophillization, as described previously by Ngangan and McDevitt [69], 
from untreated EBs (-βGP) as well as EBs initiated to undergo osteogenic differentiation 
and mineralization (+βGP). Previous studies have demonstrated osteogenic 
differentiation and mineralization in response to βGP treatment administered from day 5 
of differentiation (see Chapter 4). Briefly, cell spheroids in each group were harvested at 
day the day of isolation by gravity-induced sedimentation for ~5 minutes in a 50 ml 
conical tube for every five 100 mm dishes, and excess media was aspirated. Spheroids 
were washed twice in phosphate-buffered saline, resuspended in sterile, deionized water, 
and aliquoted into microcentrifuge (1.5 ml) tubes (~2x10
3
 EBs per tube). After pelleting, 
tubes were frozen in water at -80°C overnight and then lyophilized overnight to generate 
devitalized material (Labconco, Kansas City, MO).  
 To assess gross morphology and characteristics, images of DBM and EBM were 
acquired using a dissecting stereomicroscope equipped with a digital camera (Nikon 
SMZ1500). EBM and DBM were also evaluated histologically. The materials were 
embedded in Histogel (Richard Allen Scientific, Kalamazoo, MI), dehydrated via an 
increasing series of ethanol and xylene rinses (Shandon Pathcentre Enclosed Processor), 
embedded in paraffin (Shandon Histocentre 2 Embedding System), cut into 5 μm-thick 
sections (Microm HM 355S Rotary Microtome), and placed on positively charged glass 
slides. Sections were stained by routine H&E (Leica AutoStainer XL). 
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To further evaluate for the presence of collagen within EBM, a modified 
Mallory’s Aniline Blue (MMAB) staining protocol was used [227]. Aniline blue is a 
constituent of commonly used Masson’s Trichrome stain protocols to demonstrate 
collagen. Briefly, deparaffinized slides were post-fixed in Bouin’s fixative before staining 
in 0.125% acid fuschin solution, differentiation in 1% phosphotungsic acid solution, and 
staining of collagen by 0.5% aniline blue solution. 
Growth factor retention within EBM and within EB cell pellets was evaluated by 
enzyme linked immunosorbent assays (ELISA) as described in Chapter 3 – General 
Methods. Unknown values were compared to a standard curve generated from known 
concentrations of individual proteins in Tissue Protein Extraction Reagent (TPER, 
Pierce). Though the antibodies used were directed against human isoforms of each 




 The end point chromogenic limulus amebocyte lysate (LAL) endotoxin test 
(Lonza, Walkersville, MD) was used to assay the levels of endotoxin present in EBM. 
Briefly, EBM samples were resuspended in 500 μL sterile PBS, placed on a rotisserie for 
30 minutes at room temperature, and centrifuged for 5 minutes at 14,000 RPPM to 
remove particulates. Endotoxin testing was performed as described in the product 
manual. Briefly, test samples and endotoxin standards reacted with the LAL for 10 
minutes, followed by the addition of a substrate solution and incubated for 6 minutes, and 
then the reaction was stopped with stop reagent (25% glacial acetic acid solution). The 
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entire reaction was performed at 37°C. Absorbance readings at 405nm were taken using a 
SpectraMax M2e plate reader, and the endotoxin concentration (EU/mL) was calculated 
using the standard curve generated using the endotoxin standard supplied with the kit. 
 
Preparation of Implants 
For intramuscular implantation, DBM and day 10 EBM were loaded into size 5 
gelatin capsules (Torpac, Fairfield, NJ) that had previously been UV-sterilized overnight. 
Previous studies have demonstrated that gelatin capsules dissolve quickly and do not 
affect osteoinductivity [2, 53]. Capsules were loaded in a biological safety cabinet in 
order to maintain sterility. 15 mg of DBM (active or inactive) was loaded into each 
capsule for positive and negative controls respectively. For day 10 EBM groups (-βGP 
EBM, +βGP EBM), 7.5 mg of inactive DBM was first loaded, and then 7.5 mg of EBM 
was added. The two materials were mixed together inside the capsule using a spatula. To 
ensure sterility before implantation in vivo, capsules were further sterilized by UV light 
overnight. Prior evaluation of the positive control DBM was conducted using the same 
protocol, so any loss in osteoinductivity resulting from the sterilization procedure was 
accounted for. In a separate study, viable day 10 EBs (~10
3
 EBs) with and without βGP 
treatment were implanted intramuscularly. EBs were resuspended in 100-200 μl of PBS 
and transferred into gelatin capsules immediately before surgical implantation.  
 
Implantation Protocol 
Material formulations were implanted according to a Georgia Institute of 
Technology Institutional Animal Care and Use Committee approved protocol. Sixteen 
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male athymic Nu/Nu mice (Harlan, Indianapolis, IN) were divided into four groups with 
four mice each (Active DBM, Inactive DBM, -βGP EBM, +βGP EBM). A nude mouse 
strain with reduced helper T cells was chosen to reduce the possibility that the observed 
response was immunological rather than due to the implanted materials themselves. 
Samples were implanted into the gastrocnemius with one implant per limb, and each 
mouse received two of the same implant, reducing systemic effects or influence of one 
implant type on the other, giving eight implants per sample. Previous studies have 
demonstrated that an implant in one limb may cause systemic effects that influence 
response to an implant of a different type in the contralateral limb [228]. 
Mice were anesthetized by inhalation of 5% isofluorane in O2, and hind limb 
implantation sites on both legs were disinfected with isopropanol and chlorhexiderm. A 
0.5 cm incision was made over each gastrocnemius, and a muscle pouch was created 
under each muscle by blunt dissection. Implants were inserted into the muscle pouch, and 
the incision was closed by wound clips before dissolution of the gelatin capsule. Mice 
were housed for 35 days under conditions suitable for their immunocompromised state 
and were given food and water ad libitum. Studies have previously demonstrated that 35 
days is sufficient to demonstrate osteoinductive activity by this model [2, 53]. 
 
Evaluation of mineralization – X-ray and micro-computed tomography (μCT) 
For evaluation of mineralization and new bone formation, animals were 
euthanized at 35 days post-implantation by carbon dioxide asphyxiation. Hind limbs were 
removed and fixed in 10% neutral buffered formalin, and limbs examined by X-ray to 
localize the site of implantation (Faxitron, Lincolnshire, IL). The number of limbs 
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containing mineralization detectable by X-ray was noted for each group, and 
mineralization at the site of implantation was then further evaluated by μCT. The samples 
were scanned in air
 
using a µCT 40 (Scanco Medical, Brüttisellen, Switzerland)
 
at 55 
kVp, 145 µA, 200-ms integration time, and a voxel size
 
of 30 µm in a 30 mm scanning 
tube. Evaluation of µCT scans used sigma, support and threshold values set at 3.3, 2, and 
70, respectively. Mineral volumes are expressed as absolute volume of mineralization. A 
minimum threshold of percent total volume containing mineralization was established 
(0.05%), above which limbs were counted as being positive for mineralization by µCT. 
Limb measurements were obtained and used to obtain an estimate of total hindlimb 
volume for these calculations. 
 
Histological evaluation 
After mineralization analysis, hind limbs were decalcified in 14% EDTA in water 
(pH 7) for two weeks (Sigma), before paraffin embedding and sectioning, with the 
progression of decalcification monitored daily by X-ray. Three consecutive cross sections 
(5 μm) were collected per slide at three different levels in the region of the implant along 
the longitudinal axis of the limb and were stained by routine hematoxylin and eosin stains 
(Leica AutoStainer XL). Each level was at least 250 μm apart from one another, and 
adjacent sections at each of the three levels were also collected for additional staining. 
The mouse tibia and fibula were used as reference points to confirm the correct 
orientation of the sections as the implants may have shifted after surgery once mice began 
applying weight to their hind limbs. All stained sections were evaluated by light 
microscopy for the presence or absence of DBM particles and new bone formation. One 
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complete section (of the nine total) per implant exhibiting the greatest amount of ossicle 
formation and residual DBM was selected. Because the selected section was the one 
containing residual DBM and the most new bone, the results were positively biased 
toward success for each implant type. To further evaluate for the presence of residual 
EBM within the implant site, the MMAB staining protocol described above was also used 
on sections adjacent to the sections chosen for scoring and histomorphometric evaluation.  
For osteoinduction scoring, the entire section was qualitatively evaluated by two 
independent observers blinded to implant type and graded according to the previously 
published semi-quantitative rating system [2, 53, 63]. A score of 0 was given when no 
residual DBM or EBM was observed within the entire section. A score of 1 was given 
when residual EBM or DBM particles were present without any new bone formation. A 
score of 2 indicated one ossicle was observed, a score of 3 indicated ossicle formation 
present at multiple sites, and a score of 4 indicated ossicle formation covering >70% of 
the entire limb section examined. Observer scoring was calibrated to an experienced 
scorer prior to the start of the experiment. In cases where observer scores disagreed, the 
disputed sections were evaluated and scored by a third observer (ZS). The overall grade 
for each implant type was obtained by averaging the eight scores for the samples in each 
group. Implants receiving a score of 1.5 or greater were considered osteoinductive. 
The same histological sections used for osteoinduction scoring were also 
evaluated by quantitative histomorphometric analysis using Metamorph™ software (v. 
7.5, Molecular Devices, Sunnyvale, CA). Images of the implant site in each section were 
captured at the appropriate magnification using a Nikon 80i Upright light Microscope 
equipped with an externally mounted digital camera (Spot Flex, Diagnostic Instruments, 
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Sterling Heights, MI). Calibrations of distance were performed according to manufacturer 
instructions accompanying the software. The areas of total ossicle formation (marrow 
space and associated new bone), new bone, and new bone marrow alone (distinct from 
DBM and limb bones) were measured. The semi-quantitative score indicated both 
whether osteoinduction occurred and the number of ossicles formed, whereas the 
quantitative histomorphometry provided an assessment of the total amount of new bone 
formed but not whether it was located as one large ossicle or as multiple smaller ossicles. 
 
Statistical analysis 
Results are presented as mean and standard error of the mean for each variable, 
with n being the number of implant sites (n=8), unless otherwise noted. In cases where 
the entire data set for a given measurement did not approximate a normal distribution 
when first examined by exploratory data analysis, including examination of box and 
whisker plots, the data were transformed by Box-Cox transformations before further 
statistical analyses [151]. For histomorphometry data, data were not normally distributed 
even after transformation, so Kruskal-Wallis, non-parametric analysis of variance 
(ANOVA) with Tukey’s post-hoc test was used to determine significant differences [229] 
and were performed using MATLAB (Mathworks, Natick, MA). Otherwise, statistically 
significant differences were determined by one-way ANOVA followed by Tukey’s post-
hoc test using Systat 12 (Chicago, IL). p<0.05 was considered significant. 
 
Results 
DBM and EBM characterization 
 124 
DBM and EBM were characterized prior to implantation for general structure, 
composition, and extractable growth factor content. By gross, macroscopic examination, 
DBM was identified as a hard, dense, and particulate material, comprised of distinct 
granular pieces with rough edges. In contrast, EBM had a “cottonball” appearance that 
was loosely packed with handling characteristics similar to that of a dry powder and still 
had the ultrastructure of individual EBs identifiable (Fig. 6.1 A left panel). These 
differences in material architecture between DBM and EBM were also observed at the 
microscopic level, as revealed by H&E staining. DBM was comprised of solid, 
eosinophilic particles on the size range of 400-1000 μm, whereas EBM had a looser 
structure, again with the architechture of individual EBs still intact (Fig. 6.1 A center 
panel). EBM macro- and microscopic structures and staining were unchanged regardless 
of day of isolation and βGP treatment and were similar to previously published data [69]. 
MMAB staining revealed abundant, positive collagen staining (blue stain) of DBM, while 
EBM was apparently devoid of collagen, based on the lack of positive aniline blue 
staining.  
ELISA was used to quantify the extractable amounts of several key growth factors 
within EBM and DBM known to be important in bone development and repair: BMP-2, 
BMP-4, and VEGF. All three growth factors could be extracted from EBM and were 
present at significantly higher levels than could be extracted from DBM by TPER buffer 
in this study (p<0.005, Fig. 6.1 B). Osteogenic differentiation of EBs under βGP 
treatment did not alter the amounts of any of these three growth factors at day 10 or day 
14, though the production of BMP-2 and BMP-4 were temporally regulated over the 
course of EB differentiation. More BMP-2 was produced and retained within +βGP EBM 
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isolated at day 14 compared to day 5 untreated EBM (p<0.05), and BMP-4 was reduced 
in day 14 +βGP EBM compared to day 5 and day 10 isolated EBMs. In a separate 
experiment to evaluate the influence of other commonly used osteogenic supplements on 
BMP-2 and BMP-4 production, EBs were cultured from day 5 to 10 with βGP along with 
dexamethasone and ascorbic acid. The addition of these other factors did not change 
levels of BMP-2 produced in EBs but significantly increased BMP-4 production 
compared to untreated samples (p<0.05). However, this increase was only 1.4 fold 




Figure 6.1. Characterization of DBM and EBM. DBM and EBM structure and 
composition were examined macroscopically (left) and microscopically revealing 
different material architectures (center, H&E) and collagen content (right, modified 
Mallory’s Aniline Blue (MMAB)) (A). Growth factors extracted from both materials 
were quantified by ELISA. More BMP-2, VEGF, and BMP-4 were extracted from EBM 
than from DBM (B). n=3 samples, Box-Cox transformation, ANOVA, Tukey’s post-hoc 
test, ***p<0.005 compared to DBM, #p<0.05 for marked comparison, %p<0.05, 




For subsequent in vivo evaluation, EBM was isolated at day 10 of differentiation. 
Since EBM formulations were all found to contain BMP-2, BMP-4, and VEGF levels on 
the same order of magnitude regardless of day of isolation, this time point was chosen 
based not only on the growth factor content, but on the presence of mineral deposits 
within EBs. In previous studies, βGP-induced mineral accumulation began by day 10 and 
increased through day 14 (see Chapter 4). Because mineral volume was used as an 
assessment in this study, the day 10 time point was chosen for isolation of EBM to avoid 
biasing these measurements. Additionally, the variability in EBM yield was decreased at 
day 10 compared to day 14. Furthermore, highly mineralized matrices may have 
decreased bioavailability of growth factors compared to less mineralized matrices 
because of decreased hydration and masking of growth factors by the mineralization [49, 
219]. After selection of culture day, the endotoxin levels of EBM prepared for 
implantation were assayed. The amounts of endotoxin contained within –βGP and +βGP 
EBM samples were found to be 0.18 ± 0.05 and 0.23 ± 0.08 EU/ml, which were less than 
the FDA guideline of 0.5 EU/mL (Fig 6.2) [230]. Taken together, EBM selected for 
implantation contained acceptably low endotoxin levels while maintaining factors known 





Figure 6.2. EB BMP production.  BMP4 and BMP-2 produced by EBs undergoing 
osteogenic differentiation were quantified from EB cell pellets by ELISA. At day 10, EBs 
treated with a combination of dexamethasone (Dex), ascorbic acid (AA) and βGP 
produced equal amounts of BMP-2  and more BMP-4 than EBs treated with βGP alone 
(p<0.005)  or left untreated (p<0.05). n=3 samples, ANOVA, Tukey’s post-hoc test, 




Figure 6.3. EBM endotoxin levels. EBM was evaluated for the presence of endotoxin by 
LAL assay. –βGP and +βGP EBM preparations were found to contain the same amount 




Validation of the nude mouse muscle-implantation assay 
The DBM used in the study was osteoinductive (osteoinduction score = 2.75 ± 
0.16), with an identical semi-quantitative score to that derived by previous studies using 
the same batch (Fig. 6.6 B). Heat inactivation resulted in a loss of this osteoinductivity 
(score = 1.13 ± 0.13), p<0.005 between inactive and active DBM). The quantitative 
histomorphometric measurements of osteoinduction (ossicle, marrow space, and new 
bone areas) were in agreement with the semi-quantitative score, demonstrating 
osteoinductivity by increases in each of these measures in response to active DBM 
compared to inactive DBM (p<0.5, Fig. 6.8). No evidence of pathological changes were 
present, such as infection of muscle wasting, with surrounding tissues normal and no 
signs of fibrosis in the sections. Additionally, the existing long bones had a normal 
histological appearance. These observations indicate that the model was valid and that the 
osteoinductive effects of EBM preparations could be assessed from the results. 
 
Viable EB implantation 
 In a separate study, day 10 EBs, both with and without βGP treatment, were 
implanted in the same nude athymic mouse intramuscular ectopic osteoinduction model. 
By 21 - 28 days post-implantation, all mice receiving viable EBs were found to have 
masses in their hindlimbs of varying sizes and were sacrificed early (Fig. 6.4 A). When 
the limbs were excised and evaluated by H&E staining, cells of all three germ lineages 




Figure 6.4. Viable EB Implantation. Viable day 10 EBs alone, with and without βGP 
treatment, were implanted in mouse hindlimbs. Large masses in the hindlimbs were 
formed by 28 days post-implantation (A), and when evaluated histologically, the masses 
were determined to be teratomas comprised of all cells from all three germ lineages (B). 
Tibia (T), Fibula (F), Scale bar in B = 250 μm. 
 
In vivo osteoinductivity of EBM – mineralization analysis 
35 days post implantation, mineralization associated with the DBM and EBM 
implant sites was detectable by X-ray (Figure 6.5 A, top panel). Multiple areas of 
mineralization were present throughout active DBM implanted samples. In contrast, 
fewer but more tightly localized areas of mineralization were observed in EBM implanted 
samples. 8 out of 8 limbs implanted with active DBM and 7 out of 8 limbs implanted 
with +βGP EBM exhibited mineralization that could be visualized by X-ray compared 
with 3 out of 8 limbs and 1 out of 8 limbs for -βGP EBM and inactive DBM, 
respectively. As expected, X-ray and μCT results matched one another, with the same 
limbs with mineralization detectable by X-ray exhibiting mineral detectable by μCT 
(>0.05% total limb volume, 0.10 mm
3
) (Fig. 6.5 A, bottom). Comparing the average 
mineral volume for each group, including limbs with no mineralization, active DBM 
(3.59 ± 1.20 mm
3
) and +βGP EBM (0.93 ± 0.47 mm
3
) had increased amounts of 
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mineralization compared to inactive DBM alone (0.06 ± 0.04 mm
3
, p<0.005, p<0.05). 
Additionally, active DBM had significantly more mineralization than –βGP EBM 
samples (0.41 ± 0.19 mm
3
, p<0.005). Based on the combined mineralization analyses, 





Figure 6.5. Evaluation of mineralization in vivo. DBM and EBM formulations were 
evaluated in a mouse intramuscular osteoinduction model. Mineralization associated with 
the material implant sites was visualized by X-ray predominantly in limbs treated with 
active DBM (8/8 limbs) and + βGP EBM (7/8 limbs) (# of limbs with mineralization 
detectable by x-ray/total number of limbs per group) (A, top). Mineralization was further 
visualized and quantified by μCT and was also found predominantly in active DBM (8/8 
limbs) and + βGP EBM (7/8 limbs) (# of limbs with mineralization detectable by μCT 
(mineral volume > 0.05% of total limb volume (0.10 mm
3
))/total number of limbs per 
group) (A, bottom). The total mineral volume per limb, quantified by μCT, was also 
found to be increased in active DBM and + βGP EBM implanted limbs (B). n=8 samples, 
Box-Cox transformation, ANOVA, Tukey’s post-hoc test, *p<0.05 compared to inactive 
DBM alone, #p<0.05 compared to –βGP EBM. 
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In vivo osteoinductivity of EBM – histological assessments and new bone formation 
Because mineralization can occur in the absence of new bone formation and new 
bone formation can occur in the absence of mineralization, further histological 
assessments were undertaken as the definitive determination of the osteoinductivity of 
these materials. H&E stained sections from each implant site were evaluated for the 
formation of ossicles, which are characterized by the presence of new bone formation, 
amalgamation of new bone with residual DBM at their interface, and associated new 
marrow space.(Fig. 6.6 A, Fig, 6.7 A). Sections evaluated from both EBM implanted 
groups were often found to have a single large ossicle per section, sometimes larger than 
the 0.78 mm
2
 field of view at 10x, while sections from the active DBM group tended to 
have multiple smaller ossicles, located within a larger area of residual DBM (Fig. 6.6 A). 
Additionally, regions of mineralization in both EBM implanted sample groups 
corresponded directly with new bone formation as evaluated histologically. When 
sections were taken directly at the location of mineralization, determined by X-ray and 
μCT, ossicle formation was observed at that site in all EBM samples that contained 
mineralization. Conversely, the size and distribution of ossicles observed in the active 
DBM group did not always appear to match directly the mineral volume measurements. 
After localization of ossicles, the EBM implanted limbs were further examined for signs 




Figure 6.6. New bone induction and osteoinduction score. H&E stained sections 
obtained from DBM and EBM implanted limbs were evaluated and scored for the 
presence of ossicles and new bone formation, with the presence of residual DBM (*), 
new bone (^), and marrow space ($) identified in active DBM and both EBM implanted 
limbs. Residual EBM (+) was also noted in EBM implanted samples (A). Bone induction 
scores were based on a semi-quantitative assessment of ossicle formation in the H&E 
stained sections, with 1 representing an implant with no osteoinductivity (B). Active 
DBM and +βGP EBM were found to be osteoinductive (score >1.5, 95% confidence 
interval) and to have significantly higher scores than both Inactive DBM and –βGP EBM. 
ANOVA, Tukey’s post-hoc test, *p<0.05 compared to inactive DBM alone, #p<0.05 
compared to –βGP EBM. 
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Though the EBM was not labeled prior to implantation, areas within or 
immediately adjacent to some of the large ossicles observed in both EBM groups 
contained material not present in any of the active or inactive DBM samples, either in 
areas of DBM, associated with ossicles, or within any normal tissue throughout the rest of 
the tissue section (Fig. 6.7 A, top). The observed material was identified as EBM based 
on its observation in only EBM implanted limbs, its location within the implant site in 
relation to residual DBM and new bone formation, and its unique H&E staining pattern. 
The EBM was found to be amalgamated with the new bone, with new bone integrating 
along the EBM boundaries in direct apposition to the material, similar in appearance to 
what was observed at the interface of new bone with residual DBM. Some EBM was 
observed embedded within newly formed bone within the large ossicles and was further 
distinguished from new bone by its speckled staining pattern (Fig. 6.7 B, top). Based on 
previous studies of EB matrix composition and staining pre-implantation, including low 
collagen-I expression by EBs (see Chapters 4, 5) and lack of positive Aniline blue 
staining in pre-implantation EBM (Figure 6.1 A), EBM did not contain much collagen. 
Because new bone and residual DBM are rich in collagen, additional stains were 
undertaken to distinguish the EBM by this difference in collagen content. MMAB stain 
was used to identify collagen rich materials within the ossicle regions (Fig. 6.7 A, 
bottom). As expected, DBM (active and inactive) and new bone both stained blue by 
MMAB, demonstrating a composition rich in collagen. However, the distinct regions of 
EBM identified by H&E were largely devoid of collagen, further supporting the 
material’s identification as residual EBM (Fig. 6.7 B, bottom).. Taken together, the 
combination of stains used demonstrated ossicle formation and the presence of residual 
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EBM in EBM implanted samples, along with the physical association of EBM with new 
bone formation. Based on the H&E stained sections, semi-quantitative measurements 
accounting for the number of limbs exhibiting ossicle formation and the number of 
ossicles formed were then undertaken to compare the osteoinductivity of each group.  
Based on semi-quantitative osteoinduction score, +βGP EBM and active DBM 
induced new bone formation by 35 days post implantation, whereas inactive DBM did 
not (Fig. 6.6 B). The +βGP EBM group was osteoinductive (score = 2.50 ± 0.27), with a 
higher semi-quantitative osteoinduction score than both inactive DBM negative control 
(p>0.005) and -βGP EBM (p<0.01) and no difference in osteoinduction score compared 
to the active DBM positive control. Though -βGP EBM was not found to be 
osteoinductive (score = 1.50 ± 0.37, mean score ± 95% confidence interval), with no 
difference in its score compared to inactive DBM, large ossicles were also formed in 4 
out of 8 -βGP EBM implanted limbs, including all three that demonstrated mineralization 




Figure 6.7. Presence of residual EBM. Representative H&E stained sections from each 
implant group were compared with adjacent sections stained by modified Mallory’s 
Aniline Blue (MMAB) stain, which demonstrates collagen in blue (A). Higher 
magnification images from a +βGP EBM implanted limb revealed that residual EBM 
stained differently by both H&E and MMAB than both residual DBM and newly formed 
bone and that EBM was embedded within the newly formed bone in EBM implanted 
limbs (B). Residual DBM (*), new bone (^), and marrow space ($), residual EBM (+). 
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Quantitative measurement of new bone formation was increased in the +βGP 
EBM group compared to inactive DBM, with no difference compared to the active DBM 
positive control. All limbs that demonstrated mineralization by X-ray and μCT exhibited 
ossicle formation when evaluated histologically (Fig 6.8 A). Based on histomorphometry, 
measures of ossicle area, new bone, and marrow space area were increased with +βGP 
EBM implants compared to inactive DBM (p<0.05), similar to measures observed in the 
active DBM implanted limbs (p<0.05 between active and inactive DBM) (Fig. 6.8 B-C). 
No difference was found in any of these measures for either +βGP EBM or active DBM 
when compared to -βGP EBM implants. In summary, mineralization quantification, semi-
quantitative osteoinduction scoring, and histomorphometric evaluations of new bone 
formation, including quantification of ossicle, marrow space, and new bone areas, all 
confirmed the finding that +βGP EBM was osteoinductive in vivo, at a level equal to that 




Figure 6.8. Quantitative histomorphometry. One H&E-stained section was evaluated 
per limb for osteoinduction scoring and histomorphometric measurements, for a total of 8 
sections per group (dotted line, A). Total ossicle area (B), new bone area (C), and new 
marrow space area (D) were measured in all sections from each implant group. Ossicle, 
new bone, and marrow space areas were increased in +βGP EBM and active DBM 
implanted groups compared to inactive DBM. n=8 samples, Kruskal-Wallis non-
parametric ANOVA, Tukey’s post-hoc test, *p<0.05 compared to inactive DBM. 
 140 
Discussion 
 The results of this study demonstrated osteoinductivity of EBM when implanted 
in vivo, which may have been attributed to retention of several osteoinductive growth 
factors, BMP-2, VEGF, and BMP-4, at levels similar to or well above those found in 
DBM. Due to the potential for teratoma formation associated with the implantation of 
viable EBs (Fig 6.4), acellular delivery growth factors produced by EBs, as in EBM, was 
the only safe method for transferring the osteoinductive potential harbored within the EB 
microenvironment to in vivo applications. The osteoinductivity of BMP-2 has been well 
characterized [22, 24]. VEGF has been found to be necessary for cartilage remodeling 
during  endochondral ossification [27], the mechanism by which new bone was formed 
within the intramuscular model used in this study[26, 63]. One osteoinductive factor 
abundant in EBM but largely devoid in DBM was BMP-4. In addition to being directly 
osteoinductive [31], BMP-4 may have served to prime endogenous, host cell populations 
that are responsive to osteoinduction. BMP-4 treatment promoted osteogenic 
differentiation of MSCs expanded ex vivo under low serum conditions, which then 
formed bone when implanted in vivo [231], and low doses of BMP-4 increased the 
survival and stemness of adipose derived stem cells, in vitro [232]. Lastly, these factors 
may have acted in a synergistic manner. Delivery of condensed DNA plasmids for BMP-
4, VEGF, and bone marrow stromal cells synergistically increased bone formation in vivo 
compared to delivery of any single component or any combination of two [233].  
The amounts of BMP-2 and VEGF extracted from EBM in this study were similar 
on a per mass basis to those described in DBM, while an order of magnitude higher 
amount of BMP-4 was present in EBM than has been reported to be in DBM. Previous 
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studies have found variable amounts of each of these growth factors within DBM, 
varying both manufacturer to manufacturer and batch to batch [25, 52]. Levels of BMP-2 
have been measured from 2 – 120 pg/mg DBM [25, 52, 59, 234], while BMP-4 has 
ranged from completely undetectable to at most 8 pg/mg DBM depending on the study 
[25, 51, 59, 61, 234]. In this study, different EBM preparations were found to contain 
extractable BMP-2 levels ranging 13 – 48 pg/mg EBM and BMP-4 levels ranging 77 – 
166 pg/mg EBM, depending on day of isolation and osteogenic differentiation (Fig. 6.1 
B). The EBM implanted in vivo in this study (day 10) contained 20 times more BMP-4 
than the highest reported amount in DBM [61]. VEGF has been reported to vary from 
0.04-0.39 pg/μg total protein between three different manufacturer formulations of DBM 
[51],which were similar to levels measured in EBs within this study (0.03-0.05 pg/μg 
total protein in EBM) (Fig. 6.1 B). The amount of growth factor extracted from DBM has 
varied with extraction method employed, accounting for the underestimation of these 
growth factors from DBM within this study, which used a mild detergent and salt 
solution, TPER. Based on ELISA results for growth factors extracted from EBM, these 
three osteoinductive factors were all present in EBM, regardless of day of isolation or 
osteogenic differentiation with βGP, motivating evaluation of EBM osteoinductive 
potential.  
When evaluated in vivo, +βGP EBM was osteoinductive with respect to 
mineralization, osteoinduction score, and histomorphometric measurements of new bone 
formation. +βGP EBM also performed the same as active DBM by the same 
measurements, but some differences were noted in the distribution and localization of 
mineralization observed and new bone formed. In all groups, limbs demonstrating 
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mineralized tissue by X-ray and μCT also exhibited ossicle formation (Fig. 6.5 A, 6.8). 
However, regions of mineralization were present in active DBM samples that did not 
directly correspond to ossicle formation by histological assessments. Re-mineralization of 
DBM may occur in the absence of new bone formation under physiological conditions 
[235, 236]. In +βGP EBM samples, new bone tended to form as one large ossicle 
compared to multiple smaller ossicles found in the active DBM group. Though the total 
marrow area per section was not increased, isolated, larger ossicles in EBM implanted 
limbs were also associated with more new marrow space per each individual ossicle. The 
development of marrow space to support the newly formed bone is important for its 
maintenance, as it provides a pool of mesenchymal and osteoprogenitor cells for 
continued remodeling of the bone, but the establishment of marrow is also dependent 
upon the formation of new bone first [237, 238]}.  
Examination of similarities and differences between DBM and EBM that may 
favor new bone formation in response to one material or the other may reveal clues to 
differential mechanisms of osteoinduction. Favoring osteoinductivity of EBM, EBM 
contained more BMP-4 than does DBM, as mentioned above. BMP-4 has been found to 
be interchangeable during osteogenesis in vivo with BMP-2 [32], the primary 
osteoinductive factor contained within DBM [22]. Aniline blue staining both pre- and 
post-implantation also demonstrated that DBM was rich in collagen whereas EBM was 
devoid of it. The observed lack of collagen within the EBM was consistent with previous 
studies demonstrating low levels of collagen-I gene expression, regardless of osteogenic 
differentiation, along with little to no apparent collagen at the protein level (see Chapters 
4, 5). The lack of a dense collagenous matrix in EBM may have facilitated vascular in 
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growth, migration of osteoprogenitor cells into the material, and easier remodeling. This 
potential difference in remodeling may explain formation of single, large ossicle in EBM 
samples instead of multiple smaller ossicles in the active DBM group, where residual 
DBM took longer to be remodeled and resorbed [63, 237]. Additionally, the less 
compacted EBM may have allowed for greater bioavailability of contained growth 
factors, which was supported by the ease of growth factor extraction in TPER, a mild 
detergent and salt solution, from EBM compared to DBM in this study. Complete protein 
extractions from DBM have been typically achieved under harsher conditions, such as 
digestion by collagenase [61] or solubilization in guanidine HCl [51]. 
Conversely, the dearth of collagen may be viewed as disfavoring osteoinduction 
by EBM. Interactions between osteoblasts and the collagen-rich bone matrix surrounding 
them are known to be important in bone development and remodeling. Osteoblast 
adhesion to collagen-I fibrils promotes osteoblastic differentiation and is mediated via 
α2β1 integrin binding of collagen [9, 10, 239]. In this study, this difference was 
circumvented by delivery of EBM with inactive DBM, potentially providing a template 
for remodeling and allowing osteoblast binding to occur around the EBM without directly 
altering the EBM composition itself. Delivery of EBM with inactive DBM not only 
eliminated this potential limitation of EBM but also facilitated its localization. 
Preliminary studies delivering EBM alone, without inactive DBM, showed mineralization 
by X-ray, suggestive of osteoinductivity, but were hindered by difficulty in localizing the 
smaller implant site and lack of previous data on how EBM may have been remodeled 
after 5 weeks in vivo. Future studies may eliminate the need for inactive DBM as a source 
of collagen by delivery of EBM within a collagen sponge.  
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–βGP EBM was not found to be osteoinductive or to have increased bone 
formation when compared to inactive EBM but was also not significantly decreased 
compared to +βGP EBM. Additionally, in isolated –βGP samples that exhibited new 
ossicle formation histologically (4 of 8 limbs), histomorphometric measurements of new 
bone formed were still similar to those obtained for +βGP samples, just observed in fewer 
limbs. Both –βGP and +βGP EBM were found to have the same content of the three 
growth factors assayed, so it would be expected that each would have similar 
osteoinductivity; however, the results indicated that growth factor content alone was not 
the sole determinant of osteoinductivity. Some ossicles were formed in response to – βGP 
EBM, with residual EBM visible and associated with new bone, suggesting the growth 
factors that remained present were still capable of inducing bone formation. This 
observation may suggest that the osteoinductive growth factors were not being retained at 
the implant site in –βGP EBM. 
The potential difference in growth factor retention may have been accounted for 
by differences in mineral composition between –βGP and +βGP EBM. Prior to EBM 
isolation at day 10, calcium phosphate containing mineralization was present within EBs 
after βGP treatment (see Chapters 4, 5). The mineralization, generated within EB in vitro, 
may have increased osteogenesis in response to implanted EBM by binding and retaining 
growth factors, particularly BMPs, which had been produced within EBs during 
osteogenic differentiation. Studies in both osteoblasts and vascular smooth muscle cells 
have demonstrated osteogenic differentiation in response to exogenously administered 
calcium phosphate precipitates via extracellular-signal regulated kinase (ERK 1/2) 
pathway activation [131, 132], the same pathway suggested to mediate phosphate 
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treatment-induced osteogenic differentiation in EBs (see Chapter 5). The phenomenon of 
calcium phosphate osteoinduction, in vitro, was likely dependent upon protein 
interactions at the surface of formed calcium phosphate within the microenvironment of 
osteogenic EBs [214] and not due to intrinsic osteoinductive properties of calcium 
phosphate materials in general. Calcium phosphate microparticles have also been 
proposed for the delivery of BMPs because of their protein binding ability [213], and so 
calcium phosphate deposits formed in vitro within EBs may have prolonged the retention 
of BMPs when +βGP EBM was implanted, in vivo. 
Though the exact mechanism of calcium phosphate osteoinductivity observed in 
vitro remains to be elucidated, surface characteristics and how they modulate 
osteoinductive protein production, entrapment, and binding appear to be important. In a 
series of in vivo intramuscular studies of calcium phosphate-containing materials in goats, 
surface geometry was found to alter the dissolution and re-precipitation of calcium 
phosphate and entrapment of organic material, including growth factors such as BMPs, 
which in turn was hypothesized to lead to observed changes in osteoinduction [208, 209]. 
In another study of osteoinduction by calcium phosphate-containing materials, materials 
with specific surface topography that may have entrapped osteoinductive factors induced 
bone formation, in vivo [214]. Additionally, osteoblastic differentiation of MSCs and 
MG63 osteosarcoma cells on titanium surfaces has been found to be modulated in 
response to surface, micron-scale roughness [215, 216]. One final explanation for the 
difference in EBM osteoinductivities could be differential expression of other growth 
factors, inhibitors, or osteogenic matrix molecules that might be present but were not 
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tested for. For example, BMP-7 is also known to be osteoinductive in isolation and is 
used clinically to induce bone formation [Stryker Biotech, Hopkinton, MA]. 
Though the most likely candidates and mechanisms have been discussed, further 
studies and characterization may elucidate the mechanism by which EBM 
osteoinductivity occurs. Additional work is also required to optimize EBM formulation to 
maximize osteoinductivity, including day of differentiation, dosing, and osteogenic 
differentiation supplements used. BMP-2 content and calcium phosphate mineralization 
are increased at day 14 of differentiation with βGP treatment though BMP-4 is reduced. 
Though only one dosage of EBM was investigated in this study, half of the mass dose 
used for the DBM positive control, EBM still performed as well as active DBM by all 
metrics assessed, suggesting a higher per mass potency of EBM, promoting equal, 
perhaps more sustainable new bone formation, based on the associated marrow space 
formed [238]. The difference in potency may be explained by differences in matrix 
composition, as DBM is comprised primarily of collagen, which is lacking in EBM. 
Equivalent dosing of EBM and DBM will allow for more direct comparisons of material 
potency and osteoinductivity. Additionally, in this study, only βGP was used to promote 
osteogenic differentiation of EBs, so the investigation of EBM derived from ESCs 
differentiated with other osteogenic supplements, such as dexamethasone, may be 
explored. It may, however, be preferable to have a more, immature, embryonic-like 
matrix. MSC-derived osteogenic matrix that was found to be osteoinductive in vitro 
failed to demonstrate osteoinductivity when evaluated in vivo [65, 78]. These results also 
raise the possibility of deriving EBM from ESCs directed to differentiate towards other 




In this study, ESC-derived material harbored bioactive, osteoinductive factors 
(BMP-2, BMP-4, VEGF) and was osteoinductive when evaluated in vivo by a nude 
athymic mouse intramuscular osteoinduction model. Additionally, osteoinductivity was 
enhanced in EBM derived from cells undergoing osteogenic differentiation. EBM 
osteoinductivity, measured by amount of mineralization induced, semi-quantitative 
osteoinduction score, and quantitative histomorphometry, was found to be at a level equal 
to that of DBM, a commercially available and widely used osteoinductive material, and 
interestingly, the same osteoinductivity was observed even though half the mass of EBM 
was delivered as active DBM, suggesting a higher potency of EBM, which may be 
attributed to its higher per mass BMP-4 content. The use of EBM presents the possibility 
of removing donor to donor and batch to batch variability that confounds the utility of 
cadaveric sourced DBM, while also suggesting the derivation of a myriad of other tissue 






 In this work, the osteogenic differentiation of mouse embryonic stem cells (ESCs) 
was investigated in response to phosphate treatment, and the mechanism by which 
phosphate induced osteogenic differentiation was examined. Subsequently, the 
osteoinductive embryoid body (EB) microenvironment induced by phosphate treatment 
was harnessed as an acellular material and evaluated for its in vivo osteoinductivity. 
Osteogenic differentiation was enhanced with phosphate treatment at the gene, protein, 
and functional levels and was accompanied by changes in expression and responsiveness 
of two 1α,25(OH)2D3 receptors. Mineral deposits formed within EBs in response to 
phosphate treatment were characterized to be calcium phosphate (CaP) precipitates, and 
the presence of CaP precipitates within the EB microenvironment was associated with 
enhanced osteogenic differentiation via activation of ERK 1/2 signaling. Finally, the 
microenvironment within EBs undergoing osteogenic differentiation, promoted by 
phosphate treatment, was captured as devitalized EB material (EBM) and was found to be 
osteoinductive in vivo, inducing new bone formation at a level equal to that of a 
commercially available and clinically utilized acellular, osteoinductive biomaterial, 
demineralized bone matrix (DBM).   
 Previous studies in more committed cell types, including osteoblasts [116], 
chondrocytes [121, 122], dental pulp cells [133], and vascular smooth muscle cells[134], 
have found phosphate treatment to regulate processes of growth and differentiation in 
mineralizing cell types. Additionally, both osteoblasts and undifferentiated ESCs have 
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high levels of alkaline phosphatase expression and activity, such that alkaline 
phosphatase has been used as a marker to identify both cell types from other cell 
populations. The commonality of high alkaline phosphatase activity suggested that the 
handling of phosphate was important to vital functions or characteristics of both ESCs 
and osteogenic cell types. Based on these findings, the first goal was to investigate if 
phosphate induced signaling and osteogenic differentiation, an effect previously found to 
be mediated through ERK 1/2 activation, was conserved in ESCs differentiated as EBs 
(Chapter 4). Methods typically used for directed osteogenic differentiation of ESCs have 
included a cocktail of factors including either 1α,25(OH)2D3 [105] or dexamethasone 
along with ascorbic acid and βGP [103, 106]. However, as the aim of this study was to 
investigate phosphate induced differentiation and not necessarily to isolate a purified 
population of osteogenic cells, βGP treatment alone was used to promote osteogenic 
differentiation. Another major difference between the current study and those previously 
reported in the literature was that, here, ESCs were maintained as EBs for the entire 
duration of differentiation. Typical methods of directed osteogenic differentiation have 
involved either plating of cells at day 5 after EB formation [103, 105] or maintaining 
ESCs in monolayer culture throughout the differentiation time course [240]. EB 
differentiation promotes mesoderm differentiation [184], a prerequisite for 
responsiveness to osteoinductive stimuli [105, 241], so future studies may seek to 
investigate the effects of phosphate upon cells grown from plated EBs as the formation of 
CaP precipitates may be altered in monolayer culture compared to the three dimensional 
environment within EBs. It also remains to be determined whether phosphate treatment 
alone can induce osteogenic differentiation of human ESCs as well since the transfer of 
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differentiation protocols from mouse to human cells has proven more challenging due to 
species differences. Further understanding of the biology of osteogenic responses to 
phosphate treatment in ESCs has broader impacts not only in the field of tissue 
engineering, where the use and control of osteogenic cell types is desired in the 
development of bone regenerative therapies, but also mineralization occurring within 
pathologic settings, such as vascular smooth muscle and valvular calcification, where 
cells  may sense and respond to phosphate treatment through the same conserved 
mechanisms investigated in the current study. 
 Additionally, the osteogenic differentiation study identified that the osteogenic 
differentiation of EBs induced by phosphate treatment was accompanied by changes in 
the expression and responsiveness of two 1α,25(OH)2D3 receptors, Pdia3 and VDR 
(Chapter 4). The presence and differential regulation of these two receptors during EB 
differentiation indicated an important role of 1α,25(OH)2D3 signaling in bone 
differentiation and development in general. Each receptor’s exact function during the 
early stages of development modeled by EB culture may be further investigated. For 
example, though Pdia3 -/- knockout is embryonically lethal by day E10.5 [190], ESCs 
may be derived from knockout mice, allowing for further examination of the receptor’s 
role in early development using the EB differentiation model to determine at what stage 
during development 1α,25(OH)2D3 activation of PDIA3 is necessary for osteogenic 
differentiation and other important developmental processes.  
 The effects of phosphate treatment on osteogenic differentiation were attributed 
directly to the formation of CaP precipitates within EBs based on studies that CaP 
precipitates, independent of phosphate concentration and either administered 
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exogenously or formed endogenously under conditions promoting CaP precipitation, 
could induce the effects previously thought to be due to phosphate transport into cells 
[130-132]. The mechanism by which these precipitates might be sensed by cells is not 
clear but likely dependent upon how the precipitates are modified within the cellular 
microenvironment, including remodeling by cells and interactions with matrix proteins 
and growth factors. Osteogenic cell-modified surfaces may then in turn promote further 
osteogenic differentiation of neighboring cells [214]. Additional material characterization 
of the CaP precipitates formed within EBs, particularly in isolation instead of within a 
mixture of cellular material, would provide further information about their structure, 
composition, and protein binding. Also, because of the the exact mechanism of PFA 
inhibition of differentiation remains unclear, for future studies, CaP formation could be 
blocked with other agents known to inhibit crystal formation, including pyrophosphate 
[130] or phosphocitrate [132]; however, though such agents may not have the same 
potential effect on phosphate transport as PFA, they can have other effects on cell 
phenotype [47]. Studies of the direct administration of CaP precipitates in pre-osteoblast 
and vascular smooth muscle cells motivates the evaluation of ERK signaling and 
osteogenic differentiation in response to the direct administration of exogenously formed 
CaP to EBs. Such a study would also aid in discrimination between the effects of the 
increased Pi compared to those of the CaP deposits themselves and is currently being 
investigated in ESCs by our lab, using hydroxyapatite microparticles [213]. However this 
approach requires incorporation the CaP from the time of EB formation, whereas for the 
current study βGP treatment was initiated at day 5. As discussed above, ESCs must 
undergo initial mesodermal differentiation before they are responsive to osteogenic 
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differentiation cues, which does not occur until approximately day 5 within EBs [184]. 
As a result, the difference in the onset of treatment motivates the investigation of the 
incorporation of CaP particles in mesenchymal stem cell (MSC) spheroids as well. More 
differentiated MSCs already have an increased propensity for osteogenic differentiation 
than less differentiated ESCs, so MSCs may begin in a state more responsive to 
differentiation cues induced by the CaP particles than ESCs.  
Whether phosphate induced differentiation is mediated through Pi uptake by cells, 
the simple presence of CaP in the microenvironment, or some combination of the two, it 
is clear from this work that ERK 1/2 signaling is activated as a result (Chapter 4, 5); 
however further elucidation of the cues or factors directly activating ERK signaling is 
required to understand the biological importance of phosphate or CaP sensing by cells 
undergoing osteogenic differentiation. The mechanism and pathways by which phosphate 
treatment induces ERK signaling, and therefore osteogenic differentiation, is still not 
completely understood, even in more committed cell types. ERK signaling is a common 
pathway activated by many cues and signals, so multiple mechanisms of activation may 
be responsible for its induction by phosphate. In this study, BMPs were found to be 
enriched within the EB microenvironment and suggested to participate in the observed 
osteogenic differentiation. In addition to Smad pathway induced effects of BMPs on 
osteogenic differentiation [8, 26], BMP induced osteoblast differentiation is known to 
require non-Smad pathway signaling as well, including activation of ERK 1/2. BMP-2 
activates ERK signaling in mesenchymal progenitor [135] and C2C12 cells [125], and 
this BMP induced activation leads to both Runx-2 [127] and osterix transcriptional 
activity[136]. Additionally, 1α,25(OH)2D3 binding of PDIA3 also stimulates a rapid ERK 
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activation [126], so potential interaction of CaP precipitate and 1α,25(OH)2D3 signals 
may also exist. It is likely that a combination of this myriad of signals is having a 
synergistic effect by converging at ERK activation, therefore inducing osteogenic 
differentiation. 
 Given recent setbacks in the translation of ESC based cell therapies to clinical 
use, the further development of acellular approaches to harness the regenerative potential 
of ESCs are more attractive than ever. After establishing that CaP precipitates created an 
in vitro osteoinductive microenvironment within EBs, we demonstrated the ability to 
harness the osteoinductive potential of these EBs by implantation in vivo, suggesting 
promising future clinical applicability of this or similar approaches (Chapter 6). The in 
vivo osteoinduction and in vitro differentiation are likely to share common mechanisms, 
as the in vivo studies evaluated factors all also present in vitro. Consequently, the same 
questions remain regarding how the presence of CaP in EBs enhances the osteoinductive 
microenvironment, so further elucidation of the mechanism by which EBM induces the 
formation of new bone is required. Since EBM is a mixture of devitalized cells and ECM, 
it is not clear whether the growth factors were originally associated with the matrix or 
sequestered within the cells and only liberated upon devitalization of the cells. However, 
difference in growth factor location also cannot be distinguished from the measurements 
of growth factor content within cell pellets. The presence of inhibitors of osteogenic 
differentiation within –βGP EBM may explain why –βGP EBM, while containing 
equivalent amounts of growth factors, was not found to be osteoinductive. Since BMPs 
are thought to be the factors responsible for the osteoinduction, the evaluation of potential 
inhibitory factors, such as Noggin, is also needed. In addition to its enrichment in growth 
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factor content, EBM may have had unique matrix and material properties that lead to its 
osteoinductivity. It was suggested by the reduced collagen content and the larger ossicle 
formation that EBM was more easily remodeled than DBM. Further evaluation for the 
presence of osteoclast remodeling of the EBM may clarify this possibility. Additionally, 
given the formation of larger marrow spaces with EBM implantation, the enhancement of 
factors promoting establishment of the bone marrow niche, such as stromal derived 
factor-1 (SDF-1/CXCL12), are also of interest for further investigation [242]. SDF-1 is a 
potent hematopoetic stem cell (HSC) chemoattractant that promotes homing and 
engraftment, and it has been demonstrated to be produced at low levels by mouse ESCs 
that increased with EB differentiation [243]. SDF-1 not only stimulates HSC 
transmigration from circulation into extravascular bone marrow space but also promotes 
HSC survival. However, its production may simply be a consequence of increased bone 
formation, as seen in response to EBM, as bone formation is important for marrow 
regeneration [237, 238], and it is produced by a variety of cells associated with bone, 
including endosteal osteoblasts and endothelial cells. However if SDF-1 is actually 
enriched within EBM itself, potential therapies to enhance bone marrow engraftment 
after transplantation could be a possibility through adjunct delivery of EBM. 
 Optimization of the derivation, preparation, and delivery of EBM or related ESC- 
derived factors may also be investigated. Only one osteogenic differentiation condition 
and one time point were evaluated in the present study. Preparations derived at different 
days would capture earlier more embryonic-like states and later more committed ones. 
Additionally, EBM derived under different osteogenic differentiation methods, including 
culture with 1α,25(OH)2D3 [105], dexamethasone, and ascorbic acid [103], could be used 
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to evaluate whether material from a more homogeneously differentiated population is 
preferable or if the presence of factors produced by multiple types of cells present within 
EBs is needed. Multiple cell types participate in the formation of bone in vivo with the 
signals directing its formation arising not just from the osteoblasts themselves but also 
from other cells, including endothelial cells and chondrocytes [3]. Consequently, the 
more embryonic, less differentiated state of EBs and their ability to generate cues to 
direct the formation of all different types of cells is what makes them a novel and 
attractive material source. Additionally, the osteoinductity of extracellular matrices from 
more differentiated and more homogeneous cell populations have already been 
investigated, using osteogenically differentiated MSCs. Though those studies 
demonstrated osteoinductivity in vitro [78], the MSC generated matrix was not 
osteoinductive when evaluated in vivo [65], likely because osteoinductive cues harbored 
within the matrix were masked by mineralization produced by the more mature and 
differentiated osteogenic cell type. Thus, the heterogeneity of EB differentiation and the 
more embryonic-like environment it recapitulates are its advantages when compared to 
acellular therapies derived from more differentiated cells or tissues.  
 The optimal dosage of EBM delivered and ratio of EBM to inactive DBM, 
including delivery of EBM alone, should be further explored in future studies. An equal 
mixture of active and inactive DBM (7.5 mg and 7.5 mg) would provide a more fair 
comparison than the positive control of active DBM alone (15 mg) used in this study as 
such a formulation would contain an equivalent mass of “active” material as implanted in 
the EBM samples (7.5 mg). Two preliminary studies were initially performed delivering 
lower mass doses of EBM (~2.5 mg) and without inactive DBM vehicle, and these 
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studies did demonstrate signs of mineralization with EBM implantation by x-ray in both 
studies and μCT in one, though substantially less than in the current study, however 
technical difficulties with histology limited the ability to draw conclusions about new 
bone formation in both. Based on mineralization analyses alone, these observations 
suggest that the investigation of lower doses (< 5mg) would yield decreased new bone 
formation. Higher doses of EBM are needed for more direct comparisons with DBM at 
the dose used for the positive control (15 mg). Varying the amount of inactive DBM used 
as a vehicle would also provide insights into the balance between growth factor and 
extracellular matrix binding-induced signaling required for osteogenic differentiation [74, 
244]. In addition to facilitating location of the implant site histologically, inactive DBM 
provides a collagenous matrix absent in EBM, which itself is an important part of 
osteogenic differentiation. Integrin mediated binding of collagen-I has been shown to 
regulate early osteoblast differentiation and control the expression of key genes in 
osteoblastogenesis [9, 10]. Therefore, it is expected that some inactive DBM is required 
in order for the osteoinductive effects of EBM to be seen. As an alternative to inactive 
DBM, EBM could be delivered within a synthetic scaffold, eliminating the need for the 
use of any allograft tissue altogether. 
 The isolation of factors from or produced by differentiating osteogenic EBs in a 
soluble form may be an attractive alternative therapeutic approach to the delivery of 
EBM, as injectable therapies are minimally invasive. Extraction of proteins, particularly 
growth factors, may be prepared from tissues or acellular materials, such as EBM. The 
extraction in Tissue Protein Extraction Reagent (TPER) used to quantify growth factor 
content in this study demonstrated that growth factors were more readily extractable from 
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EBM than DBM, without collagenase digestion or harsh ionic agents that may disrupt 
growth factor bioactivity. The ease of growth factor extraction from EBM suggested that 
growth factors were less tightly sequestered within the ECM present in EBM than growth 
factors in DBM, thus increasing bioavailability of osteoinductive factors in EBM. Also, 
conditioned media from differentiating EBs may be directly injected. However, the 
caveat for both of these aforementioned approaches to deliver factors in a soluble form is 
the short half life of growth factors in vivo as they may easily diffuse away from the site 
of injection. To overcome this limitation, biomaterials may be used to bind these 
bioactive factors. The capture and delivery of ESC secreted factors using a self assembled 
nanofiber gel has been reported for in vivo applications [245], and such a technique could 
be used to harness EB derived conditioned media or extractions. Such injectable or 
engineered delivery approaches may lose any beneficial effects of the delivery of the 
natural extracellular matrix itself, which can bind and stabilize growth factors, prolonging 
half life, or provide patterning required for processes such as mineralization [74, 212]. In 
the case of osteogenic EBM in particular, the novel osteoinductive effect may be lost by 
such methods since the CaP precipitates themselves may be playing a role in stabilizing 
the BMPs within EBs.  
 Though viable EBs undergoing osteogenic differentiation may be implanted for 
therapeutic purposes, for several reasons, the characteristics of EBM make it more 
attractive for translation to clinical practice. Viable cells may be advantageous for some 
applications because they can directly participate in osteogenesis themselves, in cases 
where host cells may have a reduced capacity to respond to osteoinductive cues, as is 
known to occur with aging. However, such a therapy necessitates preparation 
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immediately at the time of implantation to maintain cell viability, losing the handling and 
storage advantages of novel acellular materials, such as EBM, that allow them to be 
prepared in advance. In addition, when using an ESC source, the danger always remains 
that if even a small population of undifferentiated cells persists, teratoma formation is 
possible, as was observed in preliminary EBM studies that also investigated implanting 
viable day 10 EBs. Thus, to reap the therapeutic benefits of the regenerative, embryonic-
like microenvironment created by ESCs, development of an acellular therapy derived 
from ESCs, such as EBM, is the safest approach.  
 The novel findings here of EBM osteoinductivity motivate the further evaluation 
of EBM for use in bone tissue engineering and other regenerative applications. Materials 
for bone tissue engineering, such as DBM, have been evaluated for their ability to heal 
critical sized defects in bones that do not have the ability to close on their own [246]. 
Therefore, the delivery of osteogenic EB-derived EBM, by itself, with DBM, or 
embedded within a synthetic scaffold, could be evaluated for its ability to promote 
closure of critical sized defects. EBM has also been evaluated in our lab for its ability to 
promote dermal wound healing and angiogenesis. Both of these studies, however, used 
spontaneously differentiating EBs as the cell source for EBM. The current study 
represents the first use of EBM for a tissue specific application by material derivation 
from ESCs undergoing directed differentiation towards the cell type of that tissue. The 
directed differentiation of ESCs to endothelial cell phenotypes by pre-conditioning with 
fluid shear has been recently demonstrated by our lab, with upregulation of VEGF 
production enhanced when EBs formed from pre-conditioned ESCs were further cultured 
under low oxygen conditions. This increase in endothelial cell and VEGF production 
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could be exploited to yield EBM that may exhibit increased angiogenic potency, which in 
concert with βGP treatment, may yield even greater osteoinductive potential than seen in 
the current study, due to potential enrichment and capture of BMPs and VEGF. This 
approach to increase angiogenic potential could also be used in the absence of βGP 
treatment, to yield VEGF enriched EBM for delivery to other tissues requiring 
angiogenesis, such as ischemic myocardium. However, due to the observation of ossicle 
formation in isolated -βGP EBM implanted samples, one caveat is the potential for 
ectopic bone formation with the use of EBM for non-bone inductive applications, due to 
its high BMP content. The intramuscular implantation site used to evaluate 
osteoinductivity in this study is an ectopic bone formation site, one where bone does not 
normally form on its own. Similarly, any other implantation site for other applications in 
the body where EBM may be used could serve as an ectopic bone formation site as well, 
other than within bone itself. However, integrin mediated interactions with the collagen-I 
matrix, in combination with the osteoinductive factors present, are known play an 
important role osteogenic differentiation [9, 10] and would be absent when EBM is not 
delivered with inactive DBM. Additionally, untreated EB-derived EBM would also not 
contain the CaP precipitates proposed to have locally collected and enriched BMP 
content during EB differentiation.  
 The derivation of similar materials from human cell sources, including induced 
pluripotent stem cells, would eliminate the potential for cross species immunological 
interactions which may hinder the translation of the currently evaluated, mouse-derived 
EBM to clinical application. However, xenografts and xeno-derived acellular materials 
are already in use clinically, and after devitalization, xeno-derived acellular therapies 
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have improved safety and efficacy compared to xenografts [247, 248]. In comparison 
with DBM and other cadaveric sourced tissues, the further development of cell-derived 
biomaterials motivated by the current studies of EBM may one day reduce or even 
eliminate the need for donor allograft tissue, an end goal long promised by tissue 
engineering and regenerative medicine strategies, while providing the added benefit of 
also removing donor variability that may limit current therapy. Given a growing shortage 
organ and tissue donors, this potential advantage, as demonstrated in this study by EBM, 
is particularly exciting and brings that promise one step closer to fruition. 
 In conclusion, this work has demonstrated that the biological effects of phosphate 
treatment reported in a variety of other cell types are conserved in ESCs, and therefore 
potentially important in the further understanding of bone development. Furthermore it 
expands upon previous work established within our lab, developed to deliver the 
therapeutic benefits of stem cells in a cell free form, by demonstrating that the 
osteoinductive environment of differentiating ESCs may be harnessed as an acellular, 
osteoinductive biomaterial. This exciting finding demonstrates that through directed 
differentiation a tissue specific biomaterial can be derived that stimulates directed in vivo 
tissue response and formation, capturing the regenerative potential of ESCs and opening 
the door for the further development of ESC-derived materials for other applications. 
Future work will continue to elucidate the mechanisms of these effects, allowing for 
refinement of this novel approach and the development of other tissue specific therapies 
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